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Abstract 
Non ischaemic dilated cardiomyopathy (DCM) is an important cause of heart failure leading 
to chronic morbidity and death and as such is a major health burden. DCM is familial in up 
to 50% of cases but is genetically heterogeneous, hindering both genotype-phenotype 
studies and the application of genetic information for stratified patient management. 
 
TTN truncating variants (TTNtv) cause severe and familial DCM, but sometimes occur in 
healthy individuals, posing challenges for the interpretation of these variants. In this PhD 
thesis, the power of quantitative cardiac MRI (CMR) is integrated with targeted 
resequencing of TTN in order to assess the relationship between TTN genotype, cardiac 
phenotype and clinical outcomes. 
 
A prospectively recruited DCM cohort was established following CMR assessment in 374 
patients (88% Caucasian, 72% male, mean age 54 ± 35 years, mean left ventricular 
ejection fraction (LVEF) 38% ± 24.5%, mean indexed end-diastolic volume 129 ± 141 mm). 
Following several iterations of design, refinement and testing an NGS assay was produced 
that captures all TTN coding exons and splice sites. Optimal parameters for sequencing 
and analysis of variants were established and genotype data compiled from 374 
prospective, unselected cases, 155 end-stage retrospective cases, and 308 MRI 
phenotyped healthy volunteers. These data were integrated with that from 3603 population 
subjects and together used to identify molecular signatures that aid interpretation of TTN 
truncations both in DCM and as incidental findings. 
 
Overall, TTNtv were identified in 1.4% of controls, 13% of unselected and 22% of end-stage 
DCM cases (OR = 13, P= 2.8x10
-43
, DCM vs controls) confirming TTN as the commonest 
cause of genetic DCM in all patient groups.  TTNtv-containing exons in DCM have higher 
usage than those in controls (P=2.5x10
-4
) and these are estimated to have >93% probability 
of pathogenicity (likelihood ratio 14). Compared to TTNtv-ve DCM, TTNtv+ve patients had 
lower LVEF (P=0.02), thinner LV walls (P=0.02), and a higher incidence of sustained 
ventricular tachycardia (P=0.001). C-terminus TTNtv were also associated with lower LVEF 
versus N-terminus (β=-18±7%, p=0.006) and were more common in end-stage disease. 
 
Together these data provide the first insight into genotype-phenotype correlations and will 
be of benefit in variant interpretation and patient stratification in TTN-based DCM. 
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Glossary of terms  and abbreviations 
 
AHA American Heart Association 
arrayCGH Array-comparative genomic hybridization – a technique to detect 
DNA copy number variation 
ARVC Arrhythmogenic right ventricular cardiomyopathy – an inherited 
cardiomyopathy 
ATP Adenosine triphosphate,  a nucleoside triphosphate used in cells 
as a coenzyme. 
BLAST Basic Local Alignment Search Tool, finds regions of local 
similarity between sequences. 
bp Base pairs – the length of a (double-stranded) DNA sequence is 
reported in base pairs.  Standard prefixes are used to indicate 
larger units, such as kbp and Mbp 
BRU Biomedical research unit 
BSA Body surface area 
CAD Coronary artery disease 
CAPN3 Gene encoding Calpain-3 
cDNA Complementary DNA is DNA synthesized from a messenger 
RNA (mRNA) template 
CM Core-myopathies, the most common form of inherited non- 
dystrophic childhood muscle disorder,  defined by areas of 
mitochondria depletion and sarcomere disorganisation in muscle 
fibres 
CMD1GI An autosomal domainant DCM locus, located on 2q13 
CMR Cardiovascular magnetic resonance imaging.  A highly accurate 
and reproducable a medical imaging technology for the non- 
invasive assessment of the function and structure of the 
cardiovascular  system 
CNM Centronuclear myopathies, a diverse group of clinically and 
genetically heterogeneous muscle disorders defined by the 
presence of internalised nuclei in myofibers without excessive 
regeneration or structural abnormalities 
Consanguineous Refers to a union between two related individuals 
DCM Dilated cardiomyopathy – cardiomyopathy characterised by 
increased ventricular cavity size without increased wall 
thickness, often inherited 
DNA Deoxyribonucleic acid 
Dominant 
inheritance 
A pattern of inheritance in which one aberant copy of a gene is 
sufficient for the disease or trait to develop. 
EBI European Bioinformatics Institute (EMBL-EBI) is a centre for 
research and services in bioinformatics 
ECG Electrocardiogram – an ECG is a recording of the electrical 
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activity of the heart taken from the body surface 
EDMD Emery-Dreifuss muscular dystrophy, a disease characterized by 
muscular weakness and atrophy, with early joint contractures 
and  cardiomyopathy. 
EDV End diastolic volume is the volume of blood in a ventricle at end 
load or filling in diastole 
ELM The Eukaryotic Linear Motif Resource, a computational biology 
resource for investigating candidate functional sites in eukaryotic 
proteins 
EOMFC Early-onset myopathy with fatal cardiomyopathy, a sub-type of 
multi minicore disease 
ePCR Emulsion PCR, isolates individual DNA molecules along with 
primer-coated beads in aqueous droplets within an oil phase 
ESC European cardiology society 
ESP Exome sequencing project 
EST Expressed sequence tag 
ESV End-systolic volume is the volume of blood in a ventricle at the 
end of contraction, or systole 
Expressivity Variations in a phenotype among individuals carrying a 
particular genotype.  It is determined by the proportion of 
individuals with a given genotype who also possess the 
associated  phenotype 
FDA US Food and Drug Administration 
FHS Framingham heart study 
FINmaj A founder mutation within the Finnish population causing tibial 
muscular dystrophy in heterozygotes 
FN-III Fibrionectin-III domain, a repeated domain within the TTN 
protein 
GATK Genome Analysis Toolkit – open-source software for the 
analysis of next-generation sequencing data 
GC GC-content is the percentage of nitrogenous bases on a DNA 
molecule that are either guanine or cytosine 
Genotyping The process of identifying genetic variation in an individual 
genome 
GERP GERP score: A score used to calculate the conservation of each 
nucleotide in multi-species alignment 
GWAS Genome-wide association study 
Haploinsufficiency  Occurs when a diploid organism has only a single functional 
copy of a gene (with the other copy inactivated by mutation) and 
the single functional copy does not produce enough of a gene 
product (typically a protein) to bring about a wild-type condition, 
leading to an abnormal or diseased state 
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HCM Hypertrophic cardiomyopathy – cardiomyopathy characterised 
by increased ventricular wall thickness, without increased cavity 
size, usually inherited 
Heterozygote A diploid organism is heterozygous at a gene locus when its 
cells contain two different alleles of a gene on both homologous 
chromosomes. The cell or organism in question is called a 
heterozygote 
HMERF Hereditary myopathy with early respiratory failure, a disease 
which typically involves adult-onset proximal-distal weakness 
and respiratory failure in an ambulant patient 
Homozygote A diploid organism is homozygous for a particular gene when 
identical alleles of the gene are present on both homologous 
chromosomes. The cell or organism in question is called a 
homozygote 
ICC Inherited cardiac condition.  A group of largely monogenic 
disorders affecting the heart, its conducting system and 
vasculature 
Ig Immunoglobulin domain, a repeated domain within the TTN 
protein 
IHD Ischaemic heart disease – “ischaemia” means inadequate blood 
supply to an organ.  IHD encompasses a range of pathological 
processes from acute thrombosis suddenly occluding a coronary 
artery, to more gradual, progressive narrowing of large or small 
vessels supplying the heart 
INR International normalised ratio, a measure of the extrinsic 
pathway of coagulation. 
ISFC International Society and Federation of Cardiology 
JHS Jackson heart study 
LA Left atrium 
LAV Left atrial volume 
LBBB Left bundle branch block 
LGE Late gadolinium enhancement - detects accumulation of  
contrast in areas of infarction or fibrosis due to slower contrast 
kinetics and greater volume of contrast in the extracellular space 
LGMD Limb girdle muscular dystrophy 
LMNA Gene encoding LaminA/C, lamins are structural protein 
components of the nuclear lamina 
LQT Long QT syndrome – an inherited arrhythmia syndrome 
LRG Locus reference genomic sequence – a standardised framework 
for reporting the location of DNA variation 
LV Left ventricle 
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LVNC Left ventricular non-compaction - a rare cardiomyopathy 
characterised by failure of compaction of the ventricles and a 
hypertrabeculated  apprearance 
Mendelian A Mendelian trait is one that is controlled by a single locus  that 
is inherited according to Mendel's laws 
MEx1/2 The six exons at the 3' end of the TTN gene encode the M-line 
section of titin and are referred to as Mex1 to Mex6. 
MI Myocardial infarction 
MmD Multi-minicore disease describes a recessive core myopathy 
(CM) 
MRC Medical research council 
MRI Magnetic resonance imaging, a type of scan that uses strong 
magnetic fields and radio waves to produce detailed images 
mRNA Messenger ribonucleic acid 
MSA Multiple sequence alignment 
NGS Next-generation  sequencing 
NHLBI The National Heart, Lung, and Blood Institute, a division of the 
US National Institutes of Health 
NHS National Health Service (UK) 
nsSNP Non-synonymous  SNP 
PCR Polymerase chain reaction, a biochemical technology used to 
amplify  DNA 
Penetrance The proportion of individuals carrying a particular variant of a 
gene (allele or genotype) that also expresses an associated trait 
(phenotype) 
PEVK A region of Titin that is rich in proline, glutamate, valine and 
lysine 
Phenotype The composite of an organism's observable characteristics or 
traits, such as its morphology, development, biochemical or 
physiological properties, and behavior. A phenotype results from 
the expression of an organism's genes as well as the influence 
of environmental factors and the interactions between the two 
Private mutation A genetic variation that is unique to that individual or pedigree 
PSI Proportion spliced in - a score that provides the inclusion level of 
each exon 
RBHT Royal Brompton & Harefield NHS Foundation Trust 
RCM Restrictive  cardiomyopathy 
Recessive 
inheritance 
A pattern of inheritance in which both copies of a gene must be 
aberant in order for the disease or trait to develop. 
RNA Ribonucleic acid 
RV Right ventricle 
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SCD Sudden cardiac death 
SD Standard deviations 
Sequencing Determining the primary structure of a biological polymer, 
particularly the sequence of nucleotides in DNA or RNA, or of 
amino acids in a protein molecule 
SIFT Sorts intolerant from tolerant.  An online tool that predicts 
whether an amino acid substitution affects protein function, 
based on the degree of conservation of amino acid residues in 
sequence alignments derived from closely related sequences 
SNP Single nucleotide polymorhism 
SV Stroke volume is the volume of blood pumped from one ventricle 
of the heart with each beat 
TK Titin kinase 
TMD Tibial muscular dystrophy, an autosomal dominant distal 
myopathy characterised by weakness of the muscles of anterior 
compartment of lower limbs, appearing in the fourth to seventh 
decade of life.  Caused by heterozygous mutations in the M- 
band of TTN 
TR Tricuspid regurgitation 
UTR untranslated region – DNA sequence at each end of a gene that 
is transcribed to RNA, but not translated to amino acid 
VUS Variant of unknown significance.  A variation in a genetic 
sequence whose association with disease risk is unknown 
WES Whole exome sequencing 
WGS Whole genome sequencing 
WHO World health organisation 
WT Wall thickness 
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1 Introduction 
 
1.1 Inherited cardiovascular conditions and cardiomyopathy 
Inherited cardiac conditions (ICCs) are genetic conditions that affect the heart and 
circulation. These diseases are the commonest cause of sudden death in the young 
and are also a major cause of death and disability across all age groups.  ICCs can 
be broadly grouped into those affecting the heart only (e.g. cardiomyopathies or 
channelopathies), and those affecting the heart and circulation (e.g. Marfan 
syndrome or familial hypercholesterolaemia). 
 
Cardiomyopathy is an umbrella term describing a heterogeneous group of disorders 
characterised by structural and functional abnormalities of the myocardium, in the 
absence of coronary artery disease(CAD), hypertension, valvular disease or congenital 
heart disease sufficient to cause the observed myocardial abnormality. 
Cardiomyopathies can be grouped into five forms: dilated (DCM), hypertrophic (HCM), 
restrictive (RCM), arrhythmogenic right ventricular cardiomyopathy (ARVC) and left 
ventricular non-compaction (LVNC).  However, the precise classification of these 
cardiomyopathies and their subtypes has remained an area of contention owing to 
extensive genotypic and phenotypic overlap and our evolving understanding of the 
complex disease processes involved.  One recent area of consensus is the departure 
from the WHO/ISFC classification and exclusion of left ventricular (LV) dysfunction as a 
direct consequence of another cardiac abnormality including hypertension, valve 
disease, congenital heart disease and CAD, which were historically termed ‘specific 
heart muscle diseases’ or ‘specific cardiomyopathies’. 
 
In 2006 the American Heart Association (AHA) revised their definition and 
classification of cardiomyopathies
1  
and proposed their overarching division into 
primary cardiomyopathy (genetic, non-genetic and acquired) where disease is solely 
or predominantly confined to the heart muscle, and secondary cardiomyopathy 
showing myocardial involvement as part of a large number and variety of generalised 
systemic disorders (previously described as specific cardiomyopathies). 
Interestingly they included ion channel disorders (including Long QT and Brugada 
syndromes) as cardiomyopathies ‘on the basis of the scientifically reasonable (but 
largely hypothetical) assertion that ion channel mutations are responsible for altering 
the biophysical properties and protein structure, thereby creating structurally 
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abnormal ion channel interfaces and architecture’.  The organ specific distinction 
proposed by the AHA is not ideal as many ‘primary’ cardiomyopathies have extra- 
cardiac manifestations, and pathology in many ‘secondary’ cardiomyopathies can 
predominantly or exclusively involve the heart. 
 
Latterly, the European Society of Cardiology (ESC) published a clinically-orientated 
classification system in which heart muscle disorders are grouped according to 
ventricular morphology and function, and sub-classified as familial or non-familial
2
. 
The rationale being that this is the most useful method for diagnosing patients and 
managing families.  In this system familial disease is defined as the occurrence of  
the same disorder or phenotype in more than one family member which is or could 
be caused by the same genetic variant, or the occurrence of as yet sporadic disease 
due to a de novo genetic variant which could be transmitted to offspring.  Non- 
familial cardiomyopathies are sporadic and may be sub-divided into idiopathic or 
acquired cardiomyopathy in which cardiac dysfunction is a complication and not a 
direct consequence of the disease. 
 
 
1.2 Dilated  cardiomyopathy 
DCM is defined by the ESC as left ventricular dilatation and systolic dysfunction in 
the absence of abnormal loading conditions (hypertension, valve disease) or CAD 
sufficient to cause the level of systolic impairment observed. Typically the LV wall is 
thinned and there may be right ventricular dilatation and dysfunction but these are 
neither invariable nor required for the diagnosis. 
 
 
1.2.1 Epidemiology 
The prevalence of DCM remains uncertain and the only formal estimate is based on 
a study conducted from 1975 to 1984 which estimated DCM prevalence at 
approximately 1:2,700
3
. However, given that the same study underestimated the 
prevalence of HCM by tenfold, it is likely that the same may be true for DCM and it is 
now generally accepted that DCM prevalence may be as high as 1:500.  Since 
subjects may remain asymptomatic until late stage disease, it is likely that DCM has 
been under-diagnosed. A recent review put forward further persuasive arguments 
that the prevalence is closer to 1 in 250
4
: extrapolating prevalence of non-ischeamic 
cardiomyopathy from heart failure clinical trial data, deriving the prevalence of 
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idiopathic systolic dysfunction identified by echocardiography from cross-sectional 
study data, and using population-based prevalence estimates of asymptomatic LV 
dysfunction as a surrogate for DCM.  Given recent guidelines highlighting the 
importance of family screening, coupled with the implementation of more sensitive 
diagnostic imaging such as CMR, the frequency with which DCM is diagnosed is set 
to rise. The disorder may manifest at any age, in either sex and in any ethnic origin 
although it is more common in males and in blacks and typically presents in 
adulthood 
5-9
. 
 
 
1.2.2 Clinical presentation and consequences 
DCM is a major cause of morbidity and mortality and is the leading cause for heart 
transplantation
10
.  Presentation is typically with symptomatic heart failure with  
features of congestion (oedema, orthopnoea, paroxysmal dyspnoea) and/or reduced 
cardiac output (fatigue, dyspnoea on exertion).  Other complications include 
arrhythmias and/or conduction system disease and thromboembolic disease including 
stroke.  At least half of all cases of heart failure have systolic dysfunction 
11
, 
a substantial proportion of which results from DCM 
10
. 
 
 
In the early stages various compensatory mechanisms act to allow the patient to 
remain asymptomatic, sometimes for years. Ultimately these homeostatic responses 
fail and a common path of decompensation and dilatation ensues leading to 
symptomatic heart failure 
12
.  Therefore symptomatic DCM represents late disease. 
Screening and identification of DCM before the onset of symptoms enables the 
initiation of medical therapy that may delay disease progression. However, cardiac 
transplantation remains the definitive treatment for progressive DCM and heart 
failure refractory to medical or device therapy. 
 
 
1.2.3 Aetiology 
DCM is the most clinically and genetically heterogeneous of the cardiomyopathies. 
Although regarded as a single entity characterised by LV dilatation and dysfunction, 
myocyte cell death, and fibrosis, it may be more accurately thought of as a final 
common phenotype for a diverse range of cellular processes that cause myocardial 
damage 
13
.  Many common conditions such as ischaemic heart disease, and 
environmental factors such as alcohol, can lead to heart failure, and it is important to 
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asses these when making a diagnosis (Table 1.1) 
1,2
.  Unless there are characteristic 
histopathological or imaging findings, it can be difficult to prove that DCM is 
secondary to a particular factor or whether that factor is merely concurrent or 
modifying expression. The term idiopathic DCM was coined before genetic testing 
became routine and has in the past included DCM which is purely idiopathic as well 
as where a genetic cause has been identified. 
 
Table 1.1 Overview of factors that may cause secondary or syndromic DCM 
 
Toxins Alcohol, amphetamines, cocaine 
Antiretroviral agents 
Carbon monoxide 
Chemotherapeutic drugs (e.g. 
anthracyclines) 
Chloroquine,  phenothiazine 
Cobalt, lead, mercury 
Infectious Agents Bacterial 
Brucellosis, diphtheria, psittacosis, typhoid 
fever 
Fungal 
Mycobacterial 
Parasitic 
Chagas disease, schistosomiasis, 
toxoplasmosis 
Rickettsial 
Viral 
Adenovirus, Coxsackie A and B, 
cytomegalovirus, Epstein-Barr, human 
herpes virus 6, HIV, parvovirus B19, 
varicella 
Metabolic  Abnormalities Electrolyte  disturbances 
Hypocalcaemia, 
Hypophosphataemia, 
Uraemia 
Endocrine  abnormalities 
Cushing’s disease, 
Diabetes mellitus, 
Acromegaly 
Hypo/hyperthyroidism, 
Phaeochromocytoma 
Nutritional deficiencies 
Carnitine, thiamine, selenium 
Inflamatory/ infiltrative conditions Hypersensitivity  myocarditis 
Infiltrative diseases 
Haemochromatosis, 
Sarcoidosis 
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 Vasculitis 
Churg-Strauss, 
Kawasaki disease, 
Polyarteritis nodosa 
Connective tissue diseases Dermatomyositis 
Marfan syndrome 
Scleroderma 
Systemic lupus erythematosis 
Neuromuscular  Diseases Duchenne /Becker muscular dystrophy  
Erb limb girdle muscular dystrophy 
Fascioscapulohumeral  muscular  dystrophy 
Friedreich’s ataxia 
Myotonic dystrophy 
Pregnancy  
Tachyarrhythmia  
 
 
1.2.4 Familial DCM and family screening 
DCM has been estimated to be familial in 20% to 50% of cases 
14
. A medical history, 
physical examination, echocardiogram, and electrocardiogram (ECG) should be  
used to evaluate a proband's first-degree relatives to determine if any have 
asymptomatic DCM.  It is recommended that first-degree relatives with a normal 
echocardiogram and ECG be re-screened every three to five years to fully assess 
their risk.  However, screening of relatives based on phenotype is unreliable and 
requires long-term and often invasive follow up.  The variable penetrance typical of 
DCM can considerably complicate family screening, which is stressful for patients, 
costly and time-consuming.  Molecular diagnosis could aid both treatment and 
prognostication for the proband, and accurate diagnosis of family members. 
Genetic testing is available for diagnostic use by clinicians in the UK, primarily for 
familial DCM. However, although genetic testing of probands and cascade screening 
of families with ICCs is recommended by the National Service Framework for 
Coronary Heart Disease 
15 
and the National Institute of Clinical Excellence 
16 
these 
tests are not often used. 
 
Genetic testing plays an important role in the management of inherited diseases, but 
there are many caveats. One area of concern is genetic testing in children. A 
negative test may free a child from follow-up or invasive investigation but a positive 
result may have complex ramifications. For instance, many ICCs have low 
penetrance, so a positive result could result in lifestyle restrictions and anxiety for a 
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child who may never become symptomatic. On the other hand, delayed testing for 
childhood-onset conditions may lead to a delay in appropriate management. These 
potential benefits and burdens must be considered carefully. 
 
 
1.2.5 Genetic factors, molecular diagnosis and the impact of next generation 
sequencing (NGS) 
Disease aetiology lies on a continuous spectrum from genetic to environmental. A 
simple and purely genetic disease arises when a fully penetrant mutation in a single 
gene is sufficient to produce disease and is inherited in a Mendelian fashion. 
Mutations are typically in protein-coding regions of the genome, and cause 
substantial changes in protein function by altering splicing, truncating the protein, 
altering the reading frame, or substituting amino acids within critical functional 
domains. 
 
Most genetic DCM is inherited in an autosomal dominant fashion although autosomal 
recessive, X-linked and mitochondrial inheritance all occur. DCM is the end 
phenotype of diverse mutations in heterogeneous pathways ranging from  
components of the membrane-scaffolding apparatus, sarcomeric proteins, nuclear 
envelope proteins, calcium-handling proteins, transcription cofactors, RNA splicing 
and cell energy-generating machinery 
13
.  Table 1.2 shows known DCM genes and 
their cellular location/function. 
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Table 1.2 Putative DCM genes, their protein product and its cellular 
location/function 
 
 
 
Gene name Protein Location/function 
ABCC9 ATP-binding cassette C9 Ion channel 
ACTC1 Cardiac Actin Sarcomere 
ACTN2 Actinin, alpha 2 Z-disk 
ALMS1 Alstrom syndrome1 Cytoskeleton/centrosome/cilia 
ANKRD1 Ankyrin repeat protein 1 Transcription factor 
APOA1 Apolipoprotein A-I Lipoprotein 
CAV3 Caveolin-3 Plasma membrane 
CRYAB Alpha B crystallin Z-disk 
CSRP3 Cys and gly-rich protein 3 Z-disk 
CTF1 Cardiotrophin 1 Cytokine 
DES Desmin Desmosome 
DMD Dystrophin Dystrophin associated protein complex 
DNAJC19 HSP40 Homolog, C19 Mitochondrial  membrane 
DSG2 Desmoglein 2 Desmosome 
DSP Desmoplakin Desmosome 
DTNA Alpha-Dystrobrevin Dystrophin associated protein complex 
EMD Emerin Nuclear envelope 
EYA4 Eyes absent 4 Transcription factor 
FHL2 Four and half LIM protein 2 Z-disk 
FKRP Fukutin-related protein Golgi/glycosyl 
FKTN Fukutin Golgi/glycosyl 
FLT1 Fms-related tyrosine kinase 1 Kinase 
FOXD4 Forkhead box D4 Transcription factor 
FRDA Frataxin Mitochondrial Fe chaperone 
HADHA L. Chain 3-OH-Ac dehyrodgenase. Fatty acid synthesis 
HFE Hemochromatosis  gene Fe transport 
HOPX Homeobox only protein Transcription factor 
ILK Integrin-linked kinase Kinase 
LAMA2 Laminin alpha2 Extra cellular matrix 
LAMA4 Laminin alpha4 Extra cellular matrix 
LAMP2 Lysosome-Associated  Membrane 
Protein 2 
Lysosome 
LDB3 Cypher/ZASP Z-disk 
LMNA Lamin A/C Nuclear envelope 
MYBPC3 Myosin-binding protein C3 Sarcomere 
MYH6 Alpha myosin heavy chain Sarcomere 
MYH7 Alpha myosin heavy chain 7 Sarcomere 
NEXN Nexilin Z-disk 
NFKB1 NF-Kappa B1 Transcription factor 
PDLIM3 PDZ/LIM domain protein 3 Z-disk 
PLEC1 Plectin-1 Inter filament 
PLN Phospholamban Ca
2+  
cycling 
PSEN1 Presenilin 1 Membrane  protein/protease 
PSEN2 Presenilin 2 Membrane  protein/protease 
RBM20 RNA-Binding motif protein 20 RNA binding 
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SCN5A Voltage gated Na channel V alpha 
subunit 
Ion channel 
SDHA Succinate  dehydrogenase Mitochondrial 
SGCA Alpha-Sarcoglycan Dystrophin associated protein complex 
SGCB Beta-Sarcoglycan Dystrophin associated protein complex 
SGCD Delta-Sarcoglycan Dystrophin associated protein complex 
SGCG Gamma-Sarcoglycan Dystrophin associated protein complex 
SOD2 Superoxide dismutase Mitochondrial  matrix 
SYNE1 Nesprin-1 Nuclear envelope 
SYNM Desmulin Z-disk 
TAZ Tafazzin Mitochondrial 
TBX20 T-box 20 Transcription factor 
TCAP Titin-cap Z-disk 
TMPO Thymopoietin Nuclear envelope 
TNNC1 Troponin C Sarcomere 
TNNI3 Troponin I Cardiac sarcomere 
TNNT2 Troponin T Cardiac sarcomere 
TPM1 Tropomyosin,  alpha1 Sarcomere 
TTN Titin Sarcomere 
VCL (meta)Vinculin Z-disk 
 
 
 
Within the 50+ genes reputed to cause DCM, mutations are often private (unique to 
one pedigree). At the time of commencing this project only 6 DCM genes were 
available for clinical genetic testing in the UK (http://www.ukgtn.nhs.uk accessed 8th 
March 2012) and according to published frequencies these genes account for 12- 
17% of DCM. It is likely that the remainder of the genetic burden is derived from a 
large number of genes.  However, the frequency of genetic causation in persons with 
sporadic DCM remained largely unknown, and mutation frequencies provided for 
most known DCM genes should be considered preliminary, as usually only 1 or 2 
primary reports focusing on single genes are available from which to estimate 
frequencies.  Previously reported in 3 pedigrees, Titin (TTN) mutations were recently 
reported in 18-25% of selected DCM cases in a large multicenter study
17
: a 
discovery which could significantly change the landscape of genetic testing and 
family screening in DCM. 
 
NGS diagnostics for ICCs will most likely considerably reduce costs and increase 
availability if implemented in high-volume centres.  Accredited NGS analysis of 
cardiomyopathy genes has been available abroad for several years (e.g. GeneDx 
(www.genedx.com) offered a panel of 23 DCM genes in October 2009 and now 
offers a comprehensive cardiomyopathy panel including 36 DCM genes ).  During 
27  
the course of this project an NGS cardiomyopathy panel became available for the  
first time in the UK  (http://www.ukgtn.nhs.uk, http://www.ouh.nhs.uk/services).  The 
benefits of NGS, in terms of a more comprehensive genetic analysis at reduced cost, 
are likely to be striking for genetically heterogeneous conditions such as DCM. 
 
Determining whether a particular variant causes disease is one of the greatest 
challenges of contemporary clinical genetics, largely due to our limited understanding 
of the spectrum of rare but non-pathogenic genetic variation. This will               
become an increasing challenge as we are inundated with NGS data from disease- 
causing genes from research and diagnostics laboratories. Geneticists have 
traditionally relied on identifying co-segregation of a candidate variant with disease 
phenotype in a sufficiently large family, but at the population level this is not possible 
and we will increasingly need large and well-annotated databases to ascribe 
probabilistic disease scores to variants. Assigning causality to a variant is further 
complicated as many ICCs are not completely penetrant and variants in several 
genes may act together to cause disease or modify expressivity.
18-20 
NGS analysis of 
comprehensive panels of genes associated with a phenotype represents a timely 
advance, providing the tools to address these shortcomings, but also presenting 
major informatic challenges. 
 
Consequent upon the lack of comprehensive studies of DCM genetics, limited data is 
available in the literature for genotype/phenotype correlation in DCM.  In the new era 
of NGS far more longitudinal data can be gathered on these types of individuals, and 
together with an increased understanding of the role of disease modifying genes,  
may allow clinicians to better advise and treat patients. 
 
 
1.3 Personalised  medicine 
 
1.3.1 Molecular diagnostics and stratified medicine 
Human disease is heterogeneous and can be usefully classified into subtypes based 
on features that predict disease progression and treatment response—for example, 
type 1 versus type 2 diabetes or ST elevation versus non-ST elevation myocardial 
infarction. Identification of the specific molecular mechanism underlying an inherited 
disease provides another level of information for stratified medicine approaches. 
Molecular classification has enabled subtype-specific treatment for the three 
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commonest LQT syndromes,
21-26  
genotype-specific sudden cardiac death (SCD) risk 
prediction in HCM 
27 
and the identification of rapidly progressing subtypes of DCM 
requiring early transplant assessment 
28-30
.   Until now, no individual gene has been 
identified as a common enough cause of DCM to allow systematic genotype- 
phenotype correlation. As we gather more phenotype-genotype profiles in rare 
diseases (e.g. LQT 4-13
21,24
), genotype-specific risk calculators may be developed. 
Treatment may also be targeted to correct a specific molecular defect, as is already 
the case for rare cardiovascular diseases including monogenic hypertension and 
monogenic type II diabetes.
31,32
 
 
 
1.3.2 Stratifying risk in common diseases 
Recent genetic studies have identified a number of genetic variants that are 
associated with common cardiovascular diseases, including coronary artery  
disease, hypertension, diabetes, and arrhythmia.
33,34  
A number of studies have 
assessed the utility of genetic risk stratification by comparing the predictive value of 
conventional risk factors against risk factors plus genotype, but the additional power 
from current genetic markers is marginal.
35 
This is because the effect size 
associated with individual genetic variants is typically very small. Conventional risk 
factors often also assess family history, and a family history effectively interrogates 
many more genetic loci than can be meaningfully tested in a laboratory
36
. In the  
near future, deep sequencing with NGS will probably identify (rare) variants of larger 
effect size than those currently known, which may be more informative of             
risk. In situations where conventional risk stratification is limited, such as assessing 
risk of sudden cardiac death, NGS assessment of risk may be particularly 
informative.
37
 
 
1.3.3 Pharmacogenetics 
Of particular interest to clinical cardiologists are genotype-specific drug responses 
for commonly used drugs such as clopidogrel, warfarin and statins.  Common 
genetic variants in CYP2C19 reduce conversion of clopidogrel to its active 
metabolite,
38  
and studies have suggested that poor metabolisers treated with 
clopidogrel after acute myocardial infarction suffer higher rates of subsequent 
cardiovascular events than normal metabolisers,
39,40 
leading the FDA to issue a 
black box warning advising physicians of the availability of CYP2C19 genotype 
testing.
41 
While subsequent studies
42,43 
have led to divergent opinions on the 
29  
interpretation of these results, it remains a powerful illustration of the application of 
genomic information in routine clinical practice. In the case of warfarin therapy it is 
clear that genotype can predict the dose required to achieve target INR but there is 
not yet evidence of associated improved clinical outcome.
44,45  
For statins, genotype 
identifies a subpopulation at increased risk of specific statin-induced myopathy, for 
whom an alternative lipid-lowering therapy may be more appropriate.
46 
It is clear 
that the next generation cardiologist will increasingly rely on pharmacogenetics to 
guide therapy, often at the point of care. 
 
 
1.4 Novel gene and variant discovery 
Various different approaches have been employed to understand the genetics of 
human disease.  Historically candidate gene studies and linkage studies have been 
the mainstays of Mendelian gene discovery.  These genetic approaches follow the 
rare disease-rare variant hypothesis that rare diseases are caused by variants of 
large effect in one or a few genes
47
.  In contrast genomic approaches, such as 
association studies, are driven by the common disease-common variant hypothesis, 
that predisposition to common diseases such as hypertension
48  
is due to many 
common variants of modest effect acting in concert {Holm,  #75;Iyengar, 2007 
#277;Lander, 1996 #282;Reich, 2001 #283}. 
 
 
 
1.4.1 Candidate gene studies 
Candidate gene studies use sequencing of a small number of genes in a well- 
characterised disease group.  The frequency of rare variants (mutation burden) 
identified is compared with that of the control group and these are further classified in 
terms of likely pathogenicity.  Limitations of this kind of study are the sequencing 
capacity required and that the candidate genes are predetermined based on existing 
knowledge of disease pathobiology {Altshuler, 2008 #287;Moulik, 2009 #273;Meyer, 
2013 #274;Watkins, 2003 #275;Seidman, 2001 #276}. 
 
 
1.4.2 Linkage studies 
Linkage studies rely on linkage disequilibrium, recombination frequencies and 
genetic maps 
56
.  Genetic variants spread throughout the genome are used as 
markers for haplotypes and thus the sections of genome that segregate with the 
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condition can be followed
52
. Once the locus linked to the condition is identified it is 
sequenced to identify the causative variant.  This approach requires large pedigrees 
and/or distantly-related affected individuals, as large regions of the genome are likely 
to co-segregate by chance in small pedigrees
57
.  Sanger sequencing of areas of this 
magnitude is prohibitively costly and time-consuming, but is more accessible with 
NGS. 
 
 
1.4.3 Association  studies 
Following completion of the human genome project in 2003 
58 
and the HapMap in 
2005 
59 
a new approach became available.  The HapMap project was an 
international effort to identify and catalogue genetic variation across the genome 
between individuals in four distinct populations.  Imputation of untyped variants can 
be used to minimise the number of SNPs directly tested while maximising the 
information gained 
56
.  Genome wide association studies (GWAS) use genotyping 
chip technology, such as Affy6 SNP chip (Affymetrix), to catalogue genome wide 
variation in thousands of individuals cost-effectively and ascertain associations 
between variants and disease
60
.  The effect sizes of associations between variant 
and disease tend to be small, so initial hopes of predicting risk of heart disease by 
genotyping a handful of variants have not been realised 
33
.  Notwithstanding, a 
variant with a small odds ratio can still identify a new disease pathway and offer new 
insights into pathobiology
61
. There have been many GWAS studies in common 
cardiac conditions and cardiovascular quantitative traits 
34,62-71 
but due to the large 
cohorts required very few in ICCs and only in two DCM
72,73
.  As yet many loci have 
been mapped but few causative genes have been pinned down
74,75
.  NGS will 
facilitate re-sequencing these loci looking for the causative variants. 
 
 
1.5 Sequencing  strategies 
Since the 1970s the principal technique used for DNA sequencing was the Sanger 
method, 
76 
and this remains the gold standard for sequencing accuracy today. The 
current generation of automated high-throughput Sanger sequencing machines read 
∼2 million bases of sequence per day and were used to sequence the first human 
genome
77,78
.  This throughput is very low compared with the size of the human 
genome (haploid = 3x10
9 
base pairs), to overcome this, NGS technologies 
parallelise the sequencing process, thereby massively increasing throughput (up to 
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∼50 billion bases per day) at a reduced cost per base (Figure 1.1).   In the short term, 
Sanger sequencing will continue to be used as a complementary strategy to 
sequence genomic regions that are difficult to target in these ways (e.g., regions with 
high GC content or repetitive sequence) and also to validate NGS findings. As the 
accuracy and efficiency of targeted sequencing improves, it is anticipated that NGS 
will increasingly be used as a stand-alone technique
79
. 
 
 
Clinical laboratories face major challenges as a consequence of the high throughput 
of novel NGS approaches: optimising the use of capacity, processing and storing the 
large volumes of data and analysing the results, requiring a team of informaticians, 
statisticians, clinical scientists and clinicians 
80,81
. 
 
 
1.5.1 Target enrichment 
While NGS per-base sequencing costs are relatively low, the cost of sequencing 
entire human genomes remains high and is unnecessary for many diagnostic and 
research applications.  Unlike Sanger sequencing, NGS has no innate specificity. 
Such specificity can be achieved by preparing a library of DNA fragments for 
sequencing, typically either by pooling many PCR amplicons or by fragmenting 
genomic DNA and using sequence-specific hybridisation to select genomic regions  
of interest (Figure 1.1) 
79
. Neither approach is straightforward on the scales 
appropriate for NGS applications, though off-the-shelf target enrichment products 
that integrate well with NGS workflows are now available. Sequencing capacity can 
also be shared between several samples, by tagging each sample with a unique 
DNA “barcode”.  In this way it is possible to use a single NGS run to sequence either 
a handful of genes from many patients, or many genes from fewer patients. 
 
In brief, a library of DNA molecules for sequencing is first prepared, followed by 
ligation of a platform-specific adaptor sequence that provides the sequencing start 
point, independent of the sequence-content of target molecules. Molecules are 
clonally amplified, immobilised on a solid surface, and sequenced in parallel by 
synthesising DNA complementary to the immobilised template while observing the 
incorporation of each base by fluorescence imaging 
79
.  Clonal amplification occurs 
bound to beads in emulsion PCR (ePCR) wherein fragment library, PCR reagent and 
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beads are emulsified with oil in a ratio that promotes a single fragment binding to 
each bead. 
 
1.5.2 Whole exome sequencing 
It is estimated that protein-coding genes constitute only approximately 1% of the 
human genome but harbour 85% of the mutations with large effects on disease- 
related traits.  This makes targeted re-sequencing of all exons for an individual,  
whole exome sequencing (WES), an attractive and practical option. Off-the-shelf, 
whole exome target enrichment products lead to a flurry of publications identifying 
novel disease genes {Ng, 2009 #19;Choi, 2009 #2;Musunuru, 2010 #93;Haack, 2010 
#115;Ng, 2010 #100;Wang, 2010 #98}.  Direct sequencing of exomes has been 
shown to be an elegant and efficient way of searching for the causative gene for 
monogenic disorders 
88
. This approach combines the benefits of the candidate gene 
approach in its ability to detect all variants, including rare and novel variants, with the 
unbiased nature of whole genome association studies.   Exome sequencing is not 
without limitations. Since by its very design it targets only the coding region of the 
genome it does not afford interrogation of many variants that may be important for 
controlling gene transcriptional regulation or splicing.  Neither is it currently able to 
reliably and comprehensively represent structural variation. 
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Figure 1.1 Next generation sequencing (NGS) workflow. 
 
(A) Genomic DNA is fragmented and platform specific ‘adaptors’ are attached. The 
DNA is then either attached to a bead or directly to the sequencing slide. In either 
case, the DNA is clonally amplified in this location to provide a cluster of molecules 
with identical sequences. If beads are used they are then immobilised on a 
sequencing slide. Different NGS platforms employ different sequencing chemistries. 
(B) One approach to sequencing by synthesis, as employed by the Genome 
Analyser system (Illumina). The sequence of each fragment is read by decoding the 
sequence of fluorophores imaged at each physical position on a sequencing slide. 
Advanced optics allow for massively parallel sequencing. (C) Each DNA molecule 
yields one or two sequence fragments depending on whether it is sequenced from 
one or both ends. These sequence fragments are computationally aligned with a 
reference sequence and mismatches identified. 
Reproduced from Ware, Roberts & Cook 
79
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1.5.3 RNA-sequencing 
Sequenced based approaches to determine the cDNA sequence initially involved 
Sanger sequencing of cDNA or expressed sequence tag (EST) libraries which was 
low throughput, costly and generally not quantitative.  RNA-sequencing has benefited 
from the advent of NGS technologies in line with DNA sequencing, and                 
NGS experiments follow the same principle as for DNA.  In brief, a population of RNA 
(typically poly(A)+ enriched) is converted to a library of cDNA fragments with   
platform specific adaptors attached.  Each molecule, with or without amplification, is 
then sequenced on an NGS platform to obtain sequences from both ends (pair-end 
sequencing).  The resulting sequence reads are typically aligned with the reference 
genome or transcriptome, and classified as three types: exonic reads, junction reads 
and poly(A) end-reads. These three types are used to generate a base-resolution 
expression profile for each gene 
89
. Current RNA-seq technologies and analysis tools 
provide the ability to asses novel genes, alternatively spliced transcripts, post- 
transcriptional modifications, gene fusion, mutations/SNPs and changes in gene 
expression without relying on prior annotations 
90
. 
 
 
1.5.4 Publically available control cohorts 
Large publicly available control cohorts are an invaluable resource for investigating 
the differences in variant burden and type in case control studies.  These data can 
be used to prioritise a list of candidate genes or to estimate the probability of 
pathogenicity of variants.  Two well known examples are detailed below. 
 
1.5.4.1 NHLBI GO Exome Sequencing Project (ESP) 
The National Heart, Lung and Blood Institute (NHLBI)-funded ESP 
(esp.gs.washington.edu) is one of the largest medical sequencing studies ever 
undertaken.  The group includes some of the largest well-phenotyped populations in 
the United States, representing more than 200,000 individuals altogether from the: 
Women's Health Initiative (WHI), Framingham Heart Study (FHS), Jackson Heart 
Study (JHS), Multi-Ethnic Study of Atherosclerosis (MESA), Atherosclerosis Risk in 
Communities (ARIC), Coronary Artery Risk Development in Young Adults (CARDIA), 
Cardiovascular Health Study (CHS), Lung Health Study (LHS), COPD Genetic 
Epidemiology (COPDGene), Severe Asthma Research Project (SARP), Pulmonary 
Arterial Hypertension population (PAH), Acute Lung Injury cohort (ALI), Cystic 
Fibrosis cohort (CF), PennCATH, Cleveland Clinic Genebank, Massachusetts 
35  
General Hospital Premature Coronary Artery Disease Study (MGH PCAD), Heart 
Attack Risk in Puget Sound (HARPS), and Translational Research Underlying 
Disparities in Myocardial Infarction Patients' Health Status (TRIUMPH).  The current 
version dataset is comprised of a set of 2203 African-American and 4300 European- 
American unrelated individuals, totalling 6503 samples (13,006 chromosomes).  The 
frequency counts of specific variants are released without linked phenotype 
information. 
 
 
1.5.4.2 1000 Genomes project (1KG) 
The goal of the 1000 Genomes Project (www.1000genomes.org) is to identify the 
majority of genetic variants, including structural variation, that have frequencies of at 
least 1% in the populations studied.  The samples are mostly anonymous and have 
no associated medical or phenotype data.  The pilot study included three projects: 
low-read depth whole-genome sequencing of 179 individuals from four populations; 
high-read depth sequencing of two mother–father–child trios; and exon-targeted 
sequencing of 697 individuals from seven populations.  The plan for the full project is 
to sequence about 2,500 samples at 4x read depth 
91,92
. 
 
 
1.5.5 Delineation and interpretation of variants 
To assign pathogenicity to a novel variant, particularly in a gene or pathway not 
previously associated with a given disease requires two levels of evidence.   First, is 
the variant predicted or proven to alter structure, function, expression or stability of 
the gene product?  Secondly if there is a discernable effect on the protein, does this 
lead to disease?  The following in silico tools can aid in prediction of the impact of a 
variant, but confirmation requires additional tissue or animal model studies. 
 
 
1.5.5.1 Tools useful is assessing pathogenicity of novel variants in known 
disease genes 
SIFT (sift.jcvi.org), Polyphen2 (genetics.bwh.harvard.edu/pph2) and Condel 
(bg.upf.edu/group/projects/condel.php) can be used to predict the effect of variation 
on protein function by amino acid substitution.   SIFT (sorts intolerant from tolerant) 
predicts whether an amino acid substitution affects protein function, based on the 
degree of conservation of amino acid residues in sequence alignments derived from 
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closely related sequences.  PolyPhen-2 (Polymorphism Phenotyping v2) is a tool 
which predicts possible impact of an amino acid substitution on the structure and 
function of a human protein using sequence, phylogenetic and structural information. 
Condel (Consensus deleteriousness score of missense SNVs) computes a weighed 
average of the scores  of five known computational tools (SIFT, Polyphen2, MAPP, 
LogR Pfam E-value and Mutation Assessor) aimed at classifying missense  
mutations as likely deleterious or likely neutral. 
 
 
1.5.5.2 Tools useful in assessing novel candidate genes 
GeneCards (www.genecards.org) is a searchable, integrated, database of human 
genes that provides concise genomic related information, on all known and predicted 
human genes. The GeneCards human gene database extracts and integrates a 
carefully selected subset of gene related transcriptomic, genetic, proteomic,  
functional and disease information, from dozens of relevant sources 
 
UniProt (www.uniprot.org) is a comprehensive, high-quality and freely accessible 
resource of protein sequence and functional information.  It includes complete and 
reference proteome sets. The protein knowledgebase, UniProtKB, consists of two 
sections: Swiss-Prot, which is manually annotated and reviewed; and TrEMBL, 
which is automatically annotated and is not reviewed. 
 
The Basic Local Alignment Search Tool (BLAST) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) finds regions of local similarity between 
sequences. The program compares nucleotide or protein sequences to sequence 
databases and calculates the statistical significance of matches. BLAST can be used 
to infer functional and evolutionary relationships between sequences as well as help 
identify members of gene families. 
 
IntAct (www.ebi.ac.uk/intact) provides a freely available, open source database 
system and analysis tools for protein interaction data. All interactions are derived 
from literature curation or direct user submissions and are freely available. 
 
ELM (www.elm.eu.org) is a computational biology resource for investigating 
candidate functional sites in eukaryotic proteins. ELM provides core functionality 
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including filtering by cell compartment, phylogeny, globular domain clash (using the 
SMART/Pfam databases) and structure. In addition, both the known ELM instances 
and any positionally conserved matches in sequences similar to ELM instance 
sequences are identified and displayed. 
 
Coexpresdb (http://coxpresdb.jp) uses microarray expression data to provide co- 
regulated gene relationships to estimate gene functions. 
 
STRING (www.string-db.org) is a database of known and predicted protein 
interactions.  The interactions include direct (physical) and indirect (functional) 
associations; they are derived from four sources: genomic context, high-throughput 
experiments, (conserved) co-expression, and previous knowledge.   STRING 
quantitatively integrates interaction data from these sources for a large number of 
organisms, and transfers information between these organisms where applicable. 
 
 
1.6 DCM as a disease of the cardiac myocyte 
 
1.6.1 Overview of cardiac muscle and contractile function 
The myocardium is involuntary striated muscle composed primarily of  
cardiomyocytes which exist in a complex network of endothelial cells, vascular 
smooth muscle, fibroblasts and immune cells.    Gap junctions electrochemically 
coordinate contraction at the level of the cardiomyocyte and through connection to 
the extracellular matrix transduce force and coordinate contraction at the organ level 
93
. The proteins of the cardiomyocyte can be broadly categorised as contractile, 
sarcomeric skeleton, membrane associated and proteins of the intercalated disk 
94
. 
The sarcomere is the basic repeating contractile unit of muscle and is formed by an 
array of overlapping thin and thick filaments which respond to calcium to coordinate 
contraction and relaxation of the heart 
95 96
. 
 
The sarcomere is demarcated at each end by a Z-disk and in the centre by the M- 
line.  The Z-disk is a complex of ordered filaments, crosslinks and anchored proteins 
with diverse functions including signalling and transmission of tension during 
contraction
97-99
.  Similarly the M-line is responsible both for the regular packing of 
thick filaments and the uniform distribution of tension 
100 101
. The region of the 
sarcomere containing the Z-disk and thin filaments is the I-band, and the remaining 
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region containing the M-line is the A-band.  The primary component of the thin 
filament is actin, monomers of which polymerise into an elongated filament of double 
helical strands constructed upon the filamentous protein nebulin.  Tropomyosin, a 
coiled-coil protein, polymerises along the actin filament and situates in the groove 
between the actin strands. A troponin complex comprised of Troponins C, I and T 
associates with each tropomyosin subunit 
102
.  The main component of the thick 
filament is myosin. The complete myosin molecule is composed of six polypeptide 
chains consisting of two heavy chains, and two pairs of different light chains, the 
essential and the regulatory light chains.  Myosin aligns with titin and myosin binding 
protein C to form the thick filament 
102
.  Myosin has a long tail and a globular head, 
the direction of the myosin heads change polarity at the M-line, allowing interaction 
with the thin filaments anchored from the next adjacent Z-disk 
95
. 
 
T- tubules, deep invaginations of the sarcolemma, track laterally to the Z-disks and 
pair with a terminal cisterna of the sarcoplasmic reticulum at the Z-disk to form a 
diad, facilitating excitation-contraction coupling upon which cardiac contraction is 
dependant.  The initial action potential at the sarcolemmal membrane stimulates an 
influx of ions through L-type calcium channels, in turn triggering calcium-induced 
calcium release from the sarcoplasmic reticulum and a marked rise in intracellular 
calcium.   This calcium is bound by troponin C, thus altering thin filament protein 
interactions and allowing formation of strong cross bridges between actin and 
myosin.  The myosin head acts as a lever; hydrolysis of ATP produces force and the 
relative movement of myosin along actin, thus shortening the sarcomere. 
Subsequent release from Troponin C and re-sequestration of calcium in the 
sarcoplasmic reticulum allows relaxation 
102
. 
 
 
1.6.2 Mechanisms underlying heart failure in DCM 
DCM is associated with ventricular remodelling, a complex multimechanistic process 
characterised by alteration in ventricular size, shape and function following cardiac 
injury.  The process is linked to the activation of various neurohormonal, paracrine 
and autocrine factors and influenced by haemodynamic load and wall stress. 
Cardiac remodelling is driven on a histologic level by myocyte hypertrophy and 
apoptosis, fibroblast proliferation and interstitial fibrosis 
103
. 
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The histological changes associated with DCM are frequently non-specific and not all 
features may be present, but classically include myocyte hypertrophy, myocyte 
atrophy, and increased fibrosis 
104-107
.  Immunohistological examination may reveal 
interstitial and perivascular inflammatory cell infiltrates 
108,109
. Ultrastructural changes 
include myofilament depletion, enlarged and bizarrely-shaped nuclei, proliferation of 
T- tubules, and accumulation of lipid droplets and glycogen 
105
. 
 
Energy deficiency is a key concept in heart failure. The heart requires a large   
amount of energy to sustain both cellular homeostasis and contraction. Energy in the 
form of ATP synthesised in the mitochondria can be derived from a variety of 
substrates, such as glucose, fatty acids, amino acids and lactate. In the healthy  
heart, the preferred energy substrate is free fatty acids and phosphocreatine is the 
main reserve source of ATP during acute stress. During the initial compensatory 
stages of cardiomyopathy, substrate utilization continues to favour free fatty acids, 
which yield about three times more ATP than glucose but require more oxygen to 
metabolize 
110 111
.  As pathogenesis progresses in cardiomyopathy, the demand for 
ATP increases, and the levels of phosphocreatine are progressively depleted 
112
. 
During progression to decompensated heart failure energy substrate utilization shifts 
from fatty acid oxidation to glucose utilization, a less efficient means of producing 
energy 
113-115
. When the failing heart becomes energy deficient it can no longer 
sustain cellular homeostasis; the disturbance of energy metabolism, contractile 
function and gene expression can trigger programmed cell death 
111 116,117
. 
 
All three types of cell death are important in heart failure: apoptosis, necrosis and 
autophagic cell death 
118 119
.  Apoptosis is characterized by cell shrinkage and 
fragmentation into membrane enclosed apoptotic bodies that are phagocytosed. 
Plasma membrane integrity and organelle (e.g. mitochondrial) morphology are 
maintained until late in the process, and inflammation is avoided.  Apoptosis is rare 
in normal human myocardium but marginally elevated in failing hearts 
120
.  Given the 
limited ability for cardiac myocytes to proliferate it has been postulated that the rate 
of apoptosis seen in failing hearts can be an important component of HF 
pathogenesis 
121
. 
 
Necrosis has traditionally been regarded as passive and unregulated, however 
studies indicate that it is also regulated in some instances. The defining features of 
40  
necrosis are defective plasma and organelle membranes, cell and organelle   
swelling, severe ATP depletion, and marked inflammation 
122
.   Distinct, but highly 
overlapping central pathways mediate apoptosis and necrosis. The extrinsic pathway 
involves cell surface death receptors and the intrinsic pathway uses the mitochondria 
and endoplasmic reticulum. These pathways, which mediate both apoptosis and 
necrosis, are linked by multiple biochemical and functional connections
123
.  Although 
not extensively explored, initial studies suggest a role for programmed necrosis in   
the pathogenesis of heart failure 
124 125
. 
 
Autophagy is a cell survival mechanism that involves degradation and recycling of 
cytoplasmic components. This provides energy during periods of starvation and 
stress, a means for the disposal of long-lived proteins, and a mechanism for protein 
quality control
126
. Autophagy may mediate cell death under specific circumstances. A 
recent study indicated that upregulation of autophagy in the failing heart may also 
represent an adaptive response
127
. 
 
 
1.7 Titin structure and function in the cardiomyocyte 
TTN is the largest protein in the human body and plays a key role in the sarcomere. 
Several isoforms ranging in size from 5,604 to 34,350 aa are produced from among 
the 364 exons of the single TTN gene which undergoes extensive alternative 
splicing.  TTN is highly modular with ~90% of it’s mass composed of repeating 
immunoglobulin (Ig) and fibronectin-III (FN-III) domains.  The remaining ~10% 
consists of 17 unique, non-repetitive sequence motifs (situated between the Ig and 
FN-III modules) that contain several phosphorylation sites, PEVK motifs and a 
carboxy terminal kinase domain 
128
.  Two TTN filaments with opposite polarity span 
each sarcomere along its longitudinal axis forming a contiguous system within 
myofibrils.  At its N terminus TTN is embedded in the Z-disk of the sarcomere and is 
important in myofibril assembly, stabilization and maintenance
129
.  The elastic I-band 
region behaves as a bidirectional spring, restoring sarcomeres to their resting length 
after systole and limiting their stretch in early diastole
130
.  The inextensible, thick 
filament binding A-band region is thought to be critical for biomechanical sensing and 
signalling and contains the TTN kinase domain 
131,132
.  The kinase domain in 
particular may play a role in strain sensitive signalling and communication with the 
nucleus, which may effect gene expression and cardiac remodelling in DCM
133,134
. 
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The major isoforms expressed in the adult myocardium are the long N2BA isoform, 
which contains the N2A and N2B unique segments, and the short N2B isoform that 
contains the N2B unique segment only.  The two isoforms differ primarily in the I- 
band region; N2B TTN being shorter due to fewer Ig domains, a much smaller PEVK 
segment and absence of the N2A unique segment.  TTN N2B and N2BA are co- 
expressed at the level of the half sarcomere (Z-disk to M-band).  The force required 
to stretch a TTN molecule is non-linearly related to it’s fractional extension135.  For a 
given sarcomere length N2B will have greater fractional extension than the longer 
N2BA and thus N2B is stiffer
134
.  The co-expression ratio of TTN within the heart is 
not fixed but varies within and between the chambers.  The atria typically express a 
greater proportion of N2BA, and transmural gradients exist across the LV wall with 
higher expression of N2BA toward the endocardium
136
. Titin isoform shifts have been 
reported in several diseases.  Isoform shift toward a higher N2BA/N2B ratio is 
typically seen in DCM 
137
. 
 
 
1.8 Titinopathies 
 
1.8.1 Dominant titinopathies are adult onset and affect either cardiac or 
skeletal muscle but not both 
Titin was first associated with human disease in 1998 with the assignment of the 
tibial muscular dystrophy (TMD) locus to chromosome 2q31 
138 139 
by linkage 
analysis in four Finnish kindreds who all shared a common core haplotype. 
However, the first pathogenic variants in the TTN M-band were not identified for 
another three years 
140
.  TMD is an autosomal dominant late-onset distal myopathy 
with weakness and atrophy usually confined to the anterior muscles of the lower leg. 
The typical symptom of ankle dorsiflexion weakness usually presents in the 4
th 
to 7
th 
decade and walking ability is preserved.  The vast majority of cases occur in the 
Finnish population due to a founder mutation (FINmaj) in Mex6, the last exon in TTN. 
This complex 11bp variant close to the C-terminus changes four well conserved 
amino acids in the hydrophobic core of the M10 domain of M-line titin and disrupts 
calpain-3 binding in the M-band 
140
. It is noteworthy that Calpain-3 is not expressed 
in the mature myocardium 
141
. The calpains, or calcium-activated neutral proteases, 
are nonlysosomal intracellular cysteine proteases.  Calpain-3 is a muscle specific 
form and appears to have a very rapid turnover mediated by autocatalysis, possibly 
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reflecting the need for precise regulation of its activity.  Mutations on CAPN3, the 
gene encoding Calpain-3, lead to limb girdle muscular dystrophy LGMD2A. 
Histochemical analysis demonstrated specific loss of the C-terminal TTN epitopes in 
TMD muscle samples.  A French family with TMD was also found to have a single 
base change in the same Mex6 exon co-segregating with disease
140 142
. 
Interestingly one of the first large families used for linkage analysis was 
consanguineous and a minority of patients in that family had a severe limb-girdle 
muscular dystrophy (LGMD2J) and were homozygous for the FINmaj variant. 
Although initially classified as recessive these rare cases are best described as the 
homozygous manifestation of a dominant variant which manifests in heterozygotes 
with full penetrance as TMD. 
 
Shortly after the TMD locus was mapped to 2q31, this locus was also reported as the 
7
th 
familial DCM locus (CMD1GI) in a large Native American kindred with AD 
transmission of progressive, early onset DCM without rhythm disturbance 
143
. DCM 
was non-penetrant in two obligate carriers.  Although TTN was the obvious 
candidate gene, only the cardiac-specific N2B unique sequence was examined and 
no variants were found to segregate with disease.  The authors concluded that 
‘although a mutation in other regions of this massive sarcomere protein have not 
been excluded, a defect located in titin domains that are expressed in all muscles 
would most likely cause both skeletal and cardiac dysfunction [and] that the 
likelihood of a disease causing mutation elsewhere in titin sequences is low’.  In 
2002 the causative variant in this family was identified as a missense mutation in 
exon 18 of TTN leading to substitution of tryptophan for arginine in the hydrophobic 
core of the Ig-Z4 region which, being located in the Z-disc – I-band transition zone, 
was hypothesised to be a key region for organisation of the Z-disc 
144 145
.  In a 
second large pedigree, the authors also reported a 2bp insertion in TTN exon 326 
leading to a stop codon 4 aa downstream of the frameshift co-segregating with DCM 
without conduction disease following linkage mapping to 2q31. 
 
Itoh-Satoh et al used a candidate gene approach and sequencing limited to Z-disc 
coding exons of TTN (exons 2-16) and the cardiac specific N2B unique sequence in 
120 unrelated Japanese patients with DCM.  Seven TTN coding variants were 
identified, three of which were also seen in healthy controls and deemed benign
146
. 
Two of the DCM variants were found in the Z-disc: a missense variant in exon 14 co- 
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segregated with arrhythmogenic DCM in one family and a second missense variant 
in exon 3 was found in a patient with familial DCM, but without affected living 
relatives for segregation analysis.  The Z-disc missense variants were found to 
reduce the binding of alpha-actinin and T-cap respectively in yeast 2 hybrid assays. 
Within the N2B sequence two patients were found to have missense variants not 
seen in controls but familial samples were not available for segregation analysis. 
 
It was not until the advent of high throughput sequencing and target capture 
technologies that a comprehensive study of TTN in human disease was undertaken. 
In 2012, Herman et al published a report detailing the sequencing of TTN in an 
unprecedented 312 DCM patients, 231 HCM patients and 249 control subjects
17
, 
Filter-based hybridization target capture followed by NGS or Sanger sequencing was 
used to analyse TTN coding exons corresponding to the UniProt Q8WZ42-1  
transcript (equivalent to N2BA).  Three DCM cohorts (group A, n= 92; group B, n=71; 
& group C, n=149) enriched for severe and familial DCM, and cases where 
pathogenic mutation in other DCM genes had been excluded, were studied. Variants 
predicted to truncate TTN were identified in up to 25% of DCM subjects. 
Interestingly the proportion of subjects with variants predicted to truncate the TTN 
protein was higher in subjects which were studied by NGS (groups A and B, 23% 
and 20% respectively) than among the subjects in group C studied by Sanger 
sequencing (8%), leading the authors to postulate that the detection of mutations 
was better with the NGS strategy than with Sanger sequencing.  In this study the 
frequency of TTN truncating variants identified in subjects with HCM and in controls 
was similar (1% and 3%, respectively; P=0.34). In addition, each subject with HCM 
who had a TTN variant also had a pathogenic mutation in an established HCM gene, 
suggesting that TTN truncations are at most a rare cause of HCM.  In DCM cases,  
no significant differences were observed between subjects with and those without 
TTN truncating mutations with respect to the age at diagnosis, left ventricular end- 
diastolic dimensions, ejection fraction, or rates of cardiac transplantation, implantation 
of a left ventricular assist device, and death from cardiac causes. 
However, men with TTN mutations had adverse events at significantly earlier ages 
than did women. 
 
Spurred on by the mounting advances in DCM genetics a combination of exome 
sequence filtering and linkage analysis was used to prioritise a genetic cause for 
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DCM in 48 individuals from 17 families with at least three affected members, 
depleted for pathogenic variants in 16 known DCM genes
147
.  Missense variants 
were filtered against ESP exome data (frequency >0.5%, and either a PhastCons 
score >0.4 or a GERP score of >2).  A total of six TTN truncating variants (two 
frameshift, three nonsense, and one splice site variant that occurred in two families) 
were identified in seven families (41%).  Family B and D also carried rare missense 
TTN variants that also segregated with disease and although phasing was not 
explicitly discussed it is likely that the truncating and missense variants are in phase 
in these families given their co-segregation in affected members.  Families A, B, C 
and D had at least one obligate carrier with a non-penetrant or intermediate 
phenotype.  Two additional families carried TTN truncations that did not segregate 
with DCM:  A frameshift mutation in family 14 was present in only one of three 
affected members but a PSEN variant previously published with functional data 
supporting pathogenicity fully segregated with disease in this family; a nonsense 
variant in family 17 was present in two of three affected family members, but 43 
other coding variants were found to segregate fully with disease.  The authors 
surmised that these non-segregating TTN truncations may be ‘susceptibility 
variants’, however the presence of another pathogenic variant does not preclude 
pathogenicity. In this study TTN was the only gene implicated with rare variants in 
multiple DCM families replicating previous findings that TTN truncations are a 
frequent cause of DCM.  No functional data was presented. 
 
Satoh et al have not limited their studies to DCM.  The group also identified a 
missense variant in exon 14 in the TTN Z-disc that increased binding affinity of 
alpha-actinin in a patient with HCM 
148
, and a N2B missense variant co-segregating 
with HCM in two sisters.  Lopes et al 
149 
took advantage of NGS capacity and the 
recent availability of sequence data sets for large control cohorts to statistically 
compare the burden of rare variants in a panel of HCM genes between 180 
Caucasian HCM cases and 1,287 Caucasian controls from the UK10K cohort.  While 
this approach cannot speak to the pathogenicity of a given variant, it provides insight 
into the role of a given gene or genes in disease.  The panel comprised 20 genes, 
including TTN, known to be associated with HCM and DCM and 17 genes   
associated with other cardiomyopathies and arrhythmia syndromes.  11 patients  
(6%) carried potential loss of function TTN variants (10 truncations and one 
previously published missense) of which four where compound with likely pathogenic 
45  
HCM gene variants, two were compound with a variant of unknown significance 
(VUS) in desmosomal or ion channel genes, and five were the sole candidate variant 
(3%) giving a frequency comparable to previous publications 
17
. 13% of patients 
carried rare missense TTN variants in isolation, 10% compound with a desmosomal 
or ion channel VUS, and 77% compound with a likely pathogenic HCM gene variant, 
making the frequency of these rare missense TTN variants lower in HCM than in 
controls.  The authors postulate this may be because ‘the annotation of titin variants 
is made extremely complex by the large number of possible isoforms/transcripts 
which are not accounted for in existing databases’. 
 
In a series of 38 ARVC families depleted for desmosomal gene variants seven 
families (18%) carried novel missense variants in TTN
150
, a frequency below that of 
controls.  One variant, in exon 37, predicted to disrupt a highly conserved Ig-10 
domain in the I-band segregated with disease in a large family comprising eight 
affected individuals.  Gel electrophoresis, nuclear magnetic resonance, intrinsic 
fluorescence and proteolysis assays suggested the variant reduces the structural 
stability and increases proteolysis of the Ig-10 domain.  Full segregation data and 
functional studies were not reported for the remaining six variants. 
 
Hereditary myopathy with early respiratory failure (HMERF) was described in 7 
families from Sweden in 1990 and typically involves adult-onset proximal-distal 
weakness and respiratory failure in an ambulant patient.  Muscle weakness is 
variable, but MRI shows a pathognomic pattern of muscle involvement. Linkage 
initially mapped the locus to 2q31.  Currently identified families all carry missense 
mutations in TTN exon 343 encoding the fibronectin-like FN3 119 domain of the A- 
band. The most frequent mutation occurs on a common haplotype in pedigrees from 
across Europe suggesting a founder effect. The founder mutation shows a semi- 
dominant inheritance pattern with subclinical myopathy in the heterozygous parents 
153. 
 
 
1.8.2 Recessive titinopathies have diverse phenotypes and typically involve 
the M-band. 
Core-myopathies (CM), the most common form of inherited non-dystrophic childhood 
muscle disorder, are defined by areas of mitochondria depletion and sarcomere 
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disorganisation in muscle fibres.  They are phenotypically and genetically 
heterogeneous and may be autosomal dominant or recessive; in the latter case they 
are known as multi-minicore disease (MmD).  Early-onset myopathy with fatal 
cardiomyopathy (EOMFC), a sub-type of MmD, represents the first titinopathy 
reported involving both skeletal and cardiac muscle. EOMFC was localised to 2q31 
in two consanguineous families each carrying homozygous frameshift variants in the 
M-band downstream of the kinase domain (exon 358, Mex1 and exon 360, Mex3) 
151
. Skeletal muscle biopsies showed minicore lesions, centrally located nuclei and/or 
dystrophic lesions.  All children presented with congenital muscle weakness and 
childhood onset DCM with marked rhythm disturbance. Sudden death occurred in 
four of the five children before age 20, a fifth child underwent heart transplantation at 
age 15 years.  Immunofluorescence data suggested the truncated TTN protein 
incorporated into the sarcomere despite complete loss of the C-terminal epitopes 
located downstream of both deletions.  All heterozygote parents were asymptomatic. 
 
Most recently, homozygous and compound heterozygous TTN mutations were 
identified in four families in a cohort of 23 families with congenital MmD of varying 
severity in conjunction with a range of primary heart disease.  Family 1 was 
consanguineous and both affected siblings were homozygous for a frameshift 
mutation in Mex2, which leads to deletion of the terminal 522 amino acids.  Both 
siblings presented at two years with moderate muscle weakness.  Echocardiography 
detected mild DCM in one sibling age 19 years but was normal in his younger  
brother age 16 years.  In family two the proband presented at birth with an  
atrioseptal defect which resolved spontaneously, then developed moderate DCM  
with rhythm disturbance aged 16 years.  Her skeletal phenotype resembled Emery- 
Dreifuss muscular dystrophy (EDMD) but screening of the LMNA and FHLI genes 
associated with EDMD was negative.  She was found to carry compound 
heterozygous nonsense mutations in Mex1.  In family three, the proband presented 
with atrioseptal and ventriculoseptal defects requiring surgical repair and developed 
end-stage DCM requiring transplantation and rhythm disturbance aged 13.  His 
skeletal muscle phenotype is mild and stable.  He was found to carry a nonsense 
mutation within the TTN kinase domain leading to loss of 100 amino acids from the 
kinase domain along with 1,963 C-terminal amino acids.  He additionally carries a 
missense variant in exon 316 predicted to impact an Fn3 domain at the C-terminal 
end of the I-band. At the most severe end of the spectrum, in family four, the 
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proband presented with distal arthrogryposis multiplex congenita, congenital muscle 
weakness, kyphosis and neonatal heart failure due to left ventricular non-compaction 
(LVNC) and a ventriculoseptal defect.  He carried a single nucleotide deletion in the 
splice donor site 5’ of exon 38 in the I-band that was demonstrated to lead to use of 
an alternative splice-donor site (36% of reads) leading to truncation of TTN after the 
2950 N-terminal amino acids.  A truncated TTN protein of the size predicted was 
confirmed on gel electrophoresis.  In addition he carried a missense mutation in the 
highly conserved core of the TTN kinase active site.  In vitro studies suggest this 
mutation causes complete loss of function of the TK, thus the patient has no 
functioning TK, the other allele being truncated proximally.  In this small series all 
heterozygous parents were asymptomatic suggesting truly recessive disease, and 
the cardiac phenotype seems to correlate with distance of the mutation from the C- 
terminus such that, within the M-band, the more C-terminal mutations had a milder 
phenotype. 
 
Centronuclear myopathies (CNM) are a diverse group of clinically and genetically 
heterogeneous muscle disorders defined by the presence of internalised nuclei in 
myofibers without excessive regeneration or structural abnormalities.  Classic CNM 
genes encode proteins involved in excitation-contraction coupling at the triad. 
Exome sequencing in 29 unrelated CNM patients without mutations in classic CNM 
genes identified compound heterozygote truncating TTN mutations and in-frame 
insertions/deletions in five patients (17%) 
152
.  Biochemical analyses demonstrated 
increased TTN degradation and truncated TTN protein in patients’ muscles.  All 
patients presented by the age of three years with muscle weakness.  One patient 
had a mild muscular ventriculoseptal defect, there were no other cardiac 
abnormalities but the age at last follow up ranged from five to 19 years. 
Interestingly, mutations were dispersed throughout the I-band, A-band and M-band, 
whereas previously reported recessive titinopathies were restricted to the M-band. 
Only one patient carried 2 truncating variants, an A-band nonsense mutation 
(exon275) and an M-band frameshift (exon 312).  Four patients carried an inframe 
insertion/deletion or predicted splice variant as the second variant. Two mutations 
were previously described: one French TMD mutation inherited from the patients 
father in whom no abnormality was found on detailed cardiac and muscle 
examination age 44 years, and one I-band splice variant previously described in 
DCM, inherited from the probands mother who was asymptomatic but found to have 
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mild skeletal and cardiac myopathy on examination.  Parents carrying the remaining 
variants were not examined and so it remains to be seen if these are truly recessive 
mutations or the manifestation of compound heterozygote dominant mutations 
similar to LGMD2J. 
 
 
1.8.3 Titin copy number variation 
Manolakos et al
154 
described a novel microdeletion of 2q31.2 – 2q31.3 
encompassing the whole TTN gene and reviewed the literature including four other 
microdeletions encompassing TTN {Manolakos, 2011 #435;Mitter, 2010 
#437;Prontera, 2009 #439;Rifai, 2010 #438}.  Patient ages ranged from two to 36 
years and common features included premature delivery (3/5 cases), hypotonia (2/5 
cases), growth retardation, developmental delay and dysmorphic facies in all cases. 
Cardiac phenotype was notably absent, although only one adult patient was 
reported. 
 
 
1.8.4 Titin animal models 
Invertebrates such as drosophila and C.elegans do not possess a single protein 
equivalent to full length TTN that span the Z-disk, I-band, A-band and M-line regions 
of the sarcomere.  Rather, a TTN-like gene encodes the Z-disk and I-band regions 
and other genes such as stretchin, twitchin and projectin encode the A-band and M- 
line regions. 
 
Zebrafish have two TTN orthologues, ttna and ttnb, located in a tandem array on 
chromosome 9.  Both ttna and ttnb are highly orthologous to human TTN and  
encode peptide sequences corresponding to all regions of the sarcomere.  As such it 
is believed that zebrafish represent the simplest model organism that contains TTN 
molecules equivalent to full length human TTN.  The primary site of divergence of  
ttna and ttnb from human TTN is in the I-band which is heavily alternatively spliced. 
ttna but not ttnb is required for cardiac sarcomere assembly and establishment of 
cardiac contractility 
158
.  ttna is not required for assembly of the Z-bodies or thick 
filaments during early sarcomereogenesis but is required for the lateral growth of Z- 
bodies to form Z-disks and the registration of thick filaments to form the A-bands. 
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The zebrafish is an excellent model for TTN cardiomyopathy.  As oxygen is delivered 
via diffusion rather than the cardiovascular system the zebrafish embryo can tolerate 
absence of circulation, enabling dissection of the effect of the gene from the 
secondary effect of hypoxia. 
 
Mutagenesis screening identified TTN as the gene for pickwick, a group of zebrafish 
mutants wherein the heart develops normally but is poorly contractile from the first 
beat 
159
.  pickwickm171 (pik
m171 
) is a recessive lethal mutation in the N2B exon of 
ttna.  Three other alleles (pik
m242
, pik
m740
, pik
m186
) share the cardiac phenotype and 
one (pik
mVO62H
) has additional skeletal muscle involvement. The pik
m171 
cardiomyocytes are thin but do contract.  Transplantation of mutant cells into  wildtype 
hearts confirmed that cellular thinning is cell-autonomous and not   secondary to 
factors such as dysregulation of hypertrophic signals associated with low systolic 
pressure.  Nascent myofibrils form in pik mutants but normal sarcomeres are absent. 
 
There are several murine titinopathy models.  Muscular dystrophy with myositis 
(mdm) is a complex rearrangement comprising and inframe deletion within the N2A 
sequence, and an inframe insertion of a LINE element 
160
. Heterozygote Ttn
mdm 
mice 
are phenotypically normal while homozygotes display progressive muscle 
degeneration with wasting of proximal and distal muscles.  The mutation disrupts a 
putative Calpain-3 binding site.  Since the FINmaj mutation in TMD and LGMD2J 
disrupts a Calpain-3 binding site, and mutations in CAPN3, the gene encoding 
Calpain-3, cause limb girdle muscular dystrophy LGMD2A in humans it is proposed 
that the Ttn
mdm 
mutation may cause disease via disruption of Calpain-3 binding. 
 
 
The molecular pathogenesis of the FINmaj mutation was explored through  
production of a mouse model via a knock-in strategy 
161
.  The model recapitulates 
human FINmaj pathology in that in heterozygotes develop dystrophic features limited 
to specific muscles at a late stage similar to TMD, whereas homozygotes have  
earlier onset of a more severe phenotype affecting a larger number of muscles  
similar to LGMD2J.  However unlike humans the homozygous mice exhibit a dilated 
cardiomyopathy with left ventricular dysfunction and fibrosis. Loss of the C-terminal 
end of the protein in this model is associated with secondary Calpain-3 instability in 
both heterozygotes and homozygotes.  Reduction of the quantity of calpain-3 by 
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interstrain crossing with a calpain-3 deficient model revealed that the heterozygote 
FINmaj phenotype was rescued by reduction of calpain-3 but in the homozygote 
neither the cardiac nor the skeletal phenotype was ameliorated suggesting different 
pathophysiologies for these two allelic conditions. 
 
Also exploring the effects of M-line mutations, Gotthard et al used a conditional 
knock-out approach to selectively delete exons MEx1 (encoding the kinase domain) 
and MEx2 (to maintain the reading frame) in cardiac and skeletal muscle during 
development 
162
.  Excision of MEx1–2 from cardiac TTN during development leads to 
absence of homozygous offspring, suggesting a critical role for MEx1–2 in heart 
development.  Ultrastructural analyses indicate incorporation of mutant Ttn into 
sarcomeres and subsequent sarcomere disassembly.  Sarcomeres of knock out 
animals had widened, pale M-lines devoid of M-line bridges and MURF-1.  In 
contrast, the skeletal muscle specific knock out generated live homozygous offspring 
at the expected Mendelian ratios, affected by early and progressive muscle 
weakness.  Progressive sarcomere disassembly and loss of MURF-1 and myomesin 
binding was observed but unlike cardiac sarcomeres M-line widening was absent 
163
. 
To distinguish a role in sarcomere assembly from a role in stabilizing pre-existing 
sarcomeres and to address potential non-muscle functions, the same authors 
converted the conditional M-line Ttn knockout into a complete knockout using 
germline recombination 
164
.  They demonstrated that initial assembly of the  
sarcomere does not depend on the M-line region of Ttn nor the phosphorylation of T- 
cap by the Ttn kinase. Rather, M-line Ttn is required to form a continuous Ttn 
filament and to provide mechanical stability of the embryonic sarcomere. Even 
without integration of Ttn into the M band, sarcomeres show proper spacing and 
alignment of Z discs and M bands but fail to grow laterally, and ultimately 
disassemble. 
 
Functional effects of the dominant 2bp insertion (c.43628insAT) co-segregating with 
DCM in a large pedigree following linkage mapping to 2q31 
144 
were explored in a 
knock-in mouse model 
165
.  The mutation in Ttn exon 326 leading to a stop codon 4 
aa downstream of the frameshift truncates Ttn within the A-band region.  Loss of Ttn 
in homozygous mice lead to early embryonic lethality.  Electron microscopy of the 
myocardium demonstrated severe defects in sarcomere assembly with absence of 
striations.  Heterozygous mice showed normal cardiac structure and function, 
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however they developed a severe stress-induced cardiomyopathy when exposed to 
angiotensin II or isoproterenol.  Although both Ttn alleles were stably expressed at 
the mRNA level in heterozygote hearts, truncated Ttn protein was only detected at 
very low levels (1%) suggesting posttranslational degradation or modification of the 
mutant protein.  Incorporation of the mutant protein into the sarcomere was not 
confirmed or excluded.  Interestingly the authors also observed elevated 
transcription of the wild type Ttn allele in heterozygotes leading to incomplete 
compensation of expected full length Ttn protein levels. 
 
 
1.9 Cardiovascular magnetic resonance (CMR) imaging 
CMR creates images of the heart by radiofrequency excitation of hydrogen nuclei in a 
powerful magnetic field 
166 167
.  Upon relaxation, excited hydrogen nuclei emit energy 
which is converted into a reconstructed image. The orientation of the image is 
controlled by varying the main magnetic field using gradient coils. An imaging 
sequence consists of the combination of radiofrequency excitation pulses and applied 
gradients used to generate the image. The two main sequences in clinical use are  
spin echo and gradient echo. Image contrast may be weighted to demonstrate 
different anatomical structures or pathologies.  Contrast between tissues on CMR 
images relies on the fact that different soft tissue types each return to their equilibrium 
state after excitation by the independent processes of T1 (spin-lattice) and T2 (spin- 
spin) relaxation and have distinct T1 and T2 relaxation times. 
 
Cine-CMR is accepted as the gold standard for accurate and reproducible 
quantification of left and right ventricular volumes, biventricular EF, and LV mass 
obtained through manual planimetry or the use of semi-automated software.  It also 
provides a powerful means to assess tissue characteristics, viability, perfusion and 
blood flow. 
 
 
1.9.1 Standard CMR image acquisition 
CMR is performed in a standardised manner.  The body planes, orientated 
orthogonally to the long axis of the body, are used to guide scout images which in 
turn are used to establish the standard cardiac planes.  Axial, coronal and sagittal 
scout images are acquired first.  Axial images run perpendicular to the long axis of 
the body; coronal images bisect the back and front sides of the body; sagittal images 
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bisect the left and right sides of the body.  Long axis images rotate about the LV 
longitudinal axis.  Short axis images are taken perpendicular to the LV longitudinal 
axis
168   
(Figure 1.2).  For cine images MRI sequence is coordinated with 
retrospective ECG-gating, producing numerous short time frames evenly spaced in 
the cardiac cycle. These images are spliced together in a cinematic display so that 
wall motion of the ventricles, valve motion, and blood flow patterns in the heart and 
great vessels can be visualised. 
 
 
1.9.2 CMR most accurately measures ventricular morphology and function 
Although echocardiography is a useful and practical tool for assessment of DCM, 
particularly in the clinical setting, it is heavily operator dependent and reliant on good 
acoustic windows.  Furthermore, to produce volumes M-mode or 2-dimensional echo 
requires geometrical assumptions based on an idealised cardiac shape that may not 
be present in remodelled ventricles.   In patients with advanced heart failure and LV 
dilatation, the LV frequently adopts a more globular shape due to sphericalisation
103
. 
3D echocardiography overcomes some of the geometrical assumptions but still 
requires good windows, which may not be possible in a patient with markedly dilated 
ventricles.  CMR offers superior delineation of the soft tissues and the blood- 
myocardium interface with high temporal resolution
169
.  The multiplanar nature of 
CMR allows imaging of the entirety of both ventricles with an almost unrestricted field 
of view and does not require geometrical assumptions, thus excellent accuracy can 
be maintained
170
. 
 
1.9.3 CMR is highly reproducible and increases power to detect a true 
difference between patient populations 
Fast breath-hold CMR shows excellent results for interstudy reproducibility of 
biventricular volumes, ejection fraction, and LV mass
169
. 
 
The sample sizes required to show an effect can be calculated using the following 
formula: 
n = f (α, P) σ2 2 / δ2 
where n is the sample size, α the significance level, P the study power required and f 
the value of the factor for different values of α and P, with σ the interstudy SD and δ 
the desired difference to be detected. 
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Thus low SD is important as a reduction in SD leads to a squared reduction in  
sample size, and superior interstudy reproducibility results in considerably lower 
calculated sample sizes (reductions of 55% to 93%) required by CMR compared with 
echocardiography to show clinically relevant changes in LV dimensions and function. 
For example, to show a 10ml change in LV EDV in patients with heart failure would 
require 13 patients with CMR versus 66 patients with echocardiography (power of 
90%, α error of 0.05) 171,172 
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Figure 1.2        Acquisition of the cine images and short axis stack. 
 
By using transaxial (Panel A), vertical long-axis (Panel B), and  short-axis  pilot 
images (Panel C), 3 points are identified: the left ventricular apex, mid-point of the 
mitral valve plane, and left ventricular outflow tract. From these, 4-, 2-,  and  3- 
chamber cines are generated (Panels D, E, and F respectively). The 4-  and  2- 
chamber views provide 4 points on the atrio-ventricular ring to plan acquisition of 
the short-axis stack (Panel G). 
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1.9.4 Gadolinium-chelated contrast agents aid discrimination of DCM from 
other causes of heart failure 
Gadolinium-chelated contrast agents, which accumulate in areas of interstitial 
expansion, may be used to document perfusion defects, microvascular ischaemia 
and areas of fibrosis. Three phases can be assessed after gadolinium injection: the 
first pass (immediate imaging), early enhancement (first 5 minutes), and late 
enhancement (5-20 minutes after injection).  Late gadolinium enhancement (LGE) 
detects accumulation of contrast in areas of infarction or fibrosis due to slower 
contrast kinetics and greater volume of contrast in the extracellular space.  The 
differential patterns of enhancement can discriminate DCM from other causes of 
heart failure and identify otherwise latent endophenotypes
173
.  Approximately one 
third of DCM patients will have characteristic midwall fibrosis, distinct from that seen 
in infarction which is typically subendocardial or transmural in an epicardial coronary 
artery perfusion territory
174
. Although x-ray coronary angiography was historically the 
gold standard for discriminating ischaemic from non-ischaemic disease, there is 
emerging evidence that CMR with gadolinium enhancement may be more sensitive, 
particularly given that a significant proportion of patients with a diagnosis of DCM 
and normal coronary arteries have an ischaemic pattern of LGE indicative of 
previous undiagnosed infarction 
175
. Additionally myocarditis in its later stages 
typically produces a pattern of LGE in the sub-epicardium sparing the sub- 
endocardium of the lateral wall 
173
. 
 
Studies suggest that the presence of mid-wall fibrosis as detected by CMR predicts a 
worse outcome in terms of all-cause mortality or hospitalisation as well as malignant 
arrhythmia. The presence of fibrosis appears to be independent of and superior to 
LVEF in predicting outcome 
174
. 
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2 Aims of this Thesis 
 
 
1) To establish a DCM cohort with detailed clinical and CMR imaging data 
2) To optimise NGS sequencing of TTN as part of a panel of ICC genes 
3) To describe variation in TTN in DCM patients and compare this to control 
cohorts 
4) To determine whether molecular properties of TTNtv can be used to 
distinguish benign from pathogenic variation 
5) To determine whether TTNtv are associated with distinct cardiovascular 
phenotypes and can be correlated with MRI data 
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3 Materials and methods 
 
3.1 Patient and control cohort selection 
 
 
All studies were carried out according to institutional guidelines, and with appropriate 
informed consent from participants. Institutional ethics committees reviewed and 
approved all protocols (ethics #: 09-H0707-69 and 09/H0504/104). Tissue studies 
complied with U.K. Human Tissue Act guidelines. 
 
 
3.1.1 Prospectively recruited unselected DCM subjects 
Cohort  description: 
DCM patients were recruited to the Royal Brompton and Harefield Hospitals NHS 
Foundation Trust (RBHT) biobank.  The biobank prospectively collects, processes 
and stores specimens, linked to clinical data, consented for donation to research by 
patients undergoing treatment at the Trust.  Patients referred to the RBHT 
cardiovascular magnetic resonance (CMR) unit from July 2001 to August 2012 for 
evaluation of a possible diagnosis of DCM and who agreed to provide samples for 
biobanking were prospectively recruited at the National Institute for Health Research 
Cardiovascular Biomedical Research Unit, RBHT and Imperial College London 
(Unselected DCM, n=374). Referrals were from centres across Southern England. A 
diagnosis of DCM was confirmed, and evaluated against published CMR criteria 
(EF>2sd below and end diastolic volume (EDV) >2sd above the mean normalised for 
age and sex)
173 176 
by two independent Level 3 accredited CMR cardiologists (Figure 
3.1). Where serial scans were available the first diagnostic scan was used.  No 
patients had clinical symptoms or signs of active myocarditis or CMR evidence of 
infiltrative disease. 40 patients had a history of alcohol excess by UK department of 
health criteria (14 units/week for women and 21 units/week for men). Significant 
coronary artery disease (CAD) (>50% diameter luminal stenosis in any coronary 
artery) was excluded in 249 patients by coronary angiography. In 103 patients 
coronary angiogram was not performed given a low likelihood of myocardial 
ischemia based on non-invasive testing or the clinical profile of the patient (e.g. a 
young family member of a patient with known DCM). Bystander CAD, defined as 
significant CAD evaluated as insufficient to produce DCM phenotype (<2 affected 
segments with <25% late gadolinium enhancement on CMR) was present in 24 
cases. 
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Clinical data: 
Clinical data were collected for risk factors for non-ischemic DCM including history of 
alcohol excess, myocarditis, chemotherapy, iron overload and a peripartum 
presentation.  A family history of minimum 3 generations was taken with direct query 
for DCM, other cardiomyopathy, skeletal myopathy/dystrophy and sudden cardiac 
death. Significant CAD was excluded as described above.  Electrocardiographic data 
collected included, conduction disease (1
st 
degree heart block: fixed PR interval of 
>120ms; 2
nd 
degree heart block: Mobitz type1 or type 2; left bundle branch block 
(LBBB): QRS duration >120ms with LBBB pattern), atrial fibrillation, sustained and 
non-sustained ventricular tachycardia (VT) and ventricular fibrillation. Non-sustained 
VT was defined as 3 or more consecutive ventricular extra-systoles at a rate of 
>120bpm, sustained VT was defined as >30 seconds consecutive beats of VT. 
Patient clinical data were obtained by questionnaire at time of enrolment and from 
clinical records. 
 
 
3.1.2 End-stage DCM subjects 
Cohort  description: 
All end-stage DCM patients who were referred for cardiac transplantation and/or left 
ventricular device implantation between 1993 and 2011 at the Royal Brompton and 
Harefield Hospital NHS Trust were prospectively enrolled in a tissue bank.  155 
subjects for whom peripheral blood was available for DNA analysis were included in 
this study. This cohort included 84 cases from which frozen LV tissue was available 
for tissue studies.  For the end-stage cohort, diagnosis of non-ischaemic DCM was 
confirmed from patient’s medical records, however detailed clinical data was not 
collected.  Phenotype analysis was not performed on the end-stage cohort. 
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Figure 3.1 Schematic representation of study design 
 
Patients with a possible diagnosis of DCM (n=960) and additional patients (n=19) 
originally referred with a possible alternate diagnosis were recruited to the biobank. 
We excluded 442 patients referred with a possible diagnosis of DCM as not DCM 
based on CMR characteristics.  Of the 537 patients with DCM 374 had been 
sequenced at the time of preparing this thesis.  Of the 374 included here 319 were 
confirmed with DCM by strict CMR characteristics
173,176
.   A further 55 were 
diagnosed as DCM based on clinical history and supportive CMR characteristics: 
borderline LVEDVi and LVEF (EDVi>1.5SD above & EF>1.5SD below the mean for 
age and sex) were considered supportive CMR characteristics in the presence of 
corroborating clinical and/or echocardiographic evidence. Abbreviations: HCM, 
hypertrophic cardiomyopathy; IHD, ischemic heart disease; LVNC, LV non 
compaction; ARVC, arrhythmogenic right ventricular cardiomyopathy; CV, 
cardiovascular diasease; TTNtv, TTN truncating variant. 
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3.1.3 Healthy volunteers 
Cohort  description: 
Adult volunteers (age range 18-72 years, mean 40.3 years) were prospectively 
recruited via advertisement at the MRC Clinical Sciences Centre, Imperial College 
London. Participants with previously documented cardiovascular disease, 
hypertension, diabetes or hypercholesterolemia were excluded. Female subjects 
were excluded if they were pregnant or breastfeeding but were eligible if they took 
oral contraceptives. Standard published safety contraindications to magnetic 
resonance imaging were applied with a scanner weight limit of 100kg.  Normal 
cardiac morphology and function was confirmed in all healthy volunteers by CMR. 
Scans were reviewed by a Level 3 accredited CMR cardiologist and phenotype data 
was used as a baseline against which to compare the morphology of the DCM 
cohort. 
 
 
3.1.4 Population  Cohorts 
The Framingham Heart Study (FHS) is a multi-generation, prospective, population- 
based study aimed at identifying the causes of cardiovascular disease
177
. In 1948, 
5,209 men and women aged between 30 to 62, living in the town of Framingham, 
Massachusetts were enrolled. Between 1971 and 1975, the study enrolled a second 
generation, the Offspring Cohort, which consisted of 5,124 children of the original 
cohort and their spouses. The Offspring cohort has since been examined every three 
to eight years, with the last exam (exam 8), occurring between 2005 and 2008. All 
FHS phenotypic data was retrieved from NCBI dbGaP (Accession: 
phs000007.v18.p7). A random subset of 1,623 unrelated individuals in the FHS 
Offspring Cohort was sequenced as part of this study.  Sequence data is available 
from NCBI dbGaP (Accession: phs000307.v3.p7). 
 
The Jackson Heart Study (JHS)
178  
is a population-based, prospective study of 
cardiovascular disease. Between 2000 and 2003, the study enrolled 5,301 African- 
Americans aged 35 to 84 living in the Jackson, Mississippi metropolitan area. All  
JHS phenotypic data was downloaded from NCBI dbGaP (Accession: 
phs000286.v3.p1). A random subset of 1,980 unrelated subjects were sequenced as 
part of this study. The JHS sequence data is available from NCBI dbGaP  
(Accession:  phs000498.v1.p1). 
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Details of TTNtv were provided for the population cohorts and these together with 
TTNtv in the healthy volunteer cohort were compared against TTNtv in DCM for 
frequency, expression and distribution. 
 
 
 
3.2 CMR phenotyping 
 
3.2.1 CMR of prospectively enrolled DCM subjects: 
Cardiovascular magnetic resonance was performed on Siemens Sonata 1.5-T or 
Avanto 1.5-T (Erlangen, Germany).  Cine images were acquired using a steady-state 
free-precession sequence in standard 2-, 3- and 4-chamber long-axis views  (TE 
[echo time]/TR [repetition time] 1.6/3.2 ms, flip angle 60°), with subsequent  
sequential 8-mm short-axis slices (2-mm gap) from the atrioventricular ring to the 
apex.  Ventricular volumes and function were measured for both ventricles using 
standard techniques
172
. Left atrial (LA) area and length were recorded manually from 
2-chamber and 4-chamber images. The biplane area-length method was used to 
calculate LA volume (LAV) 
179
. In addition to maximum wall thickness measured in 
the short axis, mean wall thickness was measured at mid-ventricular (papillary 
muscle) level in the septum and lateral wall.  LAV, LV and right ventricular (RV) 
volumes, wall thicknesses and LV mass were indexed to body surface area (BSA). 
Image analysis was performed using semi-automated software (CMRtools, 
Cardiovascular Imaging Solutions, London, United Kingdom). Late gadolinium 
enhancement (LGE) images were acquired 10 min after intravenous gadolinium- 
DTPA (Schering, Berlin, Germany; 0.1 mmol/kg) in identical short-axis planes using 
an inversion-recovery gradient echo sequence, as previously described 
180
.    Midwall 
LGE was only deemed to be present when the area of signal enhancement could be 
seen in both phase-swapped images and in a cross-cut long-axis image, as 
previously described 
180
. 
 
 
3.2.2 CMR of prospectively enrolled healthy volunteers: 
Healthy volunteer CMR studies were performed on a 1.5T Philips Achieva system 
(Best, Netherlands). Cine images were acquired using a balanced-steady-state free- 
precession sequence in standard 2-, 3- and 4-chamber long-axis views  (TE/TR 
1.5/3.0 ms, flip angle 60°), with subsequent sequential 8-mm short-axis slices (2-mm 
gap) from the atrioventricular ring to the apex.  Gadolinium enhancement was not 
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performed.   Ventricular volumes were measured and indexed as above for the DCM 
cohort.  Anteroseptal and inferoseptal wall thickness were measured and thus was 
not used for comparison against the DCM cohort.  LAV was not measured. 
 
 
3.3 DNA preparation and quality control 
DCM samples from prospectively recruited cases were prepared at the BRU   
genetics laboratory that is equipped with an automated DNA extraction platform (EZ1 
Advanced XL, Qiagen). DNA samples were extracted from whole blood (2 x 350μl)  
as per the manufacturer’s instructions (EZ1 DSP DNA Blood Kit). 
 
Healthy volunteer samples were prepared by the Hammersmith Hospital 
Haematology Laboratory that is equipped with an automated DNA extraction 
platform (QIAcube, Qiagen). DNA samples were extracted from whole blood as per 
the manufacturer’s instructions. 
 
DNA samples from the end-stage cohort were obtained from the Royal Brompton 
and Harefield Transplant Unit Tissue Typing laboratory archive. 
 
DNA quantity and quality was assessed by nanodrop (Thermo Scientific) and 
samples aliquoted into stock solutions and diluted preparations in 96 well plates and 
stored at -80C. A 260/280 ratio of >1.7 was accepted for these samples. 
 
 
3.4 Target enrichment of TTN 
 
3.4.1 Assay design 
SureSelect (Agilent technologies) custom hybridisation capture probes were used to 
capture 204 genes implicated in cardiovascular disease, including TTN.  RNA baits 
were designed using Agilent’s eArray platform 
(https://earray.chem.agilent.com/earray/).   Other than increased bait tiling across the 
target (five-fold), standard eArray parameters were used.  Baits targeted all exons of 
all Ensembl TTN transcripts downloaded from Ensembl version 54, including UTRs, 
a 100-bp extension into adjacent introns to ensure efficient target capture and 
downstream sequencing 
181
, and 1.25 kb of upstream sequence to capture putative 
variation in key regulatory, non-coding motifs.  A total of 6340 unique 120-mer RNA 
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baits were generated for TTN, covering a target region of 168369 bp, including 
112916 protein-coding bases. 
 
Methods for the optimisation of the final assay design are presented in chapter 5 
(Design and optimisation of the Titin sequencing assay), as the optimisation strategy 
was heavily influenced by the data presented there. 
 
 
3.4.2 DNA library preparation 
DNA was extracted using standard automated approaches as above and quality and 
quantity was re-assessed by agarose gel electrophoresis and/or fluorometry (Qubit, 
Life Technologies).  3 μg of gDNA was diluted in 120ul of low TE and sheared using 
the Covaris E System.  Libraries were constructed with the SureSelect SOLiD XT 
(Agilent) kits using the Bravo Automated Liquid Handling Platform (Agilent) as per  
the manufacturer’s protocol.  Libraries were visualised before and after hybridisation 
on the Bioanalyser (Agilent) using the HS DNA Assay as per manufacturer’s  
protocol.  Libraries were hybridised with custom designed SureSelect capture 
libraries at 60
o
C for 24 hours, captured with streptavidin coated magnetic beads 
(Invitrogen Dynabeads) and amplified with 12 cycles of PCR with indexing primers. 
Libraries were quantified using qPCR and pooled in equimolar amounts before 
template bead preparation using 500pg of input library, in an automated ePCR 
EZBead station.  Template beads were enriched using standard protocols and 
loaded onto a sequencing slide. The SOLiD Experiment Tracking System software 
was used for run analysis reports. 
 
 
3.4.3 Next generation sequencing platforms 
SOLiD v3, v3+ and SOLiDv4 platforms were used for pilot studies; the SOLiD 
5500XL platform (Life Technologies) was used for NGS experiments.  The SOLiDv3 
generates up to 25Gb of sequence data from a single run using single reads.  The 
SOLiD v3+ generates up to 60Gb and the SOLiD v4 up to 100Gb of sequence data 
from a single run using paired end (50bp forward, 35bp reverse) technology.  The 
SOLiD 5500 generates up to 150Gb of sequence data (75bp forwards, 35bp 
reverse). 
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3.5 Whole genome sequencing 
TTN was sequenced using whole genome sequencing in 54 subjects from the end- 
stage DCM cohort.  Sequencing was performed by Complete Genomics, and 
variants were called using Complete Genomic Analysis Tools 
(http://www.completegenomics.com/analysis-tools/cgatools/  version:  2.2.0.26). 
Variants were filtered out if they met any of the following conditions; i) low confidence 
or incomplete calls flagged by the caller, ii) read-depth less than 10, iii) allele 
frequency less than 0.15 for heterozygous calls. 
 
 
3.6 LV tissue studies 
Tissue studies were performed on frozen LV tissue samples from 84 of our end- 
stage DCM cohort.  RNA sequencing was performed on all 84 samples, and protein 
studies in a subset of these. Control tissue used for protein studies were from 6 
unused donor hearts with no known cardiac disease. 
 
 
3.7 RNA sequencing 
Total RNA was extracted from frozen LV samples from 84 end-stage DCM cases 
using Trizol (Life Technologies) following the manufacturer’s protocol and quantified 
by UV spectrophotometry.  RNA quality was measured on the Agilent 2100 
Bioanalyser using Agilent’s RNA 6000 reagents and 250 µg of sample.  RINs ranged 
between 6.3 and 8.7 with a mean of 7.6.  4µg of total RNA was used for library 
preparation with the TruSeq RNA Sample Preparation Kit (Illumina). Barcoded cDNA 
fragments of poly(A)+ RNA were then sequenced on a HiSeq 2000 instrument from 
Illumina with 2 x 100 bp PE chemistry. Reads were mapped against the reference 
genome GRCh37 using TopHat 1.4.1
182 
supplied with the gene annotation of the 
Ensembl database 
183
.  Point mutations in the RNA-seq data were detected using the 
SAMtools suite 
184 
considering only uniquely mapping reads with no more than 2 
mismatches in 100 bp. All detected truncating mutations were checked by Sanger 
sequencing. 
 
These data were used for TTN variant analyses in conjunction with whole genome 
and targeted sequencing data.  For each individual, variants observed with the same 
zygosity in RNA-seq and whole genome data were considered validated and used to 
assess allelic balance across the gene and transcript specific degradation. 
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Thirteen TTN truncations were identified in genomic DNA from the 84 samples used 
in these studies. The allele balance of 10 truncating variants could be interrogated in 
both DNA & RNA.  There were no discordant zygosity calls.  Two variants affected 
canonical splice sites, and so were not directly represented in the RNA sequence, 
and one further variant was not called as indels >2bp are not interrogated by the 
variant calling software, but all 3 were present in the whole genome or targeted 
sequencing data and confirmed by Sanger sequencing. 
 
 
3.7.1 Exon expression estimation 
To estimate exon usage, reads covering exons (inclusion reads) and reads spanning 
exons (exclusion reads) were counted, normalised for exon length and the proportion 
of transcripts incorporating each exon was calculated (proportion spliced in (PSI) 
score
183
).  Estimated exon usage was derived from the RNA-sequencing of 84 LV 
tissue samples; these values were then applied across all cohorts to give the 
estimated expression level of each exon containing a TTNtv. 
 
 
3.8 Sanger sequencing 
All truncating and predicted splice variants identified in NGS and RNA-seq data were 
Sanger sequenced.  Approximately half of these variants were validated.  Design of 
the variant calling strategy and Sanger validation results are described in detail in 
chapter 5 (Design and optimisation of the Titin sequencing assay). 
 
 
3.9 Bioinformatics 
 
3.9.1 Bioinformatic analysis of targeted resequencing 
SOLiD 5500xl paired-end reads were demultiplexed and aligned to human reference 
genome (hg19) in colour space using LifeScope™ v2.5.1 “targeted.reseq.pe”  
pipeline.  SOLiD Accuracy Enhancement Tool (SAET) was used to improve colour 
call accuracy prior to mapping.  SAET implements a spectral alignment error 
correction algorithm that uses quality values and properties of colour space.  All  
other LifeScope parameters were used as default. Duplicate reads and those 
mapping with a quality score <8 were removed. Variant calling was performed using 
diBayes (SNPs) and small.indel modules, as well as GATK v1.5-20 
185 
and SAMtools 
v0.1.18. Variants called by any of these methods were taken forward for Sanger 
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validation.  Alignment metrics and target capture analysis were carried out by Picard 
v1.40, BedTools v2.12 and in-house Perl scripts. GATK CallableLociWalker module 
was used to classify the target genomic regions callable by minimum depth >4 with 
base quality >20 and mapping quality >10. 
 
3.9.2 Variant annotation 
To facilitate standardised variant annotation in accordance with international 
guidelines we developed a Locus Reference Genomic sequence (LRG)
186 
for TTN 
(http://www.lrg-sequence.org, LRG_391).  Variants are described relative to an 
inferred complete meta-transcript (LRG_391_t1) manually curated by the HAVANA 
group that incorporates all TTN exons, with the exception of a single alternative 
terminal exon unique to the shorter Novex-3 isoform (Figure 3.2 and Tables 3.1 & 
3.2). Variants in the Novex-3 terminal exon are reported relative to LRG_391_t2. 
 
Variants were reported using Human Genome Variation Society nomenclature. The 
functional consequences of variants were predicted using the Ensembl Perl API 
187 
Variant Effect Predictor 
188
.  Variants were classified as truncating if their 
consequence included one of following sequence ontology terms: 
“transcript_ablation”,  “splice_donor_variant”,  “splice_acceptor_variant”, 
“stop_gained”, “stop_lost” or “frameshift_variant”. 
  
 
 
Figure 3.2 A unified representation of TTN transcripts. 
 
A cartoon shows exon usage in the principal TTN cardiac transcripts (exon boundaries denoted by black lines).  The meta-transcript (LRG_t1 / 
ENST00000589042) is a manually curated inferred complete transcript, incorporating exons of all known TTN isoforms (including fetal and non- 
cardiac isoforms) with the exception of the alternative terminal exon found only in the Novex-3 transcript (LRG_t2 / ENST00000360870, shown in 
green).  The principal adult cardiac long & short isoforms are known as N2BA and N2B: exon usage for reference versions of these isoforms 
(ENST00000591111, ENST00000460472) is shown, though exon usage in vivo is more variable.    Novex-1 and Novex-2 are minor cardiac 
isoforms that differ from N2B only in the inclusion of Novex-1 and Novex-2 (ENST00000359218, ENST00000342175) unique exons (shown in 
the red and blue respectively within the N2B track) positioned within the constitutively expressed position of the early I-band and notably also 
absent from the N2BA isoform.  The lowest plot shows exon usage in human DCM (LV) as the "proportion spliced in" for each exon - that is, an 
estimate of the proportion of transcripts that incorporate each exon, derived from RNA sequencing of LV tissue from 84 patients with DCM.  PSI 
for the alternate terminal exon of Novex-3 can not be accurately estimated: estimates are spuriously overinflated due to poly-A enrichment of 
RNA during library preparation (all other transcripts share the same terminal exon) 
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Table 3.1 Reference transcript and protein identifiers for TTN 
 
 
 
Isoform Description LRG Ensembl transcript Ensembl protein RefSeq transcript RefSeq protein UniProt 
Length 
(aa) 
meta- 
transcript 
Inferred complete meta- 
transcript 
391_t1 ENST00000589042 ENSP00000467141 NM_001267550.1 NP_001254479 
 
35991 
N2-BA 
Principle cardiac long 
isoform 
 
ENST00000591111 ENSP00000465570 NM_001256850.1 
 
NP_001243779 
Q8WZ42-1 34350 
N2-A 
Soleus / skeletal long 
isoform 
  
ENST00000342992 
ENSP00000343764 
 
NM_133378.4 
 
NP_596869.4 
Q8WZ42-4 33423 
N2-B 
Principle cardiac short 
isoform 
  
ENST00000460472 
ENSP00000434586 
 
NM_003319.4 
 
NP_003310.4 
Q8WZ42-3 26926 
Novex-1 
Minor cardiac short 
isoform 
  
ENST00000359218 
ENSP00000352154 
 
NM_133432.3 
 
NP_597676.3 
Q8WZ42-8 27051 
Novex-2 
Minor cardiac short 
isoform 
  
ENST00000342175 
ENSP00000340554 
 
NM_133437.3 
 
NP_597681.3 
Q8WZ42-7 27118 
Novex-3 
Minor small cardiac 
isoform 
391_t2 
 
ENST00000360870 
ENSP00000354117 
 
NM_133379.3 
 
NP_596870.2 
Q8WZ42-6 5604 
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Table 3.2 Overview of TTN transcripts and exon usage 
 
For each of 364 TTN exons, Hg19 and LRG genomic co-ordinates are shown, along with the coordinates of the amino-acid residues encoded 
by that exon (LRG meta-transcript protein coordinates). The recommended exon numbering is shown alongside the historical numbering 
system in use in much of the literature. 
The exon rank in published cardiac transcripts is shown next for seven important transcripts, followed by a description of the exon and its 
relationship to important protein features. 
Finally, an estimate of exon usage in the heart is shown.  PSI indicates “proportion spliced in” – the proportion of expressed transcripts that 
contain the exon listed 
6
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1 1 179672150 179671939 28380 28591 - - 1 1 1 1 1 1 1 5' utr   100.00% 
2 2 179669382 179669279 31148 31251 1 31 2 2 2 2 2 2 2  Z-disk Ig-like 1 100.00% 
3 3 179667068 179666865 33462 33665 31 99 3 3 3 3 3 3 3  Z-disk Ig-like 1 100.00% 
4 4 179665409 179665122 35121 35408 99 195 4 4 4 4 4 4 4  Z-disk Ig-like 2 100.00% 
5 5 179664637 179664552 35893 35978 195 223 5 5 5 5 5 5 5  Z-disk  100.00% 
6 6 179664458 179664214 36072 36316 224 305 6 6 6 6 6 6 6  Z-disk  100.00% 
7 7 179659979 179659649 40551 40881 305 415 7 7 7 7 7 7 7  Z-disk  100.00% 
8 8 179659278 179659126 41252 41404 416 466 8 8 8 8 8 8 8  Z-disk Z-repeat 1 100.00% 
9 9 179658268 179658131 42262 42399 467 512 9 9 9 9 9 9 9  Z-disk Z-repeat 2 100.00% 
10 10 179656924 179656799 43606 43731 513 554 10 10 10 10 10 10 10  Z-disk Z-repeat 3 100.00% 
11 11 179655572 179655435 44958 45095 555 600 11 11 11    11  Z-disk Z-repeat 4 57.32% 
12 12 179654842 179654705 45688 45825 601 646 12 12 12 11 11 11 12  Z-disk Z-repeat 5 79.99% 
13 13 179654224 179654087 46306 46443 647 692 13 13 13 12 12 12 13  Z-disk Z-repeat 6 98.26% 
14 14 179650868 179650575 49662 49955 693 790 14 14 14 13 13 13 14  Z-disk Z-repeat 7 100.00% 
15 15 179650469 179650347 50061 50183 791 831 15 15 15 14 14 14 15  Z-disk  100.00% 
16 16 179649078 179648797 51452 51733 832 925 16 16 16 15 15 15 16  near Z- 
disk 
  
100.00% 
17 17 179648512 179648447 52018 52083 926 947 17 17 17 16 16 16 17  near Z- 
disk 
  
100.00% 
18 18 179647791 179647533 52739 52997 948 1034 18 18 18 17 17 17 18  near Z- 
disk 
Ig-like 3  
100.00% 
19 19 179647329 179647266 53201 53264 1034 1055 19 19 19 18 18 18 19  near Z- 
disk 
  
100.00% 
20 20 179647154 179646939 53376 53591 1055 1127 20 20 20 19 19 19 20  near Z- 
disk 
Ig-like 4  
100.00% 
21 21 179645990 179645848 54540 54682 1127 1175 21 21 21 20 20 20 21  near Z- 
disk 
Ig-like 4  
100.00% 
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22 22 179644932 179644727 55598 55803 1175 1243 22 22 22 21 21 21 22  near Z- 
disk 
  
100.00% 
23 23 179644189 179643956 56341 56574 1244 1321 23 23 23 22 22 22 23  near Z- 
disk 
Ig-like 5  
100.00% 
24 24 179643845 179643601 56685 56929 1322 1403 24 24 24 23 23 23 24  near Z- 
disk 
Ig-like 5  
100.00% 
25 25 179642702 179642431 57828 58099 1403 1494 25 25 25 24 24 24 25  near Z- 
disk 
Ig-like 6  
100.00% 
26 26 179642311 179642147 58219 58383 1494 1549 26 26 26 25 25 25 26  near Z- 
disk 
Ig-like 6  
100.00% 
27 27 179642044 179641876 58486 58654 1549 1605 27 27 27 26 26 26 27  near Z- 
disk 
Ig-like 7  
100.00% 
28 28 179641776 179640083 58754 60447 1605 2170 28 28 28 27 27 27 28  near Z- 
disk / I- 
band 
Ig-like 7/8/9/10  
 
100.00% 
29 29 179639929 179639648 60601 60882 2170 2264 29 29 29 28 28 28 29  I-band Ig-like 11 100.00% 
30 30 179639200 179638934 61330 61596 2264 2353 30 30 30 29 29 29 30  I-band Ig-like 12 100.00% 
31 31 179638837 179638565 61693 61965 2353 2444 31 31 31 30 30 30 31  I-band Ig-like 13 100.00% 
32 32 179638452 179638189 62078 62341 2444 2532 32 32 32 31 31 31 32  I-band Ig-like 14 100.00% 
33 33 179638096 179637836 62434 62694 2532 2619 33 33 33 32 32 32 33  I-band  100.00% 
34 34 179636198 179635938 64332 64592 2619 2706 34 34 34 33 33 33 34  I-band Ig-like 15 100.00% 
35 35 179635402 179635139 65128 65391 2706 2794 35 35 35 34 34 34 35  I-band  100.00% 
36 36 179635047 179634787 65483 65743 2794 2881 36 36 36 35 35 35 36  I-band  100.00% 
37 37 179634666 179634406 65864 66124 2881 2968 37 37 37 36 36 36 37  I-band Ig-like 16 100.00% 
38 38 179633660 179633400 66870 67130 2968 3055 38 38 38 37 37 37 38  I-band Ig-like 17 100.00% 
39 39 179632882 179632741 67648 67789 3055 3102 39 39 39 38 38 38 39  I-band Ig-like 18 100.00% 
40 40 179632651 179632486 67879 68044 3102 3157 40 40 40 39 39 39 40  I-band Ig-like 18 100.00% 
41 41 179631339 179631108 69191 69422 3158 3235 41 41 41 40 40 40 41  I-band  100.00% 
42 42 179629538 179629254 70992 71276 3235 3330 42 42 42 41 41 41 42  I-band Ig-like 19 100.00% 
43 43 179629029 179628904 71501 71626 3330 3372 43 43 43 42 42 42 43  I-band Ig-like 20 100.00% 
44 44 179623899 179623711 76631 76819 3372 3435 44 44 44 43 43 43 44  I-band Ig-like 20 100.00% 
45 45 179622643 179622269 77887 78261 3435 3560 45    44   Novex-1   1.55% 
46 46 179621524 179620949 79006 79581 3560 3752 46     44  Novex-2   6.91% 
47 47 179617907 179617851 82623 82679 3752 3771 47 45 45 44 45 45 45  I-band  100.00% 
48 48 179616766 179610047           46 Novex-3   83.24% 
49 49 179606648 179603868 93882 96662 3771 4698 48 46  45 46 46  N2B unique I-band Ig-like 21/22/23 98.72% 
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               sequence    
50 50 179603087 179602809 97443 97721 4698 4791 49 47 46 46 47 47   I-band Ig-like 24 100.00% 
51 51 179600801 179600238 99729 100292 4791 4979 50 48 47      I-band Ig-like 25/26 39.13% 
52 52 179599715 179599434 100815 101096 4979 5073 51 49 48      I-band Ig-like 27 21.50% 
53 53 179599333 179599055 101197 101475 5073 5166 52 50 49      I-band Ig-like 28 14.70% 
54 54 179598619 179598341 101911 102189 5166 5259 53 51 50      I-band Ig-like 29 11.82% 
55 55 179598244 179597966 102286 102564 5259 5352 54 52 51      I-band Ig-like 30 10.11% 
56 56 179597848 179597561 102682 102969 5352 5448 55 53 52      I-band Ig-like 31 11.57% 
57 57 179597445 179597167 103085 103363 5448 5541 56 54 53      I-band Ig-like 32 11.44% 
58 58 179597074 179596793 103456 103737 5541 5635 57 55 54      I-band Ig-like 33 14.53% 
59 59 179596698 179596420 103832 104110 5635 5728 58 56 55      I-band Ig-like 34 14.99% 
60 60 179596310 179596032 104220 104498 5728 5821 59 57 56      I-band Ig-like 35 32.69% 
61 61 179595930 179595652 104600 104878 5821 5914 60 58 57      I-band Ig-like 36 46.73% 
62 62 179595519 179595232 105011 105298 5914 6010 61 59 58      I-band Ig-like 37 38.86% 
63 63 179595098 179594820 105432 105710 6010 6103 62 60 59      I-band Ig-like 38 12.33% 
64 64 179594672 179594391 105858 106139 6103 6197 63 61 60      I-band Ig-like 39 14.22% 
65 65 179594293 179594015 106237 106515 6197 6290 64 62 61      I-band Ig-like 40 13.38% 
66 66 179593896 179593618 106634 106912 6290 6383 65 63 62      I-band Ig-like 41 8.06% 
67 67 179593505 179593227 107025 107303 6383 6476 66 64 63      I-band Ig-like 42 11.29% 
68 68 179593124 179592837 107406 107693 6476 6572 67 65 64      I-band Ig-like 43 9.98% 
69 69 179592590 179592312 107940 108218 6572 6665 68 66 65      I-band Ig-like 44 12.10% 
70 70 179592098 179591817 108432 108713 6665 6759 69 67 66      I-band Ig-like 45 65.99% 
71 71 179590773 179590495 109757 110035 6759 6852 70 68 67      I-band Ig-like 46 53.72% 
72 72 179590376 179590095 110154 110435 6852 6946 71 69 68      I-band Ig-like 47 52.78% 
73 73 179589265 179588987 111265 111543 6946 7039 72 70 69      I-band Ig-like 48 35.48% 
74 74 179588870 179588583 111660 111947 7039 7135 73 71 70      I-band Ig-like 49 36.44% 
75 75 179588423 179588145 112107 112385 7135 7228 74 72 71      I-band Ig-like 50 40.79% 
76 76 179588051 179587773 112479 112757 7228 7321 75 73 72      I-band Ig-like 51 38.93% 
77 77 179587664 179587386 112866 113144 7321 7414 76 74 73      I-band Ig-like 52 56.34% 
78 78 179587273 179586986 113257 113544 7414 7510 77 75 74      I-band Ig-like 53 40.31% 
79 79 179586861 179586574 113669 113956 7510 7606 78 76 75      I-band Ig-like 54 46.83% 
80 80 179585929 179585648 114601 114882 7606 7700 79 77 76      I-band Ig-like 55 49.39% 
81 81 179585390 179585112 115140 115418 7700 7793 80 78 77      I-band Ig-like 56 49.99% 
82 82 179584991 179584710 115539 115820 7793 7887 81 79 78      I-band Ig-like 57 53.78% 
83 83 179584559 179584281 115971 116249 7887 7980 82 80 79      I-band Ig-like 58 54.55% 
84 84 179584178 179583891 116352 116639 7980 8076 83 81 80      I-band Ig-like 59 10.19% 
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85 85 179583700 179583422 116830 117108 8076 8169 84 82 81      I-band Ig-like 60 7.78% 
86 86 179583327 179583049 117203 117481 8169 8262 85 83 82      I-band Ig-like 61 6.45% 
87 87 179582948 179582670 117582 117860 8262 8355 86 84 83      I-band Ig-like 62 6.13% 
88 88 179582537 179582250 117993 118280 8355 8451 87 85 84      I-band Ig-like 63 6.05% 
89 89 179582109 179581822 118421 118708 8451 8547 88 86 85      I-band Ig-like 64 10.65% 
90 90 179580501 179580220 120029 120310 8547 8641 89 87 86      I-band Ig-like 65 58.46% 
91 91 179579991 179579713 120539 120817 8641 8734 90 88 87      I-band Ig-like 66 60.89% 
92 92 179579300 179579019 121230 121511 8734 8828 91 89 88      I-band Ig-like 67 64.10% 
93 93 179578902 179578624 121628 121906 8828 8921 92 90 89      I-band Ig-like 68 67.76% 
94 94 179578099 179577812 122431 122718 8921 9017 93 91 90      I-band Ig-like 69 68.15% 
95 95 179577702 179577424 122828 123106 9017 9110 94 92 91      I-band Ig-like 70 68.04% 
96 96 179577320 179577042 123210 123488 9110 9203 95 93 92      I-band Ig-like 71 69.89% 
97 97 179576949 179576671 123581 123859 9203 9296 96 94 93      I-band Ig-like 72 69.51% 
98 98 179576076 179575789 124454 124741 9296 9392 97 95 94      I-band Ig-like 73 69.66% 
99 99 179575649 179575362 124881 125168 9392 9488 98 96 95      I-band Ig-like 74 73.85% 
100 100 179574583 179574293 125947 126237 9488 9585 99 97 96      I-band Ig-like 75 76.61% 
101 101 179572540 179572253 127990 128277 9585 9681 100 98 97      I-band Ig-like 76 80.67% 
102 102 179571681 179571589 128849 128941 9681 9712 101 99 98     N2A unique 
sequence 
I-band Ig-like 77  
79.94% 
103 103 179571466 179571181 129064 129349 9712 9807 102 100 99     N2A unique 
sequence 
I-band Ig-like 77  
82.34% 
104 104 179570084 179569901 130446 130629 9807 9868 103 101 100     N2A unique 
sequence 
I-band   
81.95% 
105 105 179569693 179569604 130837 130926 9869 9898 104 102 101     N2A unique 
sequence 
I-band   
81.86% 
106 106 179569504 179569237 131026 131293 9899 9988 105 103 102     N2A unique 
sequence 
I-band   
78.62% 
107 107 179569134 179568874 131396 131656 9988 10075 106 104 103     N2A unique 
sequence 
I-band Ig-like 78  
80.73% 
108 108 179567390 179567181 133140 133349 10075 10145 107 105 104     N2A unique 
sequence 
I-band Ig-like 79  
82.10% 
109 109 179566972 179566895 133558 133635 10145 10171 108 106 105     N2A unique 
sequence 
I-band Ig-like 79  
83.83% 
110 110 179566793 179566767 133737 133763 10171 10180 109 107 106      I-band  84.85% 
111 111 179566314 179566255 134216 134275 10180 10200 110 108 107      I-band  87.28% 
112 112 179565930 179565847 134600 134683 10200 10228 111 109 108      I-band  87.24% 
113 113 179563641 179563570 136889 136960 10228 10252 112 110 109      I-band  84.96% 
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114 114 179561895 179561848 138635 138682 10252 10268 113 111 110      I-band  83.03% 
115 115 179560996 179560592 139534 139938 10268 10403 114 112 111      I-band  84.40% 
116 116 179560137 179560075 140393 140455 10403 10424 115 113 112      I-band  82.86% 
117 117 179559633 179559556 140897 140974 10424 10450 116 114 113      I-band  75.14% 
118 118 179559403 179559326 141127 141204 10450 10476 117 115 114      I-band  73.95% 
119 119 179558735 179558649 141795 141881 10476 10505 118 116 115      I-band  65.93% 
120 120 179558416 179558336 142114 142194 10505 10532 119 117 116      I-band  62.58% 
121 121 179557307 179557224 143223 143306 10532 10560 120 118 117      I-band PEVK 1 64.28% 
 122 179556826 179556743 143704 143787 10560 10588 121 119 118      I-band PEVK 2 58.50% 
122 123 179555113 179555072            alternative exon 
- removed from 
Havana model 
   
123 124 179554623 179554540 145907 145990 10588 10616 122 120 119      I-band PEVK 3 82.93% 
124 125 179554322 179554242 146208 146288 10616 10643 123 121 120      I-band PEVK 4 28.92% 
125 126 179554100 179554017 146430 146513 10643 10671 124 122 121      I-band PEVK 5 32.66% 
126 127 179553863 179553780 146667 146750 10671 10699 125 123 122      I-band PEVK 6 22.35% 
127 128 179553505 179553404 147025 147126 10699 10733 126 124 123      I-band  24.28% 
128 129 179552951 179552838 147579 147692 10733 10771 127 125 124      I-band  38.24% 
129 130 179550325 179550245 150205 150285 10771 10798 128 126 125      I-band  45.85% 
130 131 179550057 179549980 150473 150550 10798 10824 129 127 126      I-band  27.25% 
131 132 179549716 179549633 150814 150897 10824 10852 130 128 127     Low cardiac 
expression?
17
 
I-band PEVK7  
17.33% 
132 133 179549476 179549393 151054 151137 10852 10880 131 129 128     Low cardiac 
expression?
17
 
I-band PEVK8  
18.14% 
133 134 179549140 179549057 151390 151473 10880 10908 132 130 129     Low cardiac 
expression?
17
 
I-band   
14.66% 
134 135 179548809 179548726 151721 151804 10908 10936 133 131 130      I-band PEVK9 18.60% 
135 136 179548018 179547938 152512 152592 10936 10963 134 132 131      I-band  36.96% 
136 137 179547630 179547424 152900 153106 10963 11032 135 133 132      I-band  83.51% 
137 138 179546465 179546388 154065 154142 11032 11058 136 134 133      I-band  83.20% 
138 139 179546177 179546103 154353 154427 11058 11083 137 135 134      I-band  3.79% 
139 140 179545898 179545806 154632 154724 11083 11114 138 136 135     Low cardiac 
expression?
17
 
I-band   
1.77% 
140 141 179545058 179544981 155472 155549 11114 11140 139 137 136     Low cardiac 
expression? 
17
 
I-band   
1.45% 
141 142 179544782 179544621 155748 155909 11140 11194 140 138 137     Low cardiac 
expression?
17
 
I-band   
1.41% 
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142 143 179544409 179544326 156121 156204 11194 11222 141 139 138     Low cardiac 
expression? 
17
 
I-band PEVK10  
1.13% 
143 144 179544143 179544066 156387 156464 11222 11248 142 140 139     Low cardiac 
expression?
17
 
I-band PEVK11  
1.93% 
144 145 179543557 179543474 156973 157056 11248 11276 143 141 140      I-band PEVK12 81.62% 
145 146 179543224 179543141 157306 157389 11276 11304 144 142 141      I-band PEVK13 79.60% 
146 147 179542935 179542852 157595 157678 11304 11332 145 143 142      I-band PEVK14 80.45% 
147 148 179542644 179542348 157886 158182 11332 11431 146 144 143     Low cardiac 
expression?
17
 
I-band   
2.37% 
148  179542014 179541928 158516 158602 11431 11460 147       New in meta 
transcript 
   
1.24% 
149 149 179540722 179540648 159808 159882 11460 11485 148 145 144     Low cardiac 
expression? 
17
 
I-band   
3.06% 
150 150 179540481 179540398 160049 160132 11485 11513 149          0.94% 
151 151 179539840 179539766 160690 160764 11513 11538 150 146 145      I-band  19.51% 
152 152 179539136 179539041 161394 161489 11538 11570 151 147 146      I-band  77.13% 
153 153 179538437 179538360 162093 162170 11570 11596 152 148 147      I-band  68.18% 
154 154 179537430 179537362 163100 163168 11596 11619 153 149 148      I-band  16.13% 
155 155 179537208 179537134 163322 163396 11619 11644 154 150 149     Low cardiac 
expression?
17
 
I-band   
3.15% 
156 156 179536994 179536698 163536 163832 11644 11743 155 151 150     Low cardiac 
expression?
17
 
I-band   
3.50% 
157 157 179535897 179535817 164633 164713 11743 11770 156 152 151     Low cardiac 
expression? 
17
 
I-band PEVK15  
6.09% 
158 158 179535022 179534945 165508 165585 11770 11796 157 153 152      I-band PEVK16 49.51% 
159 159 179534402 179534319 166128 166211 11796 11824 158          1.77% 
160 160 179534174 179534100 166356 166430 11824 11849 159          1.11% 
161 161 179532448 179532365 168082 168165 11849 11877 160          2.35% 
162 162 179532252 179532169 168278 168361 11877 11905 161          2.32% 
163 163 179532046 179531963 168484 168567 11905 11933 162          1.15% 
164 164 179531628 179531551 168902 168979 11933 11959 163          1.24% 
165 165 179530518 179530435 170012 170095 11959 11987 164          2.90% 
166 166 179530187 179530104 170343 170426 11987 12015 165          2.40% 
167 167 179529653 179529579 170877 170951 12015 12040 166          2.62% 
168 168 179529464 179529381 171066 171149 12040 12068 167          2.20% 
169 169 179529264 179529187 171266 171343 12068 12094 168          2.22% 
170 170 179528870 179528742 171705 171788 12094 12122 169       Boundaries re-   2.71% 
7
5
 
  
 
 
               annotated in 
meta-transcript 
   
171 171 179528629 179528546 171901 171984 12122 12150 170          2.42% 
172 172 179528437 179528354 172093 172176 12150 12178 171          2.49% 
173 173 179528243 179528160 172287 172370 12178 12206 172          5.97% 
174 174 179528076 179527993 172454 172537 12206 12234 173          4.30% 
175 175 179527782 179527693 172748 172837 12234 12264 174 154 153     Genomic 
position 
remapped in 
meta-transcript 
I-band   
 
 
73.00% 
176 176 179527539 179527456 172991 173074 12264 12292 175          3.32% 
177 177 179527343 179527260 173187 173270 12292 12320 176          5.27% 
178 178 179527145 179527065 173385 173465 12320 12347 177          2.86% 
179 179 179526949 179526869 173581 173661 12347 12374 178          5.22% 
180 180 179526755 179526675 173775 173855 12374 12401 179          4.76% 
181 181 179526569 179526486 173961 174044 12401 12429 180          1.83% 
182 182 179523982 179523899 176548 176631 12429 12457 181 155 154     Genomic 
position 
changed in 
meta- remapped 
I-band PEVK17  
 
 
15.91% 
183 183 179523815 179523732 176715 176798 12457 12485 182 156 155     Genomic 
position 
remapped in 
meta-transcript 
I-band PEVK18  
 
 
8.96% 
184 184 179523521 179523432 177009 177098 12485 12515 183          42.35% 
185 185 179523278 179523195 177252 177335 12515 12543 184          7.84% 
186 186 179523082 179522999 177448 177531 12543 12571 185          10.83% 
187 187 179522884 179522804 177646 177726 12571 12598 186          7.52% 
188 188 179522688 179522608 177842 177922 12598 12625 187          9.65% 
189 189 179522494 179522414 178036 178116 12625 12652 188          8.35% 
190 190 179522308 179522225 178222 178305 12652 12680 189          3.69% 
191 191 179519722 179519639 180808 180891 12680 12708 190          8.54% 
192 192 179519555 179519472 180975 181058 12708 12736 191          6.00% 
193 193 179519261 179519172 181269 181358 12736 12766 192          27.73% 
194 194 179519018 179518935 181512 181595 12766 12794 193          4.29% 
195 195 179518822 179518739 181708 181791 12794 12822 194          8.57% 
196 196 179518624 179518544 181906 181986 12822 12849 195          9.99% 
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197 197 179518428 179518348 182102 182182 12849 12876 196          12.17% 
198 198 179518234 179518154 182296 182376 12876 12903 197          9.52% 
199 199 179518042 179517965 182482 182565 12903 12931 198          4.52% 
200 200 179517851 179517768 182679 182762 12931 12959 199          3.36% 
201  179517658 179517575 182872 182955 12959 12987 200          3.57% 
202 201 179517463 179517380 183067 183150 12987 13015 201          2.99% 
203 202 179517268 179517185 183262 183345 13015 13043 202 157 156      I-band PEVK19 6.25% 
204 203 179517074 179516991 183456 183539 13043 13071 203 158 157      I-band PEVK20 14.71% 
205 204 179516906 179516823 183624 183707 13071 13099 204 159 158      I-band PEVK21 22.43% 
206 205 179516694 179516611 183836 183919 13099 13127 205 160 159      I-band  24.60% 
207 206 179516476 179516393 184054 184137 13127 13155 206 161 160      I-band  21.56% 
208 207 179516263 179516180 184267 184350 13155 13183 207 162 161      I-band PEVK 22 22.41% 
209 208 179516047 179515970 184483 184560 13183 13209 208 163 162      I-band  25.04% 
210 209 179515561 179515478 184969 185052 13209 13237 209 164 163      I-band PEVK 23 23.19% 
211 210 179514998 179514891 185532 185639 13237 13273 210 165 164      I-band PEVK 24 11.71% 
212 211 179514621 179514544 185909 185986 13273 13299 211 166 165      I-band PEVK 25 12.63% 
213 212 179514358 179514281 186172 186249 13299 13325 212          5.33% 
214 213 179514058 179513975 186472 186555 13325 13353 213          3.40% 
215 214 179512191 179512108 188339 188422 13353 13381 214          3.94% 
216 215 179511871 179511791 188659 188739 13381 13408 215          2.35% 
217 216 179511286 179511212 189244 189318 13408 13433 216          3.45% 
218 217 179510757 179510647 189773 189883 13433 13470 217 167 166      I-band  8.38% 
219 218 179509343 179509275 191187 191255 13470 13493 218 168 167      I-band PEVK26 8.17% 
220 219 179507044 179506964 193486 193566 13493 13520 219 169 168 47 48 48   I-band PEVK27 99.55% 
221 220 179506042 179505968 194488 194562 13520 13545 220 170 169 48 49 49   I-band PEVK28 98.41% 
222 221 179505357 179505268 195173 195262 13545 13575 221 171 170 49 50 50   I-band  100.00% 
223 222 179504837 179504775 195693 195755 13575 13596 222 172 171 50 51 51   I-band PEVK29 100.00% 
224 223 179504515 179504426 196015 196104 13596 13626 223 173 172 51 52 52   I-band PEVK30 100.00% 
225 224 179502146 179502096 198384 198434 13626 13643 224 174 173 52 53 53   I-band PEVK31 73.18% 
226 225 179501526 179501125 199004 199405 13643 13777 225 175 174 53 54 54   I-band Ig-like 80 100.00% 
227 226 179500968 179500690 199562 199840 13777 13870 226 176 175 54 55 55   I-band Ig-like 81 100.00% 
228 227 179500442 179500167 200088 200363 13870 13962 227 177 176 55 56 56   I-band Ig-like 82 100.00% 
229 228 179500031 179499892 200499 200638 13962 14008 228 178 177 56 57 57   I-band  100.00% 
230 229 179499576 179499450 200954 201080 14009 14051 229 179 178 57 58 58   I-band  100.00% 
231 230 179499356 179499093 201174 201437 14051 14139 230 180 179 58 59 59   I-band  100.00% 
232 231 179498810 179498544 201720 201986 14139 14228 231 181 180 59 60 60   I-band Ig-like 83 100.00% 
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233 232 179498403 179498140 202127 202390 14228 14316 232 182 181 60 61 61   I-band Ig-like 84 100.00% 
234 233 179498053 179497914 202477 202616 14316 14362 233 183 182 61 62 62   I-band  100.00% 
235 234 179497771 179497645 202759 202885 14363 14405 234 184 183 62 63 63   I-band  100.00% 
236 235 179497519 179497253 203011 203277 14405 14494 235 185 184 63 64 64   I-band Ig-like 85 100.00% 
237 236 179497140 179496874 203390 203656 14494 14583 236 186 185 64 65 65   I-band  100.00% 
238 237 179496027 179495761 204503 204769 14583 14672 237 187 186 65 66 66   I-band Ig-like 86 100.00% 
239 238 179495670 179495531 204860 204999 14672 14718 238 188 187 66 67 67   I-band  100.00% 
240 239 179495094 179494968 205436 205562 14719 14761 239 189 188 67 68 68   I-band  100.00% 
241 240 179494170 179494028 206360 206502 14761 14808 240 190 189 68 69 69   I-band Ig-like 87 100.00% 
242 241 179490123 179490000 210407 210530 14809 14850 241 191 190 69 70 70   I-band Ig-like 87 100.00% 
243 242 179489458 179489192 211072 211338 14850 14939 242 192 191 70 71 71   I-band Ig-like 88 47.15% 
244 243 179487494 179487397 213036 213133 14939 14971 243 193 192 71 72 72   I-band Ig-like 89 100.00% 
245 244 179486735 179486567 213795 213963 14972 15028 244 194 193 72 73 73   I-band Ig-like 89 100.00% 
246 245 179486468 179486202 214062 214328 15028 15117 245 195 194 73 74 74   I-band Ig-like 90 100.00% 
247 246 179486095 179485829 214435 214701 15117 15206 246 196 195 74 75 75   I-band Ig-like 91 100.00% 
248 247 179485720 179485442 214810 215088 15206 15299 247 197 196 75 76 76   I-band Ig-like 92 100.00% 
249 248 179485352 179484944 215178 215586 15299 15435 248 198 197 76 77 77   I-band Ig-like 93/94 100.00% 
250 249 179484839 179484715 215691 215815 15435 15477 249 199 198 77 78 78   I-band Ig-like 94 100.00% 
251 250 179484614 179484348 215916 216182 15477 15566 250 200 199 78 79 79   I-band  100.00% 
252 251 179483580 179483311 216950 217219 15566 15656 251 201 200 79 80 80   I-band Ig-like 95 100.00% 
253 252 179483218 179482916 217312 217614 15656 15757 252 202 201 80 81 81   A-band Fibronectin type-III 1 100.00% 
254 253 179482808 179482506 217722 218024 15757 15858 253 203 202 81 82 82   A-band Fibronectin type-III 2 100.00% 
255 254 179482239 179482052 218291 218478 15858 15920 254 204 203 82 83 83   A-band Fibronectin type-III 3 100.00% 
256 255 179481961 179481847 218569 218683 15921 15959 255 205 204 83 84 84   A-band Fibronectin type-III 3 100.00% 
257 256 179481740 179481456 218790 219074 15959 16054 256 206 205 84 85 85   A-band  100.00% 
258 257 179481357 179481206 219173 219324 16054 16104 257 207 206 85 86 86   A-band Fibronectin type-III 4 100.00% 
259 258 179480515 179480368 220015 220162 16105 16154 258 208 207 86 87 87   A-band Fibronectin type-III 4 100.00% 
260 259 179480211 179480034 220319 220496 16154 16213 259 209 208 87 88 88   A-band Fibronectin type-III 5 100.00% 
261 260 179479695 179479574 220835 220956 16213 16254 260 210 209 88 89 89   A-band Fibronectin type-III 5 100.00% 
262 261 179479480 179479193 221050 221337 16254 16350 261 211 210 89 90 90   A-band Ig-like 96 100.00% 
263 262 179479075 179478779 221455 221751 16350 16449 262 212 211 90 91 91   A-band Fibronectin type-III 6 100.00% 
264 263 179478664 179478478 221866 222052 16449 16511 263 213 212 91 92 92   A-band Fibronectin type-III 7 100.00% 
265 264 179478003 179477888 222527 222642 16511 16550 264 214 213 92 93 93   A-band Fibronectin type-III 7 100.00% 
266 265 179477799 179477500 222731 223030 16550 16650 265 215 214 93 94 94   A-band Fibronectin type-III 8 100.00% 
267 266 179477303 179477004 223227 223526 16650 16750 266 216 215 94 95 95   A-band Fibronectin type-III 9 100.00% 
268 267 179476889 179476784 223641 223746 16750 16785 267 217 216 95 96 96   A-band Fibronectin type-III 10 100.00% 
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269 268 179476681 179476485 223849 224045 16785 16851 268 218 217 96 97 97   A-band Fibronectin type-III 10 100.00% 
270 269 179476404 179476099 224126 224431 16851 16953 269 219 218 97 98 98   A-band Fibronectin type-III 11 100.00% 
271 270 179475998 179475720 224532 224810 16953 17046 270 220 219 98 99 99   A-band Ig-like 97 100.00% 
272 271 179475116 179474817 225414 225713 17046 17146 271 221 220 99 100 100   A-band Fibronectin type-III 12 100.00% 
273 272 179474713 179474411 225817 226119 17146 17247 272 222 221 100 101 101   A-band Fibronectin type-III 13 100.00% 
274 273 179474297 179473935 226233 226595 17247 17368 273 223 222 101 102 102   A-band Ig-like 98 100.00% 
275 274 179473635 179473333 226895 227197 17368 17469 274 224 223 102 103 103   A-band Fibronectin type-III 14 100.00% 
276 275 179473204 179472905 227326 227625 17469 17569 275 225 224 103 104 104   A-band Fibronectin type-III 15 100.00% 
277 276 179472808 179472512 227722 228018 17569 17668 276 226 225 104 105 105   A-band Fibronectin type-III 16 100.00% 
278 277 179472412 179472128 228118 228402 17668 17763 277 227 226 105 106 106   A-band Ig-like 99 100.00% 
279 278 179472041 179471748 228489 228782 17763 17861 278 228 227 106 107 107   A-band Fibronectin type-III 17 100.00% 
280 279 179470440 179470141 230090 230389 17861 17961 279 229 228 107 108 108   A-band Fibronectin type-III 18 100.00% 
281 280 179470022 179469714 230508 230816 17961 18064 280 230 229 108 109 109   A-band Ig-like 100 100.00% 
282 281 179469625 179469435 230905 231095 18064 18127 281 231 230 109 110 110   A-band Fibronectin type-III 19 100.00% 
283 282 179469032 179468603 231498 231927 18128 18271 282 232 231 110 111 111   A-band Fibronectin type-III 20 100.00% 
284 283 179467317 179467009 233213 233521 18271 18374 283 233 232 111 112 112   A-band Fibronectin type-III 21 100.00% 
285 284 179466877 179466729 233653 233801 18374 18423 284 234 233 112 113 113   A-band Ig-like 101 100.00% 
286 285 179466641 179466609 233889 233921 18424 18434 285 235 234 113 114 114   A-band Ig-like 101 100.00% 
287 286 179466514 179466385 234016 234145 18435 18478 286 236 235 114 115 115   A-band Ig-like 101 100.00% 
288 287 179466291 179465992 234239 234538 18478 18578 287 237 236 115 116 116   A-band Fibronectin type-III 22 100.00% 
289 288 179465898 179465581 234632 234949 18578 18684 288 238 237 116 117 117   A-band Fibronectin type-III 23 100.00% 
290 289 179464577 179464281 235953 236249 18684 18783 289 239 238 117 118 118   A-band Ig-like 102 100.00% 
291 290 179464172 179463873 236358 236657 18783 18883 290 240 239 118 119 119   A-band Fibronectin type-III 24 100.00% 
292 291 179463789 179463475 236741 237055 18883 18988 291 241 240 119 120 120   A-band Fibronectin type-III 25 100.00% 
293 292 179463381 179463233 237149 237297 18988 19037 292 242 241 120 121 121   A-band Fibronectin type-III 26 100.00% 
294 293 179462785 179462635 237745 237895 19038 19088 293 243 242 121 122 122   A-band Fibronectin type-III 26 100.00% 
295 294 179462546 179462265 237984 238265 19088 19182 294 244 243 122 123 123   A-band Ig-like 103 100.00% 
296 295 179460536 179460234 239994 240296 19182 19283 295 245 244 123 124 124   A-band Fibronectin type-III 27 100.00% 
297 296 179459373 179459071 241157 241459 19283 19384 296 246 245 124 125 125   A-band Fibronectin type-III 28 100.00% 
298 297 179458969 179458688 241561 241842 19384 19478 297 247 246 125 126 126   A-band Ig-like 104 100.00% 
299 298 179458594 179458295 241936 242235 19478 19578 298 248 247 126 127 127   A-band Fibronectin type-III 29 100.00% 
300 299 179458202 179457900 242328 242630 19578 19679 299 249 248 127 128 128   A-band Fibronectin type-III 30 100.00% 
301 300 179457810 179457502 242720 243028 19679 19782 300 250 249 128 129 129   A-band Fibronectin type-III 31 100.00% 
302 301 179457387 179457106 243143 243424 19782 19876 301 251 250 129 130 130   A-band Ig-like 105 100.00% 
303 302 179457004 179456705 243526 243825 19876 19976 302 252 251 130 131 131   A-band Fibronectin type-III 32 100.00% 
304 303 179456619 179456326 243911 244204 19976 20074 303 253 252 131 132 132   A-band Fibronectin type-III 33 100.00% 
7
9
 
  
 
 
305 304 179456231 179453265 244299 247265 20074 21063 304 254 253 132 133 133   A-band Ig-like 106, Fibronectin 
type-III 34/35/36, Ig-like 
107, Fibronectin type-III 
37/38, Ig-like 108, 
Fibronectin type-III 39/40 
 
 
 
 
100.00% 
306 305 179452946 179452626 247584 247904 21063 21170 305 255 254 133 134 134   A-band Fibronectin type-III 41 100.00% 
307 306 179452527 179452243 248003 248287 21170 21265 306 256 255 134 135 135   A-band Ig-like 109 100.00% 
308 307 179452144 179451845 248386 248685 21265 21365 307 257 256 135 136 136   A-band Fibronectin type-III 42 100.00% 
309 308 179451534 179451232 248996 249298 21365 21466 308 258 257 136 137 137   A-band Fibronectin type-III 43 100.00% 
310 309 179450074 179449799 250456 250731 21466 21558 309 259 258 137 138 138   A-band Ig-like 110 100.00% 
311 310 179449695 179449396 250835 251134 21558 21658 310 260 259 138 139 139   A-band Fibronectin type-III 44 100.00% 
312 311 179449305 179449003 251225 251527 21658 21759 311 261 260 139 140 140   A-band Fibronectin type-III 45 100.00% 
313 312 179448633 179448334 251897 252196 21759 21859 312 262 261 140 141 141   A-band Fibronectin type-III 46 100.00% 
314 313 179447954 179447667 252576 252863 21859 21955 313 263 262 141 142 142   A-band Ig-like 111 100.00% 
315 314 179447319 179447023 253211 253507 21955 22054 314 264 263 142 143 143   A-band Fibronectin type-III 47 100.00% 
316 315 179446935 179446633 253595 253897 22054 22155 315 265 264 143 144 144   A-band Fibronectin type-III 48 100.00% 
317 316 179446531 179446226 253999 254304 22155 22257 316 266 265 144 145 145   A-band Fibronectin type-III 49 100.00% 
318 317 179445336 179445049 255194 255481 22257 22353 317 267 266 145 146 146   A-band  100.00% 
319 318 179444956 179444666 255574 255864 22353 22450 318 268 267 146 147 147   A-band Fibronectin type-III 50 100.00% 
320 319 179444575 179444288 255955 256242 22450 22546 319 269 268 147 148 148   A-band Fibronectin type-III 51 100.00% 
321 320 179444120 179443533 256410 256997 22546 22742 320 270 269 148 149 149   A-band Ig-like 112 100.00% 
322 321 179443442 179443338 257088 257192 22742 22777 321 271 270 149 150 150   A-band Fibronectin type-III 52 100.00% 
323 322 179442912 179442715 257618 257815 22777 22843 322 272 271 150 151 151   A-band Fibronectin type-III 53 100.00% 
324 323 179442625 179442329 257905 258201 22843 22942 323 273 272 151 152 152   A-band Fibronectin type-III 54 100.00% 
325 324 179442237 179441650 258293 258880 22942 23138 324 274 273 152 153 153   A-band Ig-like 113, Fibronectin 
type-III 55 
 
100.00% 
326 325 179441558 179441256 258972 259274 23138 23239 325 275 274 153 154 154   A-band Fibronectin type-III 56 100.00% 
327 326 179441143 179424038 259387 276492 23239 28941 326 276 275 154 155 155   A-band Fibronectin type-III 57, Ig- 
like 114, Fibronectin type- 
III 58/59, Ig-like 115, 
Fibronectin type-III 
60/61/62, Ig-like 116, 
Fibronectin type-III 
63/64/65, Ig-like 117, 
Fibronectin type-III 66/67, 
Ig-like 118, Fibronectin 
type-III 68/69/70, Ig-like 
 
 
 
 
 
 
 
 
 
100.00% 
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                 119, Fibronectin type-III 
71/72/73, Ig-like 120, 
Fibronectin type-III 74/75, 
Ig-like 121, Fibronectin 
type-III 76/77/78, Ig-like 
122, Fibronectin type-III 
79/80/81, Ig-like 123, 
Fibronectin type-III 82/83, 
Ig-like 124, Fibronectin 
type-III 84/85/86, Ig-like 
125, Fibronectin type-III 
87/88/89, Ig-like 126, 
Fibronectin type-III 90/91, 
Ig-like 127, Fibronectin 
type-III 92/93/94, Ig-like 
128, Fibronectin type-III 
96/96/97, Ig-like 129, 
Fibronectin type-III 98 
 
328 327 179423364 179423068 277166 277462 28941 29040 327 277 276 155 156 156   A-band Fibronectin type-III 99 100.00% 
329 328 179422962 179422375 277568 278155 29040 29236 328 278 277 156 157 157   A-band Fibronectin type-III 100 100.00% 
330 329 179422282 179421980 278248 278550 29236 29337 329 279 278 157 158 158   A-band Fibronectin type-III 101 100.00% 
331 330 179421871 179421575 278659 278955 29337 29436 330 280 279 158 159 159   A-band Fibronectin type-III 102 100.00% 
332 331 179419879 179419592 280651 280938 29436 29532 331 281 280 159 160 160   A-band Ig-like 130 100.00% 
333 332 179419479 179419180 281051 281350 29532 29632 332 282 281 160 161 161   A-band Fibronectin type-III 103 100.00% 
334 333 179418943 179418641 281587 281889 29632 29733 333 283 282 161 162 162   A-band Fibronectin type-III 104 100.00% 
335 334 179418534 179418229 281996 282301 29733 29835 334 284 283 162 163 163   A-band Fibronectin type-III 105 100.00% 
336 335 179418123 179416357 282407 284173 29835 30424 335 285 284 163 164 164   A-band Ig-like 131, Fibronectin 
type-III 106/107, Ig-like 
132, Fibronectin type-III 
108/109 
 
 
 
100.00% 
337 336 179415987 179415694 284543 284836 30424 30522 336 286 285 164 165 165   A-band Fibronectin type-III 110 100.00% 
338 337 179415000 179414713 285530 285817 30522 30618 337 287 286 165 166 166   A-band Ig-like 133 100.00% 
339 338 179414596 179414297 285934 286233 30618 30718 338 288 287 166 167 167   A-band Fibronectin type-III 111 100.00% 
340 339 179414200 179412134 286330 288396 30718 31407 339 289 288 167 168 168   A-band Fibronectin type-III 
112/113, Ig-like 134, 
Fibronectin type-III 
114/115, Ig-like 135, 
 
 
 
100.00% 
8
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                 Fibronectin type-III 116  
341 340 179412032 179411730 288498 288800 31407 31508 340 290 289 168 169 169   A-band Fibronectin type-III 117 99.80% 
342 341 179411632 179411327 288898 289203 31508 31610 341 291 290 169 170 170   A-band Fibronectin type-III 118 99.54% 
343 342 179411229 179410939 289301 289591 31610 31707 342 292 291 170 171 171   A-band Ig-like 136 99.59% 
344 343 179410843 179410547 289687 289983 31707 31806 343 293 292 171 172 172   A-band Fibronectin type-III 119 99.47% 
345 344 179410420 179410115 290110 290415 31806 31908 344 294 293 172 173 173   A-band Fibronectin type-III 120 99.02% 
346 345 179409233 179408928 291297 291602 31908 32010 345 295 294 173 174 174   A-band Fibronectin type-III 121 99.14% 
347 346 179408842 179408561 291688 291969 32010 32104 346 296 295 174 175 175   A-band Ig-like 137 99.28% 
348 347 179408389 179407796 292141 292734 32104 32302 347 297 296 175 176 176   A-band Fibronectin type-III 
122/123 
 
99.43% 
349 348 179407676 179407389 292854 293141 32302 32398 348 298 297 176 177 177   A-band Ig-like 138 99.48% 
350 349 179407290 179406991 293240 293539 32398 32498 349 299 298 177 178 178   A-band Fibronectin type-III 124 99.43% 
351 350 179406311 179406009 294219 294521 32498 32599 350 300 299 178 179 179   A-band Fibronectin type-III 125 99.59% 
352 351 179405097 179404795 295433 295735 32599 32700 351 301 300 179 180 180   A-band Fibronectin type-III 126 99.68% 
353 352 179404693 179404109 295837 296421 32700 32895 352 302 301 180 181 181   A-band Ig-like 139, Fibronectin 
type-III 127 
 
99.78% 
354 353 179403978 179403673 296552 296857 32895 32997 353 303 302 181 182 182   A-band Fibronectin type-III 128 99.84% 
355 354 179403566 179403267 296964 297263 32997 33097 354 304 303 182 183 183   A-band Fibronectin type-III 129 99.83% 
356 355 179402644 179402069 297886 298461 33097 33289 355 305 304 183 184 184   A-band Ig-like 140 99.85% 
357 356 179401970 179401665 298560 298865 33289 33391 356 306 305 184 185 185   A-band Fibronectin type-III 130 99.88% 
358 357 179401302 179400709 299228 299821 33391 33589 357 307 306 185 186 186   A-band Fibronectin type-III 131, 
Ig-like 141 
 
99.11% 
359 358 179400576 179394968 299954 305562 33589 35458 358 308 307 186 187 187   M-band Ig-like 142, Fibronectin 
type-III 132, Protein 
kinase, Ig-like 
143/144/145/146/147/148 
 
 
 
99.89% 
360 359 179394843 179394687 305687 305843 35459 35511 359 309 308 187 188 188   M-band Ig-like 149 99.62% 
361 360 179393946 179393255 306584 307275 35511 35741 360 310 309 188 189 189   M-band Ig-like 150 99.80% 
362 361 179393154 179393001 307376 307529 35742 35793 361 311 310 189 190 190   M-band Ig-like 151 99.95% 
363 362 179392475 179392173 308055 308357 35793 35894 362 312 311 190 191 191   M-band  99.42% 
364 363 179392034 179390716 308496 309814 35894 35991 363 313 312 191 192 192   M-band Ig-like 152 100.00% 
8
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3.9.3 Splice variant prediction 
To identify splice variants outside of the essential splice site comprised of two 
conserved intronic bases, AlamutHT 
190  
was used to calculate Maximum Entropy
191
, 
Neural Network (NNSplice), Splice Site Finder (SSF), Human Splice Finder (HSF), 
and Gene Splicer (GS) scores for reference and alternate alleles. The FHS cohort 
was used to generate a threshold value for calling splice variant predictions: for each 
variant in the splicing region (donor: -3 to +6, acceptor: -20 to +3), the wild type 
splicing score was subtracted from the variant score to give a score change value 
and then converted to percentiles. Variants that scored above the 90
th  
percentile by 
at least 3 algorithms and above the 70
th 
percentile by all applied algorithms were 
considered conservative splicing variant predictions.  In the instance where one or 
more algorithm did not produce a score for a variant, 4/4 or 3/3 algorithms scoring 
above the 70
th  
percentile was considered sufficient.  For variants meeting 
conservative splicing variant criteria in the FHS cohort the minimum absolute score 
change for each prediction algorithm was applied as a threshold across all cohorts 
(Table 3.3).   These thresholds were selected to be more conservative than the 
previously applied Maximum Entropy Score difference <= -2 threshold
17  
and to 
exclude variants found more frequently than in 1 in 1,000 individuals. 
 
Table 3.3 Minimum absolute score change for each prediction algorithm applied 
as threshold across all cohorts 
 
 Absolute score change threshold 
70
th 
percentile 90
th 
percentile 
Maximum Entropy (MaxEnt) -0.89 -1.73 
Neural Network (NNSplice) -0.53 -5.9 
Splice Site Finder (SSF) -0.077 -0.590 
Human Splice Finder (HSF) -0.25 -3.2 
Gene Splicer (GS) -0.91 -1.81 
 
 
3.10 Statistical  analyses 
 
3.10.1 Overview 
Statistical analyses were performed using R (http://www.R-project.org). Comparisons 
between groups were performed using Mann-Whitney or Fisher’s exact tests, as 
appropriate.  Standard linear regressions were used to evaluate the relationship 
between TTN genotype and cardiovascular phenotypes. Multivariate models were 
generated using known clinical covariates and optimised to minimise Bayesian 
84  
information criterion. The relationships between morphologic parameters and TTN 
genotype were assessed by ANOVA between nested linear models. 
 
 
 
3.10.2 Determining the likelihood that a TTNtv found in an individual with DCM 
is pathogenic 
Excluding Novex, low expression & predicted splice site variants: 
Total TTNtv burden in controls = 31/3911 = 0.8% 
Total TTNtv burden in cases = 72/529 = 14% 
 
 
In order to estimate the proportion of variants in cases that are truly pathogenic, the 
burden of TTNtv in controls without overt disease is taken as an estimate of the 
burden of benign variation in both cohorts (0.8%). The burden of pathogenic TTNtv in 
cases is therefore estimated at 13.2%. 
 
In an individual with DCM, the likelihood that a TTNtv is pathogenic = 13.2/0.8 = 16.5, 
and the probability of pathogenicity = 13.2/14 = 94% 
 
 
3.10.3 Stratification of DCM and linear modelling 
For prospectively recruited DCM subjects, linear modelling was used to robustly 
assess the relationship between TTN genotype and cardiac phenotype. In these 
analyses, we sought to determine which of four inter-related positional factors were 
most informative: distance of the TTNtv from the N-terminus; cardiac expression of 
the variant exon; the transcripts affected by the TTNtv; and location inside/outside   
the A-band. Taken together, these genotype-based descriptors significantly improved 
model performance for six parameters, namely LV EF, RV EF, LV SVi, RV SVi, LVMi, 
and lateral WTi. For LV EF, presence inside/outside the A-band was most informative, 
whereas distance from the N-terminus was the strongest predictor for the              
other parameters. Definitive models were then constructed, with TTN genotype 
defined by presence/absence of TTNtv and the distance of the TTNtv from the N- 
terminus, while taking age and sex into account. With these refinements, TTN 
genotype remained a significant predictor of five phenotypic indices (LV EF, RV EF, 
LV SVi, RV SVi and lateral WTi) 
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4 Deep phenotyping of a DCM cohort 
 
4.1 Introduction 
A principle goal of genetic research is to identify specific genotypes that are 
associated with human phenotypes
192
.  Increasing the accuracy and completeness of 
phenotype information ensures that genetic investigations have maximal power to 
identify a variant influencing the presence of this manifestation, and determine 
genotype-phenotype correlation
193
. Deep phenotyping, the precise and 
comprehensive analysis of phenotypic abnormalities in which the individual 
components of the phenotype are observed and described,
194 
is vital in a complex 
and heterogeneous condition such as DCM. With advances in high throughput 
genotyping technologies the rate limiting step has become the collection of sensitive 
and specific phenotype information in large samples of study participants
195
. 
Geneticists are now accustomed to highly precise technologies: genotype miscall 
rates are now typically less than 0.5%, whereas measurement error in phenotypes 
has, until recently, received less attention. Confounding factors, including study 
heterogeneity originating from clinical sources such as phenocopy or a common final 
disease picture can be minimized as careful measurement of environmental risk 
factors and disease sub-phenotypes can provide valuable clues to 
pathophysiology
195
.   The importance and utility of high quality phenotype data was 
demonstrated by the identification of MLL2 mutations as a cause of Kabuki 
syndrome, a discovery made possible only once a phenotypic stratification strategy 
was employed 
86
. 
 
CMR has been applied for the measurement of LV volumes, systolic function and LV 
mass for several years in the clinical arena
176
.  The excellent accuracy and 
reproducibility that make CMR the gold standard technique 
169 
also make it the ideal 
tool for deep phenotyping in this study.  The greatest restriction to the use of CMR 
probably remains the limited distribution and availability of scanners, and in the 
research setting the cost of such detailed phenotyping for a large cohort.  As such 
until recent studies published by the RBHT CMR unit 
179,180
, studies using CMR 
phenotyping were limited to much smaller cohorts 
196-200
. 
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4.2 Aims 
 
 
 To collect and curate data on a large cohort of idiopathic DCM patients, with 
detailed and accurate phenotype data gained through CMR analysis to 
maximise the power of genotype phenotype analyses 
 To explore the data collected for this cohort both independently and in 
comparison to a healthy volunteer cohort in order to identify any unexpected 
or unexplained measurements or distributions as a QC step 
 To describe the cohort and ensure selection of appropriate statistical tests for 
subsequent  analyses. 
 
 
4.3 Results 
Consecutive patients referred for cardiac evaluation by CMR were prospectively 
recruited and biobanked. Figure 4.1 shows the relation of LVEF and LVEDVi for the 
four most frequent diagnoses following initial assessment and highlights complete 
overlap in these parameters for DCM and ischeamic cardiomyopathy (IHD) patients 
as well as a lesser overlap for HCM and ostensibly normal scans. 
 
 
4.3.1 Establishing a DCM cohort using CMR phenotyping and comparison to 
the normalised mean for LVEF and LVEDVi 
The difficulty in making an accurate diagnosis of DCM (discussed in introduction 
section 1.2.3 Aetiology) and the particular utility of CMR in this study is demonstrated 
by the proportion of patients referred with a possible diagnosis of DCM in whom the 
diagnosis was excluded following CMR:  Of the 960 patients referred with a 
preliminary diagnosis of DCM only 518 were confirmed to have DCM, and 442 were 
assigned a different diagnosis. A full list of the alternate diagnoses is shown in Figure 
3.1. A large proportion of those in whom DCM was excluded were relatives of a DCM 
proband undergoing family screening (n=130). An additional 19 patients referred with 
other preliminary diagnoses were found to have DCM on CMR, see Figure 3.1 for full 
details. In total 537 patients with DCM were recruited and biobanked at the time of 
preparation of this thesis.  Full phenotype data was collected and recorded for the  
first 374 cases (for whom TTN sequence data was also available). 
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Figure 4.1 Relation of LVEF and LVEDVi for the four most frequent diagnoses on 
initial CMR analysis 
 
IHD= ischaemic cardiomyopathy, NAD= no abnormality detected on CMR, HCM= 
hypertrophic  cardiomyopathy 
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Of the 374 included here 319 were confirmed to have DCM using strict CMR 
characteristics
173,176 
(LVEDVi>2SD above & LVEF>2SD below the mean for age and 
sex) by two experienced, Level 3 CMR accredited cardiologists blinded to information 
on genetic status. Normalised mean LVEDVi and LVEF for age and sex were derived 
from a study by Maciera et al 
176 
undertaken at the RBHT CMR unit using the same 
scanners as this study, thus reducing bias in measurement between cohorts. The 
authors found that most clinical parameters of LV volume and systolic/diastolic 
function are significantly and independently influenced by gender, age and BSA.  
Their findings suggest that the interpretation of LV parameters in borderline clinical 
cases, such as early cardiomyopathy, should be referred to age, gender and body 
surface area (BSA) normalised values in order to determine normality, or severity of 
abnormality. An algorithm was developed to perform comparison to normalised  
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values as recommended. Following this all cases given a diagnosis of DCM but not 
meeting strict criteria were revaluated and passed to a level 3 CMR accredited 
cardiologist to confirm exclusion from this study or inclusion based on clinical history 
and supportive CMR characteristics:  borderline EDVi and EF (EDVi>1.5SD above & 
EF>1.5SD below the mean for age and sex) were considered supportive CMR 
89  
characteristics in the presence of corroborating clinical and/or echocardiographic 
evidence. A further 55 cases were classified as DCM based on clinical history and 
supportive CMR characteristics. Most patients in this group met criteria for reduced 
LVEF but not increased LVEDVi (LVEDVi>2SD below and LVEF 1.5-2SD above the 
mean (n=8); LVEDVi 1.5-2SD above and LVEF>2SD below the mean (n=40); 
LVEDVi 1.5-2SD above and LVEF 1.5-2SD below the mean (n=8)). One mild familial 
case that would otherwise have been excluded was included based on meeting 
criteria once adjusted for age and sex. 
 
Figure 4.2 shows a formal comparison of the effect of age and sex on continuous 
CMR parameters for the DCM cohort. Interestingly four important markers of DCM 
severity follow opposing trends compared to the healthy asymptomatic subjects 
studied by Maciera et al 
176
:  In healthy subjects LVEF increases with age whereas in 
DCM LVEF decreases with increasing age for both males and females. In healthy 
subjects LVEDVi decreases with increasing age whereas in DCM LVEDVi remains 
unchanged in males and increases slightly with age in females. In healthy subjects 
LV SVi decreases with increasing age whereas LV SVi increases with age in both 
males and females. In healthy subjects LV mass indexed to BSA (LVMi) decreases 
with increasing age in males and remains unchanged in females whereas in DCM 
LVMi increases with age in both males and females. 
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Table 4.1 Full demographic data and results for categorical variables. 
See general methods for details of variables recorded 
Categorical variable  N Number with 
data available 
Percentage 
Ethnicity   374  
Caucasian 329  88.0% 
Asian subcontinent 16  4.3% 
Afrocaribbean 12  3.2% 
African 4  1.1% 
Chinese 3  0.8% 
Mixed 1  0.3% 
Other 9  2.4% 
Female  104 374 27.7% 
Preliminary diagnosis   374  
DCM 354  94.7% 
Arrhythmia 4  1.1% 
ARVC 4  1.1% 
IHD 4  1.1% 
HCM 2  0.5% 
Other 6  1.6% 
Family history   299  
DCM 51  17.1% 
SCD 15  5.0% 
ARVC 1  0.3% 
HCM 0  0% 
Skeletal myopathy 0  0% 
NYHA class   345  
1 159  46.1% 
2 138  40.0% 
3 46  13.3% 
4 2  0.6% 
History of myocarditis  14 301 4.7% 
Normal coronary arteries  250 274 91.2% 
Bystander myocardial 
infarction 
 
24 368 6.5% 
Alcohol excess  45 320 14.1% 
Chemotherapy  15 298 5.0% 
Iron overload  5 318 1.6% 
Peripartum  8 334 2.4% 
Conduction disease  97 306 31.7% 
Sustained VT  30 131 22.9% 
Atrial fibrillation  91 315 28.9% 
Mitral regurgitation  62 373 16.6% 
LVNC  7 366 1.9% 
GAD suggestive of 
myocarditis 
 
26 361 7.2% 
Mid wall GAD   367  
None 246  65.6% 
Limited 89  23.7% 
Extensive 32  8.5% 
Most affected midwall 
segment 
  122  
Anterior 4  3.3% 
Inferior 16  13.1% 
Lateral 24  19.7% 
Septal 78  63.9% 
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Figure 4.2 The effect of age and sex on continuous CMR parameters for the 
DCM cohort 
 
Each parameter is plotted against age at time of scan.  Plots show individual cases 
as points (red=female, blue=male) with regression lines and 95% confidence 
intervals (red=female, blue=male) . 
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4.3.2 Exploration of CMR parameters in a DCM cohort and comparison to 
healthy volunteers 
Frequency density and distribution of cardiac morphology and function as measured 
by CMR was explored in DCM cases and healthy volunteers. As some 
measurements are expected to differ for males and females, both the DCM and 
healthy volunteer cohorts were stratified accordingly 
176
. Figure 4.3 shows frequency 
density plots of CMR parameters for males and females in the DCM and healthy 
volunteer cohorts alongside probability density histograms with raw and smoothed 
density curves for the DCM cohort only (probability density histograms are not 
stratified by gender). Volumetric and contractility parameters show the expected 
difference between males and females for both DCM patients and healthy volunteers 
(namely lower EF and larger volumes in males compared to females) with the 
greatest difference between sexes observed for LVMi and right ventricular EF, EDVi 
and ESVi (Figure 4.3a-c). Negligible gender difference was observed for biventricular 
SVi and for all wall thickness measurements. 
 
For all cardiac parameters the spread of the DCM cohorts was greater than that of  
the healthy volunteers, as may be expected, likely reflecting the broad spectrum of 
disease in DCM cohorts. The mean of four important markers of DCM severity (LV 
EF, EDVi, ESVi and LVMi) was substantially distinct from the healthy volunteer  
cohort (P<9.8 x10
-58
), and three additional parameters were significantly different 
(P<0.0007) calculated using a Wilcoxon rank sum test with continuity correction 
(Table 4.2). On visual inspection, the distributions of CMR phenotypes for the DCM 
cohort are grossly normal. For LVEF and RVEF the frequency density has a shoulder 
suggestive of a bimodal distribution, which could indicate population stratification or 
the presence of two subpopulations. Exploring this using the probability density 
histograms the shoulder in the frequency density curve appears to be a stochastic 
effect suggesting this is a function of the degree of smoothing applied in the 
generation of the plot rather than a true bimodal distribution (Figure 4.3a and d). 
LVEF has a platykurtic distribution, limited on the right by the diagnostic criteria 
(EF>2SD below the normalised mean) and on the left by compatibility with life.  ESVi 
and to a lesser extent EDVi show a positive skew, most likely due to exclusion of low 
EDVi by diagnostic criteria limiting the distribution on the left. Left ventricular EF,  
EDVi and ESVi are most discriminatory for DCM, while the distribution for right 
ventricular EF, EDVi and ESVi show greater overlap with the healthy volunteer cohort 
and the biventricular SVi is not discriminatory. Wall thickness for the healthy 
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volunteer cohort was not measured at the same position as in the DCM cohort (the 
healthy volunteer cohort comprises a separate study) so direct comparison cannot be 
made (Figure 4.4). 
 
Table 4.2 Comparison of means assesses the difference between DCM and 
healthy volunteer cohorts. 
 
 
 
 DCM Healthy 
volunteer 
Confidence 
intervals 
Difference 
in location 
P value 
Mean sd Mean sd 
LV EF 39.1 12.9 64.3 5.4 23;  27 25 6.0x10
-102
 
LV EDVi 129.2 39.4 81.9 14.1 -43;  -35.9 -39.3 4.1 x10
-78
 
LV ESVi 82.0 39.5 29.6 8.4 -46.6;  -38.7 -42.5 4.3 x10
-101
 
LV SVi 47.1 13.5 52.3 7.9 3.24;  6.82 5.0 4.1 x10
-08
 
RV EF 51.7 14.3 46.2 22.1 -2;  2 5.6 x10
-05
 0.912 
RV EDVi 88.0 24.8 77.0 39.1 -4.66;  3.33 -0.5 0.777 
RV ESVi 44.4 22.1 34.2 18.9 -8.83;  -2.69 -5.6 0.0001 
RV SVi 43.7 13.3 42.6 21.8 1.68;  6.17 3.9 0.0007 
LVMi 92.1 27.6 61.6 14.0 -30.4;  -24.5 -27.4 9.8 x10
-58
 
Max WTi 10.4 2.2  
Septal WTi 8.3 1.9 
Lateral WTi 6.1 1.6 
LAVi 62.2 25.8 
Age at 
diagnosis 
 
52.1 
 
13.9 
Age at 
scan 
 
53.7 
 
13.6 
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Figure 4.3      Frequency density plots of CMR parameters for males and females in 
the DCM and healthy volunteer cohorts alongside probability density histograms with 
raw and smoothed density curves for the DCM cohort 
(probability density histograms are not stratified by gender) 
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in DCM cases and healthy volunteer controls 
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LV EDVi frequency density 
in DCM cases and healthy volunteer controls 
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d) 
RV EF frequency density 
in DCM cases and healthy volunteer controls 
 
 
RV EF probability histogram and density curve 
in DCM cases 
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RV ESVi frequency density 
in DCM cases and healthy volunteer controls 
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g) 
LV SVi frequency density 
in DCM cases and healthy volunteer controls 
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Figure 4.4 Frequency density plots of CMR parameters for males and females in 
the DCM cohort alongside probability density histograms with raw and smoothed 
density curves 
 
(probability density histograms are not stratified by gender) 
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Figure 4.5 Overview comparison of continuous CMR parameters between DCM 
and healthy volunteer cohorts stratified by gender. 
 
DCM= dilated cardiomyopathy, HVOL= healthy volunteers, M=male, F=female 
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4.4 Discussion 
 
4.4.1 Demographics 
This DCM cohort was prospectively recruited from consecutive referrals to the RBHT 
CMR unit and is representative of the typical through-the-door patients seen in a 
CMR unit in South East England.  As such, the majority of patients are Caucasian 
(88%) and male (72%). The frequency of midwall late gadolinium enhancement  
(32%) is consistent with previous studies in DCM 
174
.  The quantification of valve 
regurgitation is a strength of CMR because of its capability of measuring accurate 
ventricular stroke volumes and comparing this with the measurement of great vessel 
flow from velocity mapping. In isolated valve regurgitation, the regurgitant volume and 
fraction are simply calculated from the difference in LV and RV stroke volumes, thus 
isolated mitral regurgitation regurgitation results in an excess LV stroke volume. 
Despite a general consensus and the wealth of publications stating that mitral valve 
disease and ventricular tachycardias are well recognised complications of DCM,  
there is a paucity of publications quoting their prevalence in DCM 
174,201-203
.  In this 
cohort 19% of patients had moderate to severe MR as determined by CMR, slightly 
fewer than previously published estimates using ECHO (24%) 
204 
although this might 
be expected due to the higher accuracy of CMR.  In this cohort there was sufficient 
data to make a determination regarding sustained VT at, or prior to, the time of 
diagnosis in 131 (35%) patients.  Thirty patients (22%) had sustained VT  
documented electrographically (standard or ambulatory ECG). In 101 patients there 
was sufficient evidence to exclude sustained VT (absence of sustained VT on 
ambulatory ECG or clear documentation of absence of suggestive symptoms i.e. 
palpitations, dizziness, syncope/pre-syncope in conjunction with absence of VT on 
standard ECG), but in 244 cases (65%) ambulatory ECG monitoring was not 
performed and/or documentation of symptoms prior to presentation was not sufficient 
to exclude sustained VT.  The prevalence of sustained VT in this cohort (23%) is 
higher than previously published  (3% sustained VT requiring hospitalisation and 4% 
SCD)
174 
and this may be due to a negative bias in ascertainment of cases without 
sustained VT, i.e. symptomatic or high risk patients are more likely to undergo 
ambulatory ECG monitoring, and there is likely a bias toward failure to document 
negative findings e.g. absence of suggestive symptoms.  However, since I was blind 
to TTN genotype while collecting this data any inflation in the prevalence of sustained 
VT in the cohort as a whole should not influence the validity of genotype-phenotype 
correlation. 
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Due to the difficulty in determining whether a particular risk factor for DCM is the 
primary cause in any given case, or merely a coincident or contributory factor, 
patients with a history of alcohol excess (14.1%), chemotherapy (5%), iron overload 
(1.6%), myocarditis (4.7%), small (bystander) myocardial infarction (6.5%) or 
peripartum presentation (2.4%) were not excluded.  If these risk factors were indeed 
the cause of DCM in these patients it would contaminate the homogeneity of the 
idiopathic DCM phenotype in this cohort and could reduce the power of this study to 
detect genotype-phenotype correlation.  As an example of the problems associated 
with determining causality in an individual, excessive alcohol intake is reported in a 
wide range (3–40%) of DCM patients, but data regarding the incidence, prevalence, 
mortality and morbidity rates related to alcoholic cardiomyopathy are lacking. 
Environmental factors (e.g. cobalt, arsenic) and genetic predisposition (e.g. HLA-B8, 
alcohol dehydrogenase alleles) have been proposed as modifiers in the development 
of alcoholic cardiomyopathy.  Further, it is difficult to establish a definite causal 
relationship between heavy alcohol consumption and heart failure, given the  
beneficial effects seen with low to moderate to levels of consumption and the fact that 
many heavy alcohol users never develop overt heart failure. Ultimately there exist no 
unique identifying features, clinical or laboratory (including histological changes), that 
set alcoholic cardiomyopathy apart from other causes of heart failure and the 
diagnosis remains one of exclusion 
205,206
.   In view of the probabilistic nature of 
assigning a cause to DCM, and since the presence of a relative risk factor does not 
preclude a genetic factor as the primary cause, cases were included where there is 
lack of certainty regarding aetiology.  In this way the cohort also remains 
representative of DCM patients typically seen in clinic.  In contrast, patients with 
evidence of active myocarditis (endomyocardial biopsy or CMR) or ischaemic heart 
disease deemed sufficient to account for severity of DCM (large myocardial infarction 
on CMR) were excluded. 
 
 
4.4.2 CMR parameters of morphology and function 
A small number of DCM patients and healthy volunteers had outlying measurements 
and these scans were reviewed.  Outlying indexed measurements in DCM patients 
were found to be due to particularly high or low BSA, and extremes of age due to the 
difference in normalised mean LVEDVi and LVEF. Outlying indexed measurements 
in the healthy volunteers were all in young adult males with a low BSA. It is 
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recognized that indexing by BSA has reduced utility at extremes of BSA, and that 
using lean body mass, at least in males, is more precise 
207
. However, lean body 
mass was only available for the healthy volunteer cohort and is not routinely 
measured or recorded for patients.  After a review of the literature I decided to use to 
BSA as this is superior to height, height squared, and weight and is the most 
commonly used and clinically relevant index 
208
. 
 
The distribution of the measurements for the DCM cohort was robustly assessed in  
R, using a Wilcoxon rank sum test with continuity correction, and visualized by the 
probability density histogram and frequency curves. One issue that was considered 
was the question of outliers.  On one hand, it is best to be inclusive of as much data 
as possible to increase power. On the other it is important to identify outliers that may 
be in some way unrepresentative of the cohort overall.  In this case each outlier in  
turn was examined and the majority were retained.  A second issue is that of data 
transformation. This is typically used in order to normalise distribution and thus 
improve statistical analysis. However, using non-transformed data keeps analysis 
focussed on the originally measured parameter.  The data presented here, without 
transformation, was judged compatible with downstream genotype-phenotype 
analysis using robust methods in spite of the presence of outlier cases. 
 
 
4.4.3 Limitations of relying on CMR 
 
Amongst limitations of CMR, metallic implants and intracardiac devices (pacemaker, 
ICD) represent the only absolute contra-indication 
209
. Although gadolinium contrast 
agents are relatively safe, their use is restricted in chronic renal failure (GFR <30 
ml/min) due to the small but real risk of nephrogenic systemic fibrosis, which is 
increased by concurrent heart failure 
210
.  Severe claustrophobia, clinical instability  
and the first trimester of pregnancy are among relative contra-indications and a CMR 
scanner weight limit of 100kg is applied.  CMR remains somewhat limited by 
arrhythmias interfering with ECG triggering and by a patients poor ability to perform 
breath-holds, both of which are not infrequent in a patient with advanced heart failure. 
Although the study was designed to prospectively recruit DCM cases without  
selection bias, this effort may have been undermined by the inherent limitations of 
CMR. The limitations for intracardiac devices and arrhythmias may have reduced the 
proportion of patients with arrhythmogenic DCM, including LMNA associated DCM 
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and thus may have introduced occult genetic stratification of the cohort 
211
.  The 
limitation for clinically unstable patients, breatholding and arrhythmias may have 
reduced the proportion of patients with advanced or decompensated disease.  Not all 
patients with DCM are referred for CMR assessment.  Recruiting patients from the 
CMR unit may have introduced bias for severe yet stable DCM, or for unusual cases. 
 
Although detailed CMR phenotyping was performed for all DCM patients on a 
research basis and in a standardised manor, all other clinical data was collected from 
patient records.  As a result there is a frustrating amount of missing clinical data, 
either because tests were not performed (in particular ambulatory ECG recording 
195
) 
or due to difficulty obtaining clinical records from GPs and specialists in other 
hospitals. 
 
4.5 Summary 
 
This DCM cohort represents prospective recruitment over several years in a large, 
specialist CMR unit.   The depth and breadth of phenotype data coupled with high 
throughput sequencing of biobanked DNA samples in such a large cohort presents  
an unrivalled resource for genotype-phenotype associations.  Although not entirely 
homogenous in terms of ethnicity and potential contributing risk factors, the DCM 
cohort is representative of the type of patient seen in a typical CMR unit in South  East 
England and as such, the results of this study can be applied directly to such a clinic. 
The variance for continuous parameters is higher in DCM than in healthy volunteers.  
This broad distribution of CMR measurements reflects the fact that the cohort 
represents the full spectrum of disease from mild to severe.  As expected, lower 
contractility and larger volumes are observed in males compared to females for both 
the DCM and healthy volunteer cohorts.  Deviation from normal distribution in  the 
DCM cohort, likely due to the diagnostic criteria, is seen for EF, EDVi and ESVi. 
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5 Design and optimisation of the Titin sequencing assay 
 
5.1 Introduction 
Several factors could be expected to influence overall sequencing performance.  At 
the time of commencing this thesis we had early access to SureSelect (Agilent) target 
enrichment compatible with the SOLiD sequencing platform.  Throughout we have 
continued to work collaboratively with Agilent using early access products including 
their assay re-design service. The scope of research into TTN genetics had been 
restricted by size of the TTN gene and it’s extensive alternative splicing events until 
the advent of NGS and target enrichment technologies 
17,212,213
.  Current data about 
the genomic co-ordinates of all TTN exons and which of these are expressed in the 
heart and were thus relevant to cardiac biology were not available.  As such 
development of a comprehensive and consistently high performance assay involved 
concurrent troubleshooting and investigation on several fronts including target 
definition, factors affecting hybridisation, effect of sequencing parameters, iterative 
redesign of the assay, optimisation of library preparation, and efficiency of overall 
performance. 
 
Performance of a given target enrichment assay is assessed relative to the target 
genomic region(s) it is designed to capture.  The initial assay design (Assay 1) 
targeted all published exons in the two major cardiac transcripts of TTN (N2BA, 
ENST00000591111 & N2B, ENST00000460472) 
189
.  During the iterative redesign 
process we took the opportunity to re-define the assay target following review of the 
evidence for each TTN exon and generation of a meta-transcript 
(ENST00000589042) by HAVANA
183
. Evidence of exon usage in the LV, derived de- 
novo from RNA-sequencing data (see section 3.7 RNA Sequencing) was also 
incorporated. 
 
Study design, including variant calling parameters, was planned to maximise 
sensitivity (potentially at the expense of specificity), and variants were then validated 
by Sanger sequencing.  The technical sensitivity of capture-based NGS approaches 
is very high at good sequencing depth (>99% at 20x read depth 
214
) and in this study 
the major determinant of sensitivity relates to target enrichment efficacy and 
uniformity.  Even with good overall depth of sequencing there are particular regions 
that are either not enriched successfully or where reads cannot be mapped uniquely 
to the genome due to repetitive sequence (TTN contains several short exons with a 
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high degree of homology).  Callability describes the percentage (%) of target 
sequence which is sequenced with sufficient depth and quality such that a 
heterozygous variant can be identified
215
, and defines the proportion of target 
sequence that can be studied.  This is likely the most informative single metric for 
addressing assay performance and sensitivity of variant calling, and is used here as 
the primary metric of assay performance.  Callability can also be used to confirm 
equivalent overall sequencing performance between cohorts enabling fair 
comparison of results. 
 
Coverage is often used interchangeably to describe depth of sequencing (vertical 
coverage) and the proportion of target sequenced (horizontal coverage) 
216,217
.  To 
avoid any potential confusion the term coverage is not used here.  Similarly 
sequence capture (and many other terms) are used interchangeably with target 
enrichment in the published literature
217-219
.  Here target enrichment refers to the 
enrichment of target DNA relative to genomic DNA during NGS library preparation. 
Sequence capture is used to describe the usable sequence data obtained following 
NGS and is a function of both target enrichment, NGS performance and mapping and 
QC of sequencing reads. 
 
 
5.2 Aims 
 Definition of the genomic regions encoding the TTN gene 
 Identification and optimisation of factors affecting target enrichment and 
overall sequencing performance 
 Development of a final comprehensive and consistently high performance 
assay. 
 To gather high quality sequence data for TTN in our DCM cohort 
 
 
 
5.3 Results 
 
5.3.1 Definition of the target region and development of a TTN LRG 
As discussed in section 1.7 of the introduction (Titin structure and function in the 
cardiomyocyte), TTN undergoes extensive alternative splicing, including 15 splice 
variants recorded in Ensembl
220,221
.  Until recently, variant reporting in coding 
coordinates was difficult, as it required the use of several transcripts to obtain 
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complete exon annotation
17
. It was also unclear which exons were truly included in 
each transcript and were expressed in the heart 
17 212
. 
 
To facilitate standardised variant annotation in accordance with international 
guidelines we developed a Locus Reference Genomic sequence (LRG)
186 
for TTN 
(http://www.lrg-sequence.org, LRG_391).   LRG records contain internationally 
recognized stable reference genomic DNA sequence for a genomic region, essential 
transcripts and proteins for variant reporting and an exon numbering system. 
 
Together with the European Bioinformatic Institute (EBI, www.ebi.ac.uk) we 
developed an inferred complete meta-transcript (LRG_391_t1) manually curated by 
the HAVANA group that incorporates all TTN exons, with the exception of a single 
alternative terminal exon unique to the shorter novex-3 isoform 
189 
(Figure 3.2 A 
unified representation of TTN transcripts and tables 3.1 Reference transcript and 
protein identifiers for Titin and 3.2 Overview of TTN transcripts and exon usage). A 
second LRG transcript, LRG_391_t2, novex3 isoform  (NM_133379.4), was also 
included to allow reporting of variants within the alternate terminal exon 
213
. 
 
 
5.3.2 GC ratio affects hybridization efficiency 
Variability in assay performance is a function of efficiency of hybridisation which is 
known to be sensitive to factors such as GC content
181
.  A previous study has shown 
that a distinctive feature of the SureSelect system is that it outperforms other 
hybridisation-based enrichment systems in regions of low GC content
222
.  We have 
found that the SureSelect system performs relatively poorly in regions of high GC 
content, particularly in the first exon of many genes
223
. The poorly captured region in 
TTN has a higher GC ratio than the rest of the gene (Figure 5.1) suggesting that this 
may be the underlying cause or poor performance in this region. However when 
callability is plotted against GC ratio it can be seen that there is no correlation in this 
instance (Figure 5.2).  Indeed both the TTN exons with the highest and lowest GC 
ratio are captured effectively. 
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Figure 5.1 Callabitity and GC content of TTN exons 
 
Points in the upper plot show the percentage of each exon sequenced with sufficient 
depth and quality to call variants, calculated as a mean across samples from the 
DCM cohort.  Points in the lower plot show the GC ratio for each exon.  Exon 
numbering is according to LRG_391_t1.  The first, GC rich, exon is captured well but 
a short section between exon 165 and 195 is captured poorly. 
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Figure 5.2 Relationship between GC content and callability for TTN exons 
 
The percentage callable for each exon calculated as a mean across samples is 
plotted against the GC ratio for that exon. Each point represents an exon in 
LRG_391_t1.  Most exons with GC>0.5 are captured well. 
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5.3.3 Sequencing depth affects overall assay performance 
Irrespective of target enrichment design, the percentage of bases callable increases 
with increasing sequencing depth (Figure 5.3) illustrating the relationship between 
read depth and capability at a global level.  The percentage callable in early runs 
which had a lower mean depth of sequencing was strongly dependent on the 
sequencing depth of each sample.  At a mean read depth < x100, increase in read 
depth greatly increases callability, after which the effect begins to plateau.  At an 
average read depth of approximately x300 the callability reaches saturation 
(approximately 95% callable) after which increasing read depth does not improve 
callability. The fact that the maximum callability is less than 100% may be explained 
by factors such as high GC content leading to poor hybridisation efficiency or 
inadequate tiling leading to ineffective capture of particular genomic sequences, and 
increasing mean read depth will not resolve these problems 
223 
(see below). 
 
 
Figure 5.3 Relationship between sequencing depth and callability for target 
enrichment assays 
 
Samples plotted here are from a variety of pilot studies, using several different 
SureSelect assay designs including both off the shelf whole exome and smaller 
custom assays.  For each sample the percentage of bases that are callable across 
the complete target is plotted against the mean sequencing depth achieved for that 
sample (reads on target are normalised for target size). The dashed line represents 
the maximum % callable achieved for any sample, as the callability seems to have 
approached  saturation. 
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5.3.4 Assay design optimisation 
Using Assay 1 the median callability achieved for TTN at optimal sequencing depth 
was 97%. Callability for other genes in the assay was variable. It has been shown 
previously that SureSelect target enrichment has uneven performance: enrichment, 
and thus read depth, is variable across a given design or target 
223
.  One solution to 
improve assay performance is to increase the mean depth of sequencing per sample, 
in an effort to push the depth of sequencing of borderline regions above variant  
calling threshold.  However this is inefficient as increasing overall sequencing depth 
will also increase sequencing of regions that are well captured, consequently it is 
preferable to redistribute read depth across the target through iterative re-design. 
 
Some regions of the assay target were captured consistently poorly despite optimal 
average sequencing depth (Figure 5.4).  A minority of regions were excluded from   
the initial design due to strict eArray bait design parameters such as repeat masking 
(https://earray.chem.agilent.com/earray).   Although not quantifiable, failure in bait 
design during production may also have occurred.  In collaboration with Agilent we 
undertook iterative redesign of the whole assay to redistribute sequence depth 
together with specific optimisation of TTN target enrichment by removal of repeat 
masking and manual optimisation of bait design for poorly performing regions. Agilent 
have been working on algorithms for this, increasing the number of baits in poorly 
performing regions, and reducing the number in regions that capture well. This can   
be achieved by either altering the number of copies of each bait, or by increasing the 
number of distinct baits. The exact details of the algorithm have not been shared with 
us. 
 
During the assay redesign we took the opportunity to include additional TTN exons 
based on the newly developed LRG (see above) 
213
, and thus the target for Assay 1 
differs slightly to all other designs. We provided Agilent with the same target criteria 
as for Assay 1 (100bp overhang into exons, plus upstream sequence), albeit with 
additional TTN exons, along with aligned sequencing reads from our first sequencing 
runs, and received a “rebalanced” library design. 
 
Two single gene iterations were trialed for TTN, assay designs TTNv1 and TTNv2, 
which differed from each other in that repeat masking was used for TTNv1 but not 
TTNv2, and as such TTNv2 contained more baits (target size 271,902bp vs. 
281,431bp). Callability of some TTN exons was improved by assay redesign, but a 
108  
small region of 30 short exons with a high degree of sequence homology (exon 165- 
195) remains poorly captured (Figure 5.4). Both the small size and high homology of 
these exons may affect both the capture and eventual mapping of sequencing reads. 
 
Figure 5.4 Callability per exon for iterative assay designs 
 
Points for each assay show the percentage of each exon sequenced with sufficient 
depth and quality to call variants, calculated as a mean across samples.  Exon 
numbering is according to LRG_391.  Vertical grey lines mark the domain boundaries 
between Z-disc, I-band, A-band, and M-band (from left to right).  Points denote exon 
number and are not representative of exon size.  Figure 5.4 a) shows all coding  
exons (2-364). Figure 5.4 b) shows just the region from within the I-band (exons 173- 
193) where TTNv1 and TTNv2 perform differently. 
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Although both TTNv1 and v2 outperformed Assay 1, TTNv2 slightly outperformed 
TTNv1:  Both assays failed to capture the same four whole exons, and v1 failed to 
capture one further exon. Assay TTNv1 partially captured 12 exons and assay v2 
partially captured 10 exons (Table 5.1). That callability of exons 175-198 remains 
poor despite assay redesign and optimal sequencing depth suggests factors other 
than assay design influence overall sequencing performance of this region. 
 
Table 5.1 Exons not fully captured by TTN single gene assays TTNv1 and 
TTNv2 
 
The number of bases per exon which are callable, sequenced at low read depth 
insufficient to call variants (low capture), and with no sequence capture mapped (not 
covered) are shown for each of the assays. 
 
 TTN v1 TTN v2 
 
exon 
 
Callable 
Low 
capture 
Not 
covered 
 
Callable 
Low 
capture 
Not 
covered 
175 0 64 45 89 0 0 
176 0 35 68 0 80 23 
177 0 0 103 0 30 73 
180 0 53 47 0 41 59 
181 0 32 71 0 68 35 
182 0 65 38 0 0 103 
183 0 33 70 15 51 37 
184 0 13 96 0 3 106 
185 0 0 103 0 0 103 
186 0 0 103 0 5 98 
187 0 0 100 22 53 25 
188 0 56 44 50 26 24 
191 40 21 42 41 18 44 
192 0 24 29 0 0 53 
197 0 0 54 0 0 54 
198 25 42 33 80 0 0 
216 87 7 6 93 5 2 
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The final optimized design, Assay 2, comprised optimisation of Assay 1 plus TTNv2 
and performs consistently well. Assay 1 was designed before the TTN meta-transcript 
was developed and the LRG was created.  Thus baits were not designed for some of 
the exons and performance of Assay 1 assessed by callability with regard to the LRG 
meta-transcript is consistently inferior to other assays. In order to bring meta- 
transcript target capture of samples already sequenced using Assay 1 in line with 
subsequent samples sequenced using Assay 2, a ‘Top-up Assay’ was produced. The 
design of the Top-up Assay was simply those additional baits by which Assay 2 
differed from Assay 1. New libraries were prepared and sequenced.  Sequencing 
reads for Assay 1 and the Top-up Assay were combined (‘Assay 1 & Top-up’) prior to 
mapping to the genome and callability achieved using this approach is comparable to 
Assay 2 (Figure 5.5) for most samples. 
 
 
5.3.5 Library preparation and NGS performance 
There are several ways in which library preparation and sequencing can affect overall 
performance.  The most simple is differences in design of the assay used for library 
preparation, as discussed above.  However a few of the samples sequenced with 
Assay 1 & Top-up still showed poor callability (<90%, Figure 5.5). 
 
Libraries were prepared and sequenced in batches. One possible explanation for the 
small but distinct group of samples performing poorly is a batch effect in library 
preparation or sequencing.  However this does not appear to be the case: there are a 
few samples in each run which perform poorly (Figure 5.6). 
 
Libraries were barcoded and pooled for sequencing, thus if an individual sample was 
underrepresented in the pool it would have been sequenced to a shallower depth and 
this may adversely affect performance as discussed above. The depth of sequencing 
for individual libraries ranged from approximately 20x to >400x. Assay 1 was 
sequenced at less than 50x, which together with the assay design may explain poor 
performance.  Some Assay 1 & Top-up libraries performed poorly despite optimal 
sequencing depth, thus sequencing depth does not appear to be the cause of their 
poor performance (Figure 5.7). 
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Figure 5.5 Beeswarm plot of callability for each assay design measured against 
the meta-transcript LRG_391_t1. 
 
 
 
100 
Relationship between Elid and callability 
 
 
95 
●● 
●●●●●● 
●●●●●●●● 
●●●●●●●●●●●●●● 
●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● 
●●●●●  ●●●●●●●●●●●● 
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●● 
●●●●●●●●●●●●●●●●●●●●●●●●●●●● 
●●●●●●●● 
●● 
●● 
 
90 
●●●● 
 
 
 
●●●●●●●●●● 
● ●● 
●●●●●●●●●●● 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
●●●● 
●●●●●● 
●●●●●●●● 
●●●●●●●●●●●●●●● 
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● 
●●●●●●●●●●●●●●●●●●●●●●●●●●● 
●●●●●●●●●● 
● 
 
 
 
elid 
● Assay 1 
● Assay 1 & top−up 
● Assay 2 
●● 
●● 
●●●●● 
 
●● 
●●● 
●● 
 
● 
● 
● 
 
● 
 
80 
 
Assay 1 Assay 1 & top−up Assay 2 
Elid 
 
 
 
 
 
 
Figure 5.6 Beeswarm plot of callability stratified by sequencing run, measured 
against the meta-transcript LRG_391_t1. 
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Figure 5.7 Relationship between sequencing depth and callability for TTN 
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5.3.6 Improving sequencing efficiency 
Target enrichment increases the amount of target DNA relative to genomic DNA and 
thus reduces the sequencing capacity per sample required to obtain usable sequence 
data for a region of interest.  The efficacy of an assay, the target enrichment factor, 
can be calculated as 
 
Enrichment Factor = Reads on Target / Total mapped reads 
Target size / Genome size 
 
Although Assay 1 & Top-up perform comparably to Assay 2 for most samples, the 
enrichment factor for Assay 2 is far greater (Figure 5.8).  Thus libraries prepared with 
Assay 2 should reach callability saturation at a lower depth of sequencing, however 
this remains to be determined as all samples enriched using Assay 2 were in fact 
sequenced to a high depth: min 95.9x, max 98.0x, median 97.2x, mean 97.2x, sd 
0.47. 
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Figure 5.8 Relationship between sequencing depth and enrichment for TTN 
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5.4 Discussion 
Since the first sequencing runs using SureSelect target enrichment sequencing 
capacity has increased six-fold (from 25Gb of single end reads on the SOLiDv3 to 
150Gb of paired end reads (75bp forwards, 35bp reverse) on the SOLiD5500). 
Increased read length and paired-end reads have increased the proportion of 
sequence data that maps uniquely to the genome and is thus usable, further 
increasing practical capacity 
 
Iterative assay redesign has improved capture of some TTN exons and allowed 
refinement of the target region to reflect the TTN meta-transcript.  Manual rebalance 
and reduction of baits in the regions with highest sequence depth improves evenness 
of assay performance 
223  
and should reduce the saturation threshold for sequencing 
depth, however this remains to be determined.  Given our understanding of the 
importance of adequate sequencing and our increase in capacity, all samples are 
sequenced to well above the saturation threshold. 
 
Despite Assay redesign a few TTN exons remain poorly captured.  These exons are 
clustered in a region of high CG content, however there are exons with a much 
higher GC content that are captured well, suggesting there is some other sequence 
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factor or tertiary structure at play.  The exons in this region are short (81-90bp) and 
highly homologous, possibly affecting mapping of reads uniquely to the genome. 
This assay is designed to target exons with a 100bp overhang into introns, and 
previous studies have shown this improves capture of smaller exons
181
.  Future 
increases in read length may facilitate unique mapping of these exons and thus 
improve callability.  Indeed, recent sequencing runs of an unrelated cohort enriched 
using Assay 2 and sequenced on the Illumina HiSeq platform which has longer reads 
(150bp forward and reverse) had 100% callability.  Although the effect of increased 
read length cannot be dissected from other differences between the Illumina and Life 
Technologies NGS platforms which use different chemistries, the improved capture  
on a longer read platform supports unique read mapping as the factor limiting capture 
in this study. 
 
Some samples sequenced using Assay 1 plus Top-up performed poorly.  No batch 
effects in library preparation, pooling or sequencing were identified, but it may be an 
effect of the amount or quality of DNA used in the library preparation of those 
individual samples.  All libraries prepared with Assay 2 performed well, as these were 
prepared and sequenced most recently the consistency in performance may reflect 
our increased experience in using SureSelect and troubleshooting of the protocol for 
library preparation on the liquid handling platform (Bravo, Agilent). 
 
 
5.5 Summary 
In summary, optimisation of an effective TTN sequencing assay involved careful 
definition of the target region through review of TTN exon usage and establishment of 
a meta-transcript and LRG; optimisation of the target capture assay through iterative 
design and testing; resolving poorly covered regions both though manual bait design 
and by removing repeat masking features in the design process; and finally taking  
into consideration potential batch effects.  The net result has been the development   
of an assay which performs well and provides reliable sequence capture (> 97%) 
across the TTN gene. There remains a region of 30 short exons (representing 
approximately 5% of the total coding sequence) which was captured poorly by this 
assay.  Analysis of DNA sequence including GC content suggests this is more likely a 
problem of mapping than of target enrichment as is supported by results of recent 
sequencing on a longer read NGS platform that achieve 100% callability. It is   
possible that TTNtv are under-detected in the region of poor callability, particularly in 
115  
the small number of samples sequenced using Assay 1 only.  The impact of this is 
discussed in detail in chapter 6. 
116  
6 Integrated allelic, transcriptional, and phenomic dissection of the cardiac 
effects of titin truncations in health and disease 
 
6.1 Introduction 
Diagnostic sequencing of TTN will only be useful if causality can be confidently 
ascribed to individual variants.  TTNtv cause severe and familial DCM
17 
with age- 
dependent and incomplete penetrance, features that have hindered definition of the 
spectrum of clinical manifestations and insights into disease mechanisms.
224  
The 
significance of TTNtv found in the general population or in less severe, and often 
sporadic, DCM remains uncharacterised.  Additionally, it is unknown whether 
molecular properties of TTNtv can distinguish benign from pathogenic variation, or 
indicate the degree of risk for DCM. To address these issues TTN was sequenced in 
five cohorts spanning the full spectrum cardiac physiology: healthy volunteers with 
full cardiovascular evaluation (n=308), community-based cohorts with longitudinal 
clinical data (3,603 participants in the Framingham (FHS
177
) and Jackson (JHS
178
) 
Heart Studies), prospectively-enrolled unselected DCM patients (n=374) and end- 
stage DCM patients considered for transplantation (n=155). 
 
 
6.2 Aims 
 Compare sequencing capture between cohorts to assess validity of 
comparison 
 Explore burden and distribution of variants between cohorts to estimate 
likelihood of pathogenicity and determine factors that distinguish pathogenic 
variants 
 Explore relationship between TTN genotype and DCM phenotype to 
determine the potential for prognostication and personalised management 
 
 
6.3 Results 
 
6.3.1 Comparison of sequencing capture between cohorts to assess validity of 
comparison 
Prior to comparing the variants found in each cohort it is important to confirm that no 
error is introduced by the differences in sequencing and variant analysis pipelines for 
each cohort (see general methods).  The sequencing capture for all cohorts was 
compared and although there were minor differences, these were not significant 
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(Figure 6.1). It was not possible to asses capture of TTN in end-stage DCM samples 
sequenced by Complete Genomics (n=54), however no difference in the frequency of 
TTNtv was observed in end-stage cohort samples sequenced using targeted capture 
(20/101, 19.8%) as compared to whole genome sequencing (10/54, 18.5%). 
 
Figure 6.1 TTN sequencing capture for each cohort 
 
Points for each cohort show the percentage of each exon sequenced with sufficient 
depth and quality to call variants, calculated as a mean across samples.   Error bars 
show the 95%CI.  Exon numbering is according to LRG_391. Vertical grey lines mark 
the domain boundaries between Z-disc, I-band, A-band, and M-band (from left to 
right).  Points denote exon number and are not representative of exon size.  (a) all 
coding exons (2-364). (b) shows the region within the I-band (exons 150-220; 6315 
bp; 2105aa; ~5% of the gene) that exhibited the poorest callability in all cohorts.  The 
exons in this region are small and contain repetitive sequence affecting capture and 
mapping of reads in all cohorts. 
Red = Healthy Volunteers (n=308), Orange = JHS (n=1,980), Magenta = FHS 
(n=1,623), Dark blue= Unselected DCM (n=374), Pale blue = End-stage DCM 
(n=155) 
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6.3.2 Burden of TTNtv in health and disease 
Fifty-six TTNtv affecting full-length TTN were identified in 3,911 controls (1.4%): of 
which 9 were found in healthy volunteers (2.9%), 16 in the FHS (1.0%) and 31 in JHS 
participants (1.6%). Eighty-three DCM patients carried TTNtv (total TTNtv in DCM 
versus controls, OR=13(9-18), P= 2.8x10
-43
; Table 6.1): 49 in the unselected DCM 
patients (13%) and 34 in end-stage DCM patients (22%).  Comparing variants found 
in health and disease: nonsense, frameshift, and canonical splice site TTNtv were 
substantially enriched in DCM patients (78/607 (12.9%), OR = 17(11-25); P = 1.9x10
-
 
45
). Additional variants predicted to alter non-canonical splice signals were also 
enriched in DCM (OR = 4.2(1.8-9.7); P = 0.0017) but often occurred in combination 
with another TTNtv. A full list of TTNtv and novex-3 truncating variants in each cohort 
is shown in Tables 6.1-6.5 
 
 
6.3.3 Distribution of TTNtv in health and disease 
The locations of TTNtv were non-uniformly distributed within and between study 
cohorts (Figure. 6.2). To better understand the effects of individual TTNtv, three 
interrelated positional factors were explored: location of the variant with respect to the 
A-band, transcripts affected, and variant exon usage level. 
 
As a previous study of severe and familial DCM showed TTNtv enrichment in the A- 
band
17
, the distribution of TTNtv across the spectrum of health and disease was 
explored. TTNtv were more commonly located in the A-band in cases than controls 
(61/87 case variants located in A-band, vs. 21/56 in controls, OR=3.9(1.8-8.3), 
1.4x10
-4
), due both to an enrichment of A-band variants in DCM patients (compared 
with a uniform distribution: 61/87 variants in A-band, vs. 18235/35991 residues; OR = 
2.3(1.4-3.6), P = 3.4x10
-4
), and an opposing trend, towards A-band sparing, in 
controls (35/56 variants outside A-band, OR=0.58(0.34-1.0), p= 0.06).  A-band 
enrichment was most pronounced in end-stage DCM patients (OR = 3.5(1.6-8.5), P = 
7.8x10
-4
) and a concordant trend in less severe, sporadic DCM (OR = 1.7(0.97-3.1),  
P = 0.07) (Figure. 6.2 & 6.3).  Enrichment of variants in the A-band in DCM was 
robust to controlling for non-uniform distribution of potential truncation sites along the 
TTN gene (Figure. 6.3). 
. 
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Table 6.1 TTN truncating variants identified in UK prospective DCM cohort 
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Variants affecting meta-transcript (LRG_391_t1) 
10AP01669 179641966 58564 c.4724_4728delTGAAA p.Met1575SerfsX6 27 1 Y Y Y Frameshift 
10RW00786 179635212 65318 c.8307_8308delTG p.Ala2770HisfsX4 35 1 Y Y Y Frameshift 
10DW00512 179605317 95213 c.12643_12644delCA p.Gln4215ValfsX16 49 0.98 Y Y  Frameshift 
14MW01583 179605203 95327 c.12757C>T p.Gln4253X 49 0.98 Y Y  Nonsense 
10GG01869 179577042 123488 c.27607G>A p.Glu9203Lys 96 0.69 Y 
  Splice variant 
prediction 
10JF01835 179571683 128847 c.29267-2A>C 
 
103 0.82 Y 
  Canonical splice 
variant 
12SK00375 179571661 128869 c.29062delG p.Ala9688GlnfsX7 102 0.8 Y   Frameshift 
12PB00376 179554624 145906 c.31763-1G>A 
 
123 0.83 Y 
  Canonical splice 
variant 
10SB00367 179547631 152899 c.33113-1delG 
 
137 0.83 Y 
  Canonical splice 
variant 
12MD01102 179544980 155550 c.33643+1G>A 
 
142 0.02 Y 
  Canonical splice 
variant 
 
12MA01291 
 
179517277 
 
183253 
 
c.39044-9T>A 
 20 
3 
 
0.06 
 
Y 
  Splice variant 
prediction 
10RC00179 179500851 199679 c.41447delG p.Gly13816AlafsX18 227 0.99 Y Y  Frameshift 
10PC00581 179500825 199705 c.41473C>T p.Arg13825X 227 0.99 Y Y  Nonsense 
10JM01592 179495983 204547 c.43792delG p.Val14598X 238 0.99 Y Y  Frameshift 
10BC00144 179485581 214950 c.45757_45756dupA p.Tyr15253IlefsX15 248 0.98 Y Y  Frameshift 
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10WS00448 179485525 215005 c.45812T>G p.Leu15271X 248 0.98 Y Y  Nonsense 
10VS00240 179482115 218415 c.47697C>A p.Cys15899X 255 0.98 Y Y  Nonsense 
10DR00069 179481846 218684 c.48100+1G>A 
 
257 0.98 Y Y 
 Canonical splice 
variant 
10CH00929 179480145 220385 c.48527G>A p.Trp16176X 260 0.98 Y Y  Nonsense 
10JN00724 179477082 223448 c.50170C>T p.Arg16724X 267 0.98 Y Y  Nonsense 
10LP00987 179477082 223448 c.50170C>T p.Arg16724X 267 0.98 Y Y  Nonsense 
10RN00513 179477082 223448 c.50170C>T p.Arg16724X 267 0.98 Y Y  Nonsense 
10LB00067 179474002 226529 c.52036_52035insTT p.Leu17346PhefsX4 274 0.98 Y Y  Frameshift 
10DH00882 179473511 227020 c.52228_52227dupAGAAA p.Asp17410ArgfsX25 275 0.98 Y Y  Frameshift 
12AM00400 179470140 230390 c.54106+1G>T 
 
281 0.98 Y Y 
 Canonical splice 
variant 
10JS00726 179470136 230394 c.53881+5G>A 
 
280 0.98 Y Y 
 Splice variant 
prediction 
10HH00944 179466515 234015 c.55528-1G>A 
 
288 0.98 Y Y 
 Canonical splice 
variant 
10JF01881 179466199 234331 c.55525_55531delGACAGGA p.Asp18509SerfsX29 288 0.98 Y Y  Frameshift 
10SF00976 179466199 234331 c.55525_55531delGACAGGA p.Asp18509SerfsX29 288 0.98 Y Y  Frameshift 
 
10RN00513 
 
179462261 
 
238269 
 
c.57544+4A>G 
 29 
5 
 
100 
 
Y 
  Splice variant 
prediction 
10AL00811 179458293 242237 c.58957+2T>C 
 
300 0.98 Y Y 
 Canonical splice 
variant 
12SR01222 179455521 245009 c.60931C>T p.Arg20311X 305 0.98 Y Y  Nonsense 
10TM00933 179453427 247103 c.63025C>T p.Arg21009X 305 0.98 Y Y  Nonsense 
10CS01472 179441341 259189 c.69630C>A p.Tyr23210X 326 0.97 Y Y  Nonsense 
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12JL01327 179436553 263977 c.74306dupA p.Asn24769LysfsX2 327 0.96 Y Y  Frameshift 
10BK01803 179432675 267855 c.78184G>T p.Glu26062X 327 0.96 Y Y  Nonsense 
10JC00262 179432352 268178 c.78507delT p.Gly26170ValfsX3 327 0.96 Y Y  Frameshift 
10DM00077 179429597 270933 c.81262_81269delCAGATGCT p.Gln27088CysfsX5 327 0.96 Y Y  Frameshift 
10PP00413 179429597 270933 c.81262_81269delCAGATGCT p.Gln27088CysfsX5 327 0.96 Y Y  Frameshift 
12NP00167 179429538 270992 c.81321C>G p.Tyr27107X 327 0.96 Y Y  Nonsense 
10CP00605 179428346 272184 c.82513delA p.Ile27505PhefsX20 327 0.96 Y Y  Frameshift 
10PP00465 179425769 274761 c.85090C>T p.Arg28364X 327 0.96 Y Y  Nonsense 
12MH00114 179424219 276311 c.86640delC p.His28881ThrfsX2 327 0.96 Y Y  Frameshift 
12JL00046 179423219 277311 c.86967G>A p.Trp28989X 328 0.95 Y Y  Nonsense 
12ML01299 179422273 278257 c.87716delG p.Gly29239AspfsX32 330 0.95 Y Y  Frameshift 
10MV00215 179417877 282654 c.89751_89750dupG p.Val29918SerfsX3 336 0.95 Y Y  Frameshift 
10TD00812 179417541 282989 c.90086_90088delAAGinsA p.Glu30029AspfsX7 336 0.95 Y Y  Frameshift 
10KF00073 179413670 286860 c.92683C>T p.Arg30895X 340 0.96 Y Y  Nonsense 
10AG01687 179411209 289321 c.94849_94855delGATGCCC p.Ala31618TyrfsX37 343 0.97 Y Y  Frameshift 
10KW01906 179410548 289982 c.95415_95416+2delCAGT 
 
344 0.97 Y Y 
 Canonical splice 
variant 
10CS01784 179404524 296006 c.98265_98268dupAACA p.His32757AsnfsX4 353 0.99 Y Y  Frameshift 
14CT01557 179399346 301184 c.101996G>A p.Trp33999X 359 1 Y Y  Nonsense 
12PF00041 179393849 306681 c.106629delA p.Ala35544ProfsX2 361 1 Y Y  Frameshift 
 
Variants affecting Novex 3 transcript only (LRG_391_t2) 
12FB00047 179614105 86425 c.13022C>G p.Ser4341X 48 na   Y Nonsense 
1
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Table 6.2 TTN truncating variants identified in the FHS Offspring cohort 
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Variants affecting meta-transcript (LRG_391_t1) 
17431 179659646 40884 c.1245+3A>G  7 1.00 Y Y Y Splice variant prediction 
5630 179647533 52997 c.3100G>A  18 1.00 Y Y Y Splice variant prediction 
8864 179629515 71015 c.9727C>T p.Q3243* 42 1.00 Y Y Y Nonsense 
15956 179621404 79126 c.10799C>A p.S3600* 46 0.07    Nonsense 
12004 179621351 79179 c.10852C>T p.Q3618* 46 0.07    Nonsense 
11278 179621019 79511 c.11183_11184insG p.G3728fs 46 0.07    Frameshift 
13791 179598245 102285 c.15776-1G>T  55 0.10 Y   Canonical splice variant 
14685 179559325 141205 c.31426+1G>C  118 0.73 Y   Canonical splice variant 
530 179506963 193567 c.40558+1G>A  220 0.98 Y Y  Canonical splice variant 
1508 179473609 226921 c.52128_52128delT p.F17376fs 275 0.98 Y Y  Frameshift 
26653 179453946 246584 c.62506C>T p.R20836* 305 0.98 Y Y  Nonsense 
21151 179442329 258201 c.68824G>A  324 0.97 Y Y  Splice variant prediction 
9484 179430224 270306 c.80635C>T p.Q26879* 327 0.96 Y Y  Nonsense 
19648 179422272 278258 c.87716_87716delG p.G29239fs 330 0.95 Y Y  Frameshift 
11733 179404241 296289 c.98551C>T p.R32851* 353 0.99 Y Y  Nonsense 
21570 179404241 296289 c.98551C>T p.R32851* 353 0.99 Y Y  Nonsense 
 
Variants affecting Novex-3 transcript only (LRG_391_t2) 
35 179616683 83847 c.10443_10443delA p.K3481fs 48 na   Y Frameshift 
21984 179613466 87064 c.13660_13661insA p.I4554fs 48 na   Y Frameshift 
13496 179613422 87108 c.13705G>T p.E4569* 48 na   Y Nonsense 
21368 179613187 87343 c.13939_13939delG p.E4647fs 48 na   Y Frameshift 
14608 179611821 88709 c.15305_15305delC p.T5102fs 48 na   Y Frameshift 
 1
2
3
 
 
Table 6.3 TTN truncating variants identified in the JHS cohort 
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Variants affecting meta-transcript (LRG_391_t1) 
J127199 179649078 51452 c.2494G>T  16 1.00 Y Y Y Splice variant prediction 
J183455 179648447 52083 c.2841G>T  17 1.00 Y Y Y Splice variant prediction 
J306717 179640236 60294 c.6355G>T p.E2119* 28 1.00 Y Y Y Nonsense 
J544442 179632884 67646 c.9164-2A>T  39 1.00 Y Y Y Canonical splice variant 
J507994 179622355 78175 c.10592C>G p.S3531* 45 0.02    Nonsense 
J193179 179621089 79441 c.11113_11113delA p.R3705fs 46 0.07    Frameshift 
J503785 179621089 79441 c.11113_11113delA p.R3705fs 46 0.07    Frameshift 
J550924 179603088 97442 c.14093-1G>A  50 1.00 Y Y  Canonical splice variant 
J547288 179584983 115547 c.23386C>T p.R7796* 82 0.54 Y   Nonsense 
J120020 179577419 123111 c.27328+5G>A  95 0.68 Y   Splice variant prediction 
J226108 179577042 123488 c.27607G>A  96 0.69 Y   Splice variant prediction 
J548074 179571683 128847 c.29042-2A>C  102 0.80 Y   Canonical splice variant 
J550083 179571683 128847 c.29042-2A>C  102 0.80 Y   Canonical splice variant 
J558930 179571683 128847 c.29042-2A>C  102 0.80 Y   Canonical splice variant 
J508635 179558336 142194 c.31594G>T  120 0.63 Y   Splice variant prediction 
J162495 179514543 185987 c.39895+1G>T  212 0.14 Y   Canonical splice variant 
J206585 179480363 220167 c.48460+5G>A  259 0.98 Y Y  Splice variant prediction 
J510863 179480363 220167 c.48460+5G>A  259 0.98 Y Y  Splice variant prediction 
J554679 179480363 220167 c.48460+5G>A  259 0.98 Y Y  Splice variant prediction 
J560750 179480363 220167 c.48460+5G>A  259 0.98 Y Y  Splice variant prediction 
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J506451 179442329 258201 c.68824G>A  324 0.97 Y Y  Splice variant prediction 
J578580 179435736 264794 c.75123T>A p.Y25041* 327 0.96 Y Y  Nonsense 
J545511 179425847 274683 c.85008_85011delTAGT p.V28336fs 327 0.96 Y Y  Frameshift 
J550577 179414849 285681 c.91715_91716insA p.N30572fs 338 0.96 Y Y  Frameshift 
J545771 179414064 286466 c.92288_92289insAAAAG p.S30763fs 340 0.96 Y Y  Frameshift 
J567853 179414064 286466 c.92288_92289insAAAAG p.S30763fs 340 0.96 Y Y  Frameshift 
J154955 179407385 293145 c.97192+4A>G  349 0.98 Y Y  Splice variant prediction 
J541798 179398711 301819 c.102630_102630delA p.K34210fs 359 1.00 Y Y  Frameshift 
J542193 179397934 302596 c.103408G>T p.E34470* 359 1.00 Y Y  Nonsense 
J316117 179397250 303280 c.104092C>T p.R34698* 359 1.00 Y Y  Nonsense 
J551172 179394966 305564 c.106374+1delG  359 1.00 Y Y  Canonical splice variant 
 
Variants affecting Novex-3 transcript only (LRG_391_t2) 
J133254 179613716 86814 c.13410_13411insA p.K4470fs 48 na   Y Frameshift 
1
2
4
 
 1
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Table 6.4 TTN truncating variants identified in end-stage DCM 
 
Both 20IR01555 and 20JR01203 were independently recruited as probands, but retrospectively identified as very likely related.  Both samples have been 
retained in this cohort as recruitment was not biased by family history. 
20JM01785 contains 2 TTNtv, a frameshift and a canonical splice variant.  20HS01530 contains 2 TTNtv, a frameshift and a splice variant prediction. Without 
phasing it is not known whether these variants are in cis or trans.  For burden testing between cohorts the number of individuals with TTNtv rather than the total 
number of TTNtv was used. 
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Variants affecting meta-transcript (LRG_391_t1) 
20HS01530 179647533 52997 c.3100G>A p.Val1034Met 18 100 Y Y Y Splice variant prediction Y 
20SF01658 179647533 52997 c.3100G>A p.Val1034Met 18 100 Y Y Y Splice variant prediction Y 
20AH01746 179647533 52997 c.3100G>A p.Val1034Met 18 100 Y Y Y Splice variant prediction  
20VW01643 179506964 193566 c.40558G>C p.Val13520Leu 220 100 Y Y  Splice variant prediction Y 
20JT01288 179494968 205562 c.39358C>T p.Pro13120Ser 240 98 Y Y  Splice variant prediction  
20MC01968 179494967 205563 c.44281+1G>A  240 98 Y Y  Canonical splice variant  
20SG01639 179485012 215518 c.46236C>A p.C15412* 249 100 Y Y  Nonsense Y 
20JH01781 179483495 217035 c.46782C>A p.Tyr15594* 252 100 Y Y  Nonsense  
20JB01501 179478665 221865 c.49346-1G>A  264 98 Y Y  Canonical splice variant  
20RD01430 179477004 223526 c.50247_50247delT p.F16749fs 267 100 Y Y  Frameshift Y 
20JL01448 179471841 228689 c.53488G>T p.G17830* 279 100 Y Y  Nonsense Y 
20PD01505 179458948 241582 c.58172delA p.Asp19391fs 298 100 Y Y  Frameshift  
20VW01643 179457005 243525 c.59627-1G>A  303 100 Y Y  Canonical splice variant Y 
20EG01127 179452435 248095 c.63601C>T p.Arg21201* 307 100 Y Y  Nonsense  
20SW01468 179450018 250512 c.64453C>T p.R21485* 310 100 Y Y  Nonsense Y 
20JD01577 179444429 256101 c.67495C>T p.R22499* 320 100 Y Y  Nonsense  
20PS01433 179441649 258881 c.69412+1G>A  325 100 Y Y  Canonical splice variant Y 
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20CW01447 179441015 259515 c.69843_69843delA p.K23281fs 327 100 Y Y  Frameshift Y 
20HS01530 179440067 260463 c.70791_70791delA p.E23597fs 327 100 Y Y  Frameshift Y 
20FG01148 179436521 264009 c.74338C>T p.Arg24780* 327 100 Y Y  Nonsense  
20SF01123 179434743 265787 c.76116_76117insA p.Asn25372fs 327 100 Y Y  Frameshift  
20SB01532 179434473 266057 c.76383_76386delTAAT p.Asn25462fs 327 100 Y Y  Frameshift  
20DH01701 179429341 271189 c.81518delC p.Pro27173fs 327 100 Y Y  Frameshift  
20LN01500 179424398 276132 c.86459_86460delCT p.S28820fs 327 100 Y Y  Frameshift Y 
20BM01499 179422457 278073 c.87624C>A p.Y29208* 329 100 Y Y  Nonsense Y 
20DB01655 179417723 282807 c.89900_89903delATTA p.N29967fs 336 100 Y Y  Frameshift Y 
20AA01165 179417305 283225 c.90322_90323insT p.Glu30108* 336 100 Y Y  Frameshift  
20AK01584 179413187 287343 c.93166C>T p.R31056* 340 100 Y Y  Nonsense Y 
20JM01785 179411593 288937 c.94562dupC p.Thr31522fs 342 96 Y Y  Frameshift  
20PA01474 179408239 292291 c.96460_96461insA p.T32154fs 348 99 Y Y  Frameshift Y 
20DS01225 179404524 296006 c.98265_98268dupAACA p.His32757fs 353 100 Y Y  Frameshift  
20LB01523 179404491 296039 c.98299_98300delAG p.R32767fs 353 100 Y Y  Frameshift Y 
20PS01566 179404286 296244 c.98506C>T p.R32836* 353 100 Y Y  Nonsense Y 
20IR01555 179401029 299501 c.100445C>A p.S33482* 358 99 Y Y  Nonsense Y 
20JR01203 179401029 299501 c.100445C>A p.Ser33482* 358 99 Y Y  Nonsense  
20RD01346 179400320 300210 c.101021_101022delGA p.Arg33674fs 359 100 Y Y  Frameshift  
20JM01785 179393000 307530 c.107377+1G>A  362 100 Y Y  Canonical splice variant  
 
Variants affecting Novex-3 transcript only (LRG_391_t2) 
20JL01558 179612656 87874 
c.14470_14471insCACA 
CTCCATA 
p.R4824fs 48 
   
Y Frameshift Y 
1
2
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Table 6.5 TTN truncating variants identified in healthy volunteers 
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Variants affecting meta-transcript (LRG_391_t1) 
14AG01422 179647533 52997 c.3100G>A p.Val1034Met 18 100 Y Y Y Splice variant prediction 
14SS01830 179621351 79179 c.10852C>T p.Gln3618X 46 7    Nonsense 
14JD01896 179588844 111686 c.21142C>T p.Arg7048X 74 36 Y   Nonsense 
14EC01433 179560998 139532 c.30803-2A>G  115 84 Y   Canonical splice variant 
14KN01429 179553775 146755 c.32095+5G>A  126 22 Y   Splice variant prediction 
14AH01539 179549632 150898 c.32554+1G>C  131 17 Y   Canonical splice variant 
14MO01427 179486054 214476 c.45391delA p.Ile15131TyrfsX46 247 100 Y Y  Frameshift 
14JM01448 179444855 255675 c.67159delA p.Ile22387X 319 100 Y Y  Frameshift 
1
2
7
 
  
Figure 6.2 TTN exon usage in the heart and distribution of TTNtv in healthy volunteers, FHS and JHS participants, unselected and end-stage DCM patients. 
Upper half shows the location of TTNtv identified in each cohort.  TTNtv in the A-band and distal I-band are enriched, as previously described
17
, in both end-stage 
and unselected DCM patients with reciprocal paucity in population and healthy volunteer cohorts. 
Lower half: A schematic of the TTN meta-transcript is shown together with N2BA, N2B and Novex3 transcripts and corresponding TTN sarcomere regions 
demarcated: Z-disk (red), I-band (blue), A-band (green), and M-band (purple).    The meta-transcript (LRG_391_t1 / ENST00000589042) is a manually curated 
inferred complete transcript, incorporating exons of all known TTN isoforms (including fetal and non-cardiac isoforms) with the exception of the alternative 
terminal exon found only in the novex-3 transcript (LRG_391_t2 / ENST00000360870, shown in dark green).  The principal adult cardiac long & short isoforms 
are known as N2BA and N2B: exon usage for reference versions of these isoforms (ENST00000591111, ENST00000460472) is shown, though exon usage in 
vivo is variable (see below).   Novex-1 and novex-2 are rare cardiac isoforms that differ from N2B only in the inclusion of novex-1 and novex-2 unique exons 
(ENST00000359218 & ENST00000342175 shown in the red and blue respectively within the N2B track). 
PSI : depicts calculated exon usage based on RNASeq data (see section  5.7.1 Exon expression estimation): grey bars represent exon usage (0%-100%) as 
the "proportion spliced-in" (PSI) for each exon. 
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Figure 6.3 Sites susceptible to truncating events are non-uniformly distributed within the TTN gene but do not influence clustering effects in the A band. 
 
In the top track a cartoon of the TTN meta-transcript is shown, with regions of the sarcomere demarcated as follows: Z-disk (red), I-band (blue), A-band (green), 
and M-band (purple). The “PEVK” domain of Titin is shown in yellow, the N2B sequence in dark green and the N2A sequence in dark blue.  As exon lengths are 
non-uniform the number of exon boundaries (and hence sites at which splicing may be disrupted) are shown using a 400bp sliding window along the TTN 
transcript.  Short exons in the PEVK region lead to an excess of exon boundaries and potential splice site variants, with a relative depletion of splice sites in the 
A-band (P= 8.7x10
-16
; Fisher test for number of potential splice sites in the A-band vs. rest of the gene by length), where some exons are longer. Despite this, 
variants affecting splice donor / acceptor sites in DCM cases cluster in the A-band.   Nonsense susceptibility is also non-uniform, the PEVK region is relatively 
invulnerable to nonsense variation (P= 1.3x10
-8 
(Fisher test for number of potential nonsense variants in the A-band vs. rest of the gene by length)), as the 
codons representing these four amino acids can not be converted to a stop codon through a single nucleotide substitution.  While this may explain some of the 
observed clustering in nonsense variants, an enrichment of variants in the A-band is still observed when controlling for this effect (P= 9.1x10
-6
; Fisher test for 
number of TTNtv in A-band vs. rest of gene by number of potential variant sites). 
 
 
 
 
● ●   ● 
●   ● 
 
● ● ● 
 
 
● 
● 
 
●      ●       ● ● ● 
 
● 
 
● 
● ● ● 
 
 
 
 
● ● ●       ● ● ● 
● ● ● ● 
● ●   ● ● ●   ● ● ● 
● ● 
●   ● 
● 
● 
● ● ● ● ● ● ● ● ● ● 
● 
● 
● 
● 
 
 
 
 
● 
● ● ● ● ● ● ● ● ● ● ● ● ● 
●      ●       ● ● 
● 
● ● 
 
●   ● 
 
● ● ● 
 
● 
● 
 
● ● ● ● 
 
 
 
 
 
 
 
 
● ● 
●  ●   ● 
● 
 
 
 
● ● 
● 
● 
● ● 
● 
●● ●    ●     ● 
 
 
 
 
 
 
 
● ● 
●    ●     ●   ● 
● ● ●● ●     ● ● 
 
 
 
 
 
 
 
● ●  ● 
● ● 
● 
 
 
 
 
 
 
 
●● 
●● ●      ● 
 
 
 
 
 
 
● 
● ● 
●  ●   ● 
● 
● ●    ●       ● ● ● 
● ●●       ● ●● ●  ● 
●  ●     ●  ● 
● ● ● ● 
● ●  ●   ● 
●● ● ● ●● ● 
● ●● 
● ●    ● ● 
●  ● ● 
●● 
●   ● ● ● ●  ● ●   ● ● ●       ●      ●● ●  ● ●●     ●● ●●● ●        
●● 
●       ●●● ● 
●●●● 
● 
●   ●●● 
●●● ● ● 
●       ●   ● 
● ●● ● 
●  ● ● ● 
● ● 
● ●   ● 
●●● ● 
●●● ● 
●● ●●● 
●●● ●  ● 
●●    ●● 
● ●   ● ● ● 
●●      ●● 
● ●       ●● ●  ● ●●●
● 
●● ●●        ● ●    ●●  ● ● ●     ●       ●●  ● ● ● ● ●● ● 
●   ● 
●● ● 
●      ● ● 
●●    ● 
● 
●    ●● 
● ●● 
● 
●   ●   ●   ● 
●   ● 
● 
●   ●●●● ●     ● 
●      ●   ● ●     ● 
● 
●  ●●● ● 
● 
● ● ●  ● 
●● ●● 
●    ●      ● 
● ●● 
● ● 
●   ●● 
● 
●  ● 
●   ● ● 
●   ●● ● 
● ● 
● ●● 
● ● ●  ● ● 
●● ●   ●  ● ● ● 
● ● ● ● ● ● 
●   ● 
● ●● 
 
 
● 
● 
●● ● ● ● 
●       ● ● ● 
●  ●  ●●●   ●●● 
●   ●●● ●●● 
●● ●● 
 
 
0 
●●●●●  
 
codon position 
 
35991 
 
nonsense/splice susceptibility = number of potential nonsense/splice sites in a fixed window 
window size =  100bp for nonsense, 400bp for splice sites 
1
2
9
 
n
o
n
s
e
n
s
e
 s
u
s
c
e
p
ti
b
ili
ty
 
s
p
lic
e
 s
u
s
c
e
p
ti
b
ili
ty
 
0
 
1
0
 
2
0
 
0
 
5
 
1
0
 
1
5
 
130  
Distal exons, including those that encode the A-band portion of TTN, are annotated as 
being constitutively expressed in cardiac isoforms, whereas many proximal exons, 
particularly in the I-band, are variably spliced in different isoforms (see introduction 
section 1.7). Recent studies suggest that variants impacting only a subset of gene 
transcripts are less likely to cause loss-of-function than variants impacting all isoforms 
225
.  TTNtv that altered both N2BA and N2B were strongly enriched in DCM patients 
versus controls (OR=19(12-29), P = 5.5 x 10
-46
) and associated more strongly with DCM 
than TTNtv that affected only the long isoform (OR=3.8(1.4-9.2), P=0.008, Table 6.6). By 
contrast TTNtv found in controls were more likely to fall outside the two principal cardiac 
transcripts: in novex, foetal or alternative exons (13 variants in 7406bp encoding non- 
cardiac exons, vs. 49 variants in 103052bp encoding cardiac exons, OR=3.7(2.0-6.7), 
P= 2.0 x 10
-4
).  Variants unique to the shorter novex-3 TTN isoform were not significantly 
enriched in DCM (0.37% DCM versus 0.15% controls, OR=2.5(0.36-13), P =0.24). 
Though this study is not powered to definitively exclude a small excess of variants in the 
novex-3 terminal exon, this isoform does not span the cardiac sarcomere
189  
and these 
variants are unlikely to be pathogenic. Given the lack of evidence of pathogenicity these 
variants are excluded from subsequent analyses. 
 
Average cardiac TTN exon usage (PSI) was determined de novo from human heart LV 
samples (n=84, subset of end-stage cohort) and used to annotate each TTN exon 
(section 3.7, RNA Sequencing, and Table 3.2).  PSI gives important information distinct 
from conventional transcript information.  A number of exons annotated as incorporated 
into the N2BA isoform previously had limited evidence of cardiac expression, and the 
new RNAseq data supports this: 39/122 exons annotated as incorporated into the N2BA 
isoform had minimal evidence of cardiac expression (PSI < 0.15).  Conversely, three 
exons annotated as constitutively expressed appeared to have variable inclusion 
(intermediate PSI 0.15-0.9), as did two exons that are not included in the conventional 
N2BA/N2B descriptions. This is shown pictorially in Figure 6.4. 
 
Treating all cohorts as an ordered variable with four levels (healthy volunteers, general 
population, ambulatory unselected DCM, and end-stage DCM), a strong relationship can 
be observed between cohort and mutant exon usage (Kruskal-Wallis chi-square, P = 
4.9x10
-3
), with TTNtv-containing exons in controls having lower usage than TTNtv- 
containing exons in DCM patients (P = 2.5x10
-4
) (Figure. 6.5). This suggests that some 
variants observed in controls may be tolerated either because the putative truncating 
131  
event is rescued by exclusion of the variant exon, or because the truncated transcript 
and/or protein are expressed only at relatively low levels. 
 
Figure 6.4 Usage of TTN exons across isoforms. 
 
Each data point represents the PSI of an exon annotated as incorporated into the 
respective isoform 
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Figure 6.5 Usage of TTN exons containing TTNtv across all subject groups 
 
TTN exon usage is represented as PSI "proportion spliced-in" for each exon, which is an 
estimate of the proportion of transcripts that incorporate each exon.  Each data point 
represents the PSI of an exon containing a TTNtv separated by cohort. For splice 
variants, PSI is derived as the average PSI for exons either side of the splice junction. 
The PSI for exons containing TTNtv in control subjects is significantly lower than in 
unselected DCM cases (P=0.003, Wilcox Mann-Whitney) and all DCM cases (unselected 
and end-stage DCM cohorts) (P = 2.5 x 10
-4
). 
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Table 6.6          Burden of TTN truncating variants in DCM patients and controls 
 
Numbers of subjects with a TTNtv is shown for each group. TTNtv are classified by type, 
the affected transcript, and expression level of the variant-encoding exon. Comparisons 
between groups were assessed by Fisher’s exact test. 
a
3/374 subjects were excluded from these analyses due to relatedness to other subjects. 
b
Variants that only impact the alternative terminal exon of novex-3 are excluded elsewhere. 
c
Exon usage levels are displayed categorically based on PSI 
d
Canonical splice sites refer to the 2 intronic base pairs at the 5’ and 3’ splice junctions 
e
Variants close to canonical splice sites that are predicted in silico to alter splicing 
f
total number of individuals with TTNtv; 4 individuals with DCM (1 unselected, 3 end-stage) 
carry a second TTNtv which is a splice variant prediction in 3 cases. 
 Discovery Cohorts P value 
DCM vs. controls 
Healthy 
volunteers 
n=308 
FHS 
 
n=1623 
JHS 
 
n=1980 
Unselected 
DCM 
n=371
a
 
End-stage 
DCM 
n=155 
Unselected 
DCM 
All DCM 
Transcript affected by truncation 
N2BA & N2B 4 11 20 42 34 1.7x10
-25
 5.5x10
-46
 
N2BA only 4 2 8 7 0 0.0014 0.0089 
Neither N2BA or N2B 
(Novex-3 terminal exon 
only
b
) 
 
1 
(0) 
 
8 
(5) 
 
4 
(1) 
 
1 
(1) 
 
1 
(1) 
 
 
1 
 
 
0.7 
Totals 9 21 32 50 35 
 
Sarcomere domain 
 
A-band (18235aa) 
 
2 
 
7 
 
12 
 
32 
 
29 
 
0.011 
 
0.00014  
Non A-band (17756aa) 
 
7 
 
9 
 
19 
 
18 
 
8 
 
Totals 
 
9 
 
16 
 
31 
 
49 
 
34 
 
Usage
c 
of exon containing truncation 
 
Low (PSI <0.15) 
 
1 
 
4 
 
4 
 
2 
 
0 
 
0.25 
 
0.38 
Intermediate (PSI 0.15- 
0.9) 
 
4 
 
1 
 
7 
 
5 
 
0 
 
0.012 
 
0.044 
 
High (PSI>0.9) 
 
4 
 
11 
 
20 
 
42 
 
34 1.7x10
-25
 5.5x10
-46
 
 
Totals 
 
9 
 
16 
 
31 49
f
 34
f
 
 
Variant type 
 
Frameshift variant 
 
2 
 
3 
 
7 
 
22 
 
15 4.9x10
-16
 4.0x10
-25
 
 
Stop gained 
 
3 
 
7 
 
6 
 
15 
 
12 7.3x10
-09
 2.3x10
-15
 
Canonical splice sites
d
 
 
2 
 
3 
 
7 
 
9 
 
5 2.9x10
-05
 2.3x10
-07
 
Splice variant predictions
e
 
 
2 
 
3 
 
11 
 
4 
 
5 
 
0.089 
 
0.0017 
 
Totals 
 
9 
 
16 
 
31 49
f
 34
f
 1.4x10
-25
 2.8x10
-43
 
  
Table 6.7 TTN truncating variants in publicly available control populations 
 
Abbreviations: ESP = exome sequencing project, 1kg = 1000 genome project. Variants are described with respect to the meta-transcript 
(LRG_391_t1), with the exception of variants only affecting the novex-3 alternative terminal exon that are reported with respect to novex-3 
(LRG_391_t2). 
 
*Several variants were found with considerable frequency in one population only, raising the possibility that these may be artefacts.  The 3 
marked variants were excluded from further analyses, as the observed allele frequencies suggest population stratification, allele ascertainment 
bias, or artefact (p<0.05, Fisher test).  None of these 3 variants are restricted to one ethnic group in the relevant population, and so would be 
expected to be detected in both projects if true variants.  None are found in >1500 individuals sequenced at RBHT. 
The distributions of the remaining variants, with ≤23 observations in ESP or ≤2 observations in 1kg, are not statistically incompatible with 
stochastic sampling of rare variants, and so are included in analyses. 
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nonsense 
 
c.325C>T 
 
p.R109X 
 
1 
 
0 
 
4 
 
Z-band 
 
100 
NOVEX-3,NOVEX- 
1,N2B,N2A,META,NOVEX-2,N2BA 
essential 
splice site 
 
c.2370+1G>T 
  
1 
 
0 
 
14 
 
Z-band 
 
100 
N2B,NOVEX-3,N2BA,NOVEX- 
2,META,NOVEX-1,N2A 
 
nonsense 
 
c.6123G>A 
 
p.W2041X 
 
1 
 
0 
 
28 
 
Z-band 
 
100 
NOVEX-1,N2A,N2B,NOVEX- 
3,N2BA,NOVEX-2,META 
 
nonsense 
 
c.5067G>A 
 
p.W1689X 
 
1 
 
0 
 
28 
 
Z-band 
 
100 
N2BA,NOVEX-2,META,NOVEX- 
1,N2A,N2B,NOVEX-3 
 
nonsense 
 
c.6820C>T 
 
p.Q2274X 
 
1 
 
0 
 
30 
 
I-band 
 
100 
NOVEX-2,N2BA,NOVEX-3,NOVEX- 
1,N2B,N2A,META 
 
frameshift 
 
c.7871dupA 
 
p.Pro2625AlafsTer9 
 
4 
 
0 
 
34 
 
I-band 
 
100 
META,NOVEX-3,N2BA,NOVEX- 
1,NOVEX-2,N2B,N2A 
 
frameshift 
 
c.9132delA 
 
p.Ala3045GlnfsX14 
 
10 
 
0 
 
38 
 
I-band 
 
100 
N2BA,NOVEX-2,NOVEX-1,NOVEX- 
3,N2A,N2B,META 
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nonsense 
 
c.9448C>T 
 
p.R3150X 
 
1 
 
1 
 
40 
 
I-band 
 
100 
NOVEX-3,NOVEX- 
1,N2B,N2A,META,NOVEX-2,N2BA 
 
frameshift 
 
c.9749_9750delTG 
 
p.V3250Afs*40 
 
1 
 
0 
 
42 
 
I-band 
 
100 
N2A,NOVEX- 
1,META,N2B,N2BA,NOVEX-2,NOVEX-3 
essential 
splice site 
 
c.10303+2T>C 
  
1 
 
0 
 
44 
 
I-band 
 
100 
N2BA,NOVEX-2,META,NOVEX- 
1,N2A,N2B,NOVEX-3 
nonsense c.11190C>G p.Y3730X 1 0 46 I-band 7 NOVEX-2,META 
nonsense c.10799C>A p.S3600X 1 0 46 I-band 7 META,NOVEX-2 
essential 
splice site 
 
c.11254+2T>C 
  
17 
 
0 
 
46 
 
I-band 
 
7 
 
META,NOVEX-2 
essential 
splice site 
 
c.11254+1G>C 
  
0 
 
2 
 
46 
 
I-band 
 
7 
 
META,NOVEX-2 
frameshift c.11183dupG p.Leu3729ThrfsTer9 5 0 46 I-band 7 NOVEX-2,META 
frameshift c.11113delA p.R3705Dfs*2 2 0 46 I-band 7 NOVEX-2,META 
nonsense c.13243C>T p.Q4415X 0 1 48 I-band 83 NOVEX-3 
nonsense c.13568C>G p.S4523X 1 0 48 I-band 83 NOVEX-3 
nonsense c.12586G>T p.G4196X 1 0 48 I-band 83 NOVEX-3 
nonsense c.13254T>G p.Y4418X 0 1 48 I-band 83 NOVEX-3 
nonsense c.11752G>T p.E3918X 1 0 48 I-band 83 NOVEX-3 
nonsense c.13705G>T p.E4569X 1 0 48 I-band 83 NOVEX-3 
nonsense c.14122C>T p.Q4708X 1 0 48 I-band 83 NOVEX-3 
nonsense c.15313C>T p.R5105X 1 0 48 I-band 83 NOVEX-3 
nonsense c.16321C>T p.R5441X 1 0 48 I-band 83 NOVEX-3 
nonsense c.16516G>T p.E5506X 6 0 48 I-band 83 NOVEX-3 
nonsense c.16744G>T p.G5582X 0 1 48 I-band 83 NOVEX-3 
frameshift c.10782delA p.Leu3595CysfsTer13 1 0 48 I-band 83 NOVEX-3 
frameshift c.13410dupA p.Gly4471ArgfsTer14 2 0 48 I-band 83 NOVEX-3 
frameshift c.13939delG p.Glu4647LysfsTer54 4 0 48 I-band 83 NOVEX-3 
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frameshift c.14415delA p.Asp4806MetfsTer23 1 0 48 I-band 83 NOVEX-3 
frameshift c.14727delA p.Leu4909PhefsTer35 1 0 48 I-band 83 NOVEX-3 
frameshift c.15305delC p.Thr5102IlefsTer2 1 0 48 I-band 83 NOVEX-3 
frameshift c.16529delT p.Val5510GlyfsTer18 1 0 48 I-band 83 NOVEX-3 
nonsense c.12587C>A p.S4196X 1 0 49 I-band 99 META,NOVEX-1,N2B,N2BA,NOVEX-2 
nonsense c.12643C>T p.Q4215X 1 0 49 I-band 99 N2BA,NOVEX-2,NOVEX-1,META,N2B 
nonsense c.15796C>T p.R5266X 1 0 55 I-band 10 N2A,META,N2BA 
essential 
splice site 
 
c.24227-2A>G 
  
1 
 
0 
 
85 
 
I-band 
 
8 
 
N2BA,N2A,META 
frameshift c.25383delG p.K8461Nfs*5 1 0 89 I-band 11 N2BA,N2A,META 
frameshift c.28016dupA p.Pro9340AlafsTer23 23 0 98 I-band 70 META,N2A,N2BA 
nonsense c.29071A>T p.K9691X 1 0 102 I-band 80 N2A,META,N2BA 
essential 
splice site 
 
c.29042-2A>C 
  
6 
 
0 
 
102 
 
I-band 
 
80 
 
META,N2BA,N2A 
essential 
splice site* 
 
c.30683-2delA 
  
374 
 
0 
 
113 
 
I-band 
 
85 
 
N2BA,N2A,META 
essential 
splice site 
 
c.31763-1G>A 
  
5 
 
0 
 
123 
 
I-band 
 
83 
 
N2A,META,N2BA 
nonsense c.31966A>T p.K10656X 1 0 125 I-band 33 N2BA,N2A,META 
essential 
splice site 
 
c.32471-1G>A 
  
2 
 
0 
 
131 
 
I-band 
 
17 
 
N2A,META,N2BA 
frameshift c.33535delG p.E11179Sfs*3 7 0 141 I-band 1 N2A,META,N2BA 
essential 
splice site* 
 
c.34291+2T>C 
  
0 
 
193 
 
147 
 
I-band 
 
2 
 
N2BA,N2A,META 
essential 
splice site 
 
c.34855+1G>A 
  
1 
 
0 
 
154 
 
I-band 
 
16 
 
N2BA,N2A,META 
nonsense c.35692A>T p.R11898X 0 2 162 I-band 2 META 
frameshift c.35739dupT p.Pro11914SerfsTer7 2 0 163 I-band 1 META 
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frameshift c.37262delA p.K12421Sfs*526 19 0 181 I-band 2 META 
essential 
splice site 
 
c.39043+1G>T 
  
1 
 
0 
 
202 
 
I-band 
 
3 
 
META 
essential 
splice site 
 
c.38960-3_38960-1delAAG 
  
1 
 
0 
 
202 
 
I-band 
 
3 
 
META 
essential 
splice site 
 
c.40558+1G>A 
  
2 
 
0 
 
220 
 
I-band 
 
100 
N2A,NOVEX-2,META,NOVEX- 
1,N2B,N2BA 
essential 
splice site 
 
c.40723+1G>T 
  
1 
 
0 
 
222 
 
I-band 
 
100 
NOVEX-1,N2A,N2B,META,NOVEX- 
2,N2BA 
 
nonsense 
 
c.43319G>A 
 
p.W14440X 
 
1 
 
0 
 
236 
 
I-band 
 
100 
META,NOVEX-2,N2BA,NOVEX- 
1,N2A,N2B 
 
nonsense 
 
c.44272C>T 
 
p.R14758X 
 
0 
 
1 
 
240 
 
I-band 
 
100 
META,NOVEX-2,N2BA,NOVEX- 
1,N2B,N2A 
 
nonsense 
 
c.48283C>T 
 
p.R16095X 
 
1 
 
0 
 
258 
 
A-band 
 
100 
NOVEX-1,N2A,N2B,META,NOVEX- 
2,N2BA 
 
nonsense 
 
c.48405T>A 
 
p.C16135X 
 
1 
 
0 
 
259 
 
A-band 
 
100 
META,NOVEX-2,N2BA,NOVEX- 
1,N2A,N2B 
 
frameshift 
 
c.48382_48383insT 
 
p.K16128Ifs*6 
 
1 
 
0 
 
259 
 
A-band 
 
100 
N2BA,NOVEX-2,META,NOVEX- 
1,N2A,N2B 
essential 
splice site 
 
c.50551+1G>A 
  
0 
 
1 
 
269 
 
A-band 
 
100 
N2B,N2A,META,NOVEX- 
2,N2BA,NOVEX-1 
 
nonsense 
 
c.60726T>A 
 
p.Y20242X 
 
0 
 
1 
 
305 
 
A-band 
 
100 
N2BA,NOVEX- 
1,N2B,N2A,META,NOVEX-2 
 
frameshift 
 
c.66523_66524delCT 
 
p.L22175Ifs*8 
 
2 
 
0 
 
317 
 
A-band 
 
100 
META,NOVEX- 
1,N2A,N2B,N2BA,NOVEX-2 
 
nonsense 
 
c.81943G>T 
 
p.E27315X 
 
1 
 
0 
 
327 
 
A-band 
 
100 
NOVEX-2,N2BA,NOVEX- 
1,N2A,N2B,META 
 
nonsense 
 
c.82273C>T 
 
p.Q27425X 
 
1 
 
0 
 
327 
 
A-band 
 
100 
META,NOVEX-2,N2BA,NOVEX- 
1,N2A,N2B 
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frameshift 
 
c.70775delT 
 
p.V23592Gfs*4 
 
1 
 
0 
 
327 
 
A-band 
 
100 
N2BA,NOVEX-2,META,NOVEX- 
1,N2A,N2B 
 
frameshift 
 
c.94167delT 
 
p.F31389Lfs*7 
 
1 
 
0 
 
340 
 
A-band 
 
100 
META,NOVEX- 
1,N2A,N2B,N2BA,NOVEX-2 
 
nonsense 
 
c.96892C>T 
 
p.Q32298X 
 
1 
 
0 
 
348 
 
A-band 
 
99 
N2B,N2BA,N2A,NOVEX- 
2,META,NOVEX-1 
essential 
splice site 
 
c.100766-1G>T 
  
0 
 
1 
 
359 
 
A-band 
 
100 
NOVEX-2,N2BA,NOVEX- 
1,N2B,N2A,META 
 
frameshift 
 
c.105814delA 
 
p.T35272Hfs*21 
 
2 
 
0 
 
359 
 
M-band 
 
100 
NOVEX-2,META,NOVEX- 
1,N2A,N2B,N2BA 
 
frameshift 
 
c.105739_105742dupGTTA 
 
p.Lys35248SerfsTer2 
 
1 
 
0 
 
359 
 
M-band 
 
100 
NOVEX-1,META,N2B,N2BA,NOVEX- 
2,N2A 
 
nonsense 
 
c.107149C>T 
 
p.Q35717X 
 
1 
 
0 
 
361 
 
M-band 
 
100 
N2A,N2B,META,NOVEX- 
2,N2BA,NOVEX-1 
 
nonsense 
 
c.106959T>A 
 
p.Y35653X 
 
1 
 
0 
 
361 
 
M-band 
 
100 
META,NOVEX-2,N2BA,NOVEX- 
1,N2A,N2B 
 
frameshift* 
 
c.106998dupA 
 
p.Ala35667SerfsTer6 
 
57 
 
0 
 
361 
 
M-band 
 
100 
N2BA,NOVEX-2,N2A,NOVEX- 
1,META,N2B 
 
frameshift 
 
c.107351delC 
 
p.S35784*fs*1 
 
3 
 
0 
 
362 
 
M-band 
 
100 
N2BA,NOVEX-2,META,NOVEX- 
1,N2A,N2B 
1
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Table 6.8 Burden, type and distribution of TTN truncating variants in publicly available 
control populations 
 
The number of alleles for each variant is shown.  No variants were homozygous.  Individuals 
are assumed to carry no more than one truncating variant, so that the allele prevalence 
approximates to the population prevalence. 
7 / 12 1kg alleles (5 / 10 distinct variants) affect only novex or other low expression exons. 
83 / 168 ESP alleles (28 / 64 distinct variants) affect these exons. 
Abbreviations: 1kg = 1000 genomes project, ESP = exome sequencing project. 
 
 
  
 
 
Total TTNtv alleles 
Excluding variants with low 
probability of pathogenicity 
(affecting only novex and other 
low expression exons) 
1kg ESP 1kg ESP 
Total TTN 12 168 5 85 
Population size 1092 6504 1092 6504 
Prevalence 1.1% 2.6% 0.46% 1.3% 
 
Essential splice site 4 39 2 19 
Frameshift 0 96 0 49 
Nonsense 8 33 3 17 
 
Z-band 0 2 0 2 
Z-band / I-band 0 2 0 2 
I-band 9 146 2 63 
A-band 2 10 2 10 
A-band / M-band 1 3 1 3 
M-band 0 5 0 5 
149  
6.3.5 Diagnostic interpretation of TTNtv in DCM 
Based on these differentiating factors, it can be estimated that TTNtv produced by nonsense, 
frameshift, or canonical splice site mutations (excluding predicted splice variants outside 
canonical splice sites) that affect highly expressed exons have at least a 93% probability of 
pathogenicity (likelihood ratio (LR) = 14) when identified in an unselected patient with DCM, 
and an even higher probability of pathogenicity in end-stage disease (≥96%, LR= 24)(see 
methods for calculation of probability of pathogenicity and LR).   These estimates are 
conservative, in that they assume all variants in controls are benign, giving an upper limit of 
the background noise. 
 
 
6.3.6 Stratification of DCM by TTN genotype 
The high accuracy and reproducibility of quantitative CMR imaging is ideally suited for 
genotype-phenotype studies
172,173
. To delineate clinical phenotypes associated with TTNtv- 
positive DCM, CMR data for patients meeting diagnostic criteria
169 ,173  
(n=319) in the 
unselected DCM cohort was integrated with TTN genotype data.  No subjects with a TTNtv 
had CMR features suggestive of a previous episode of myocarditis that could have caused 
DCM
226
, compared to 9% of subjects without TTNtv, supportive of a primary genetic cause in 
all TTNtv cases.  TTNtv-positive DCM patients had more severely impaired LV function, lower 
stroke volumes and thinner LV walls (Table 6.9) than TTNtv-negative patients. 
Consistent with these adverse intermediate phenotype associations, a difference in the 
composite endpoint of LV assist device implantation, listing for cardiac transplantation, and all 
cause mortality was observed. TTNtv-positive DCM patients reached this endpoint at      
earlier ages (P = 0.015, Figure. 6.6) and sooner after prospective enrolment (P= 0.05, Figure. 
6.6).  Midwall fibrosis, an important prognostic factor in DCM,
174,180 
was similar in patients  
with and without TTNtv, but sustained ventricular tachycardia was more common in TTNtv- 
positive patients (OR = 6.7; P = 0.001) and robust to adjustment for LV ejection fraction. 
  
 
 
 
 
 
Figure 6.6 TTNtv and survival in DCM 
 
Outcomes in unselected DCM patients with (red) and without (blue) TTNtv. The left panel shows age censored at adverse event (death, cardiac transplant or left- 
ventricular assist device (LVAD) or at age 70 years. The right panel shows adverse events after enrolment, to control for ascertainment (interval censored from 
time of enrolment to age 70 years or adverse event). Event free survival is reduced in TTNtv-positive DCM (P = 0.015) due to altered disease progression both 
before and after presentation. A trend to younger presentation (Table 6.9), and worse outcomes after enrolment (P = 0.05) combine to give reduced survival 
overall. 
 
 
Age at  death, cardiac transplant or LVAD 
by TTN genotype 
 
Time from enrolment to death, cardiac transplant or LVAD 
by TTN genotype 
 
  
0 20 40 60 80 0 2 4 6 8 10 12 14 
 
Age at adverse event (Yr) Time from enrolment to event (Yr) 
TTN+ve 
TTN−ve p =  0.05 
TTN+ve 
TTN−ve p =  0.015 
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Table 6.9 Clinical characteristics in DCM patients with and without TTNtv 
 
Unselected DCM cohort.  Values are means ± SD. Volume measurements are 
indexed to body surface area. LV, left ventricle; RV right ventricle; EDVi/ESVi end 
diastolic/systolic volume; SVi stoke volume; EF ejection fraction; LVMi LV mass; WTi 
wall thickness; VT ventricular tachycardia; NYHA New York Heart Association 
functional class. P values, not corrected for multiple testing as not independent. False 
discovery rates (FDR) 
 
 
CMR and Clinical Data TTNtv- 
negative 
(n=277) 
TTNtv- 
positive 
(n=42) 
P value False 
Discovery 
Rate 
 
 
LV 
EDVi 136 ± 38 137 ± 34.1 0.81 0.677 
ESVi 87.5 ± 39.1 93.7 ± 36.4 0.30 0.205 
SVi 48.2 ± 12.9 43.4 ± 14.1 0.11 0.041 
EF 37.5 ± 12.2 33.3 ± 13.3 0.11 0.047 
 
 
RV 
EDVi 89.4 ± 24.7 89.6 ± 26.1 0.97 0.972 
ESVi 45.2 ± 22.3 50.4 ± 25.9 0.31 0.234 
SVi 44.4 ± 12.6 39.2 ± 15.8 0.11 0.031 
EF 51.6 ± 14.1 45.2 ± 16 0.11 0.036 
LVMi 95.4 ± 27.6 87.1 ± 18.3 0.106 0.20 
Lateral WTi 3.13 ± 0.73 2.77 ± 0.713 0.003 0.02 
Mid-wall fibrosis 94 / 270 (35%) 13 / 41 (32%) 0.869 0.81 
Age at Diagnosis (years) 53.4 ± 13.4 49.3 ± 13.7 0.115 0.20 
NYHA status 
1/2/3/4 
 
116/104/36/1 
 
19/16/4/1 
 
0.692 
 
0.81 
Sustained VT 20 / 97 (21%) 9 / 14 (64%) 0.001 0.02 
Conduction Disease 82 / 227 (36%) 8 / 36 (22%) 0.130 0.30 
Family history of DCM 24 / 218 (11%) 9 / 37 (24%) 0.034 0.09 
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Distribution and functional correlates of TTNtv 
TTNtv in unselected DCM patients were considered as an allelic series in order to 
dissect positional effects and disease mechanism.  In exploratory analysis, the 
location of the variant (distance from the N-terminus of the TTN protein to the variant) 
appeared to correlate with CMR indices (Figure 6.7). Distal truncations were 
associated with lower biventricular EF and SVi, and similar trends were seen for  
other parameters of cardiac dysfunction.  Multivariate linear modelling (considering 
age, sex, TTNtv presence, and TTNtv position) was used to robustly assess the 
relationship between TTN genotype and cardiac phenotype.  Regression models 
showed that TTNtv location was significantly correlated with principle indices of heart 
function: ejection fraction and stroke volume  (P < 0.006; Tables GP10-11).  This 
positional effect on cardiac parameters was large, such that a C-terminal TTNtv  
would be associated with substantially reduced ejection fraction (absolute reductions: 
left ventricle:-18±7%, P = 0.006; right ventricle: -21±9%, P = 7.3x10
-6
) and indexed 
stroke volumes (absolute reductions: left ventricle -22±8ml/m
2
,P = 0.0017;  right 
ventricle -23±8ml/m
2
, P = 0.0013), as compared with an N-terminal TTNtv.  In  
subjects with TTNtv, the variant position explained 19-23% of the observed variation 
(R
2
) in these phenotypic indices. These positional data, together with observation that 
the burden of distal TTNtv increases in populations with increasingly severe disease, 
imply that TTNtv may not cause disease by simple haploinsufficiency.  No positional 
effect was observed for wall thickness but indexed lateral wall thickness correlated 
strongly with simple presence of a TTNtv. 
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Figure 6.7 Truncated transcript length is correlated with indices of cardiac 
impairment severity in DCM. 
The relationships between TTNtv location and cardiac morphology and function 
assessed by CMR imaging in an allelic series of cases:  we assessed 14 CMR sub- 
phenotypes in 43 prospectively recruited DCM subjects with TTNtv and strict CMR 
diagnostic criteria
173,176
. The TTNtv location (X axis) is plotted from the amino- (N) to 
carboxyl- (C) end of the protein. Distal (C-terminal) TTNtv were associated with  worse 
cardiac contractile performance and associated with diminished indexed   stroke 
volume (SVi) and ejection fraction (EF) of both left and right ventricles as compared to 
proximal truncations.  These relationships were formally assessed using linear 
modelling.  A regression line is shown for each variable. LV, left ventricle; RV, 
right ventricle; EDVi, indexed end diastolic stroke volume (ml/m
2
); ESVi, indexed end 
systolic volume (ml/m
2
), SVi, indexed stroke volume (ml/m
2
), EF ejection fraction (%). 
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Table 6.10 Linear Modelling of the relationship between TTN genotype and 
phenotype for 14 continuous variables in the unselected DCM cohort 
 
For each phenotype, 2 models are compared.  First, the phenotype is modelled as a 
function of age & sex, and the model optimized.  Statistically significant predictors are 
retained and listed in column 3.  Next, TTN genotype is added to the model.  A TTNtv 
may be present or absent (TTN), and if present is described by its protein coordinate 
(p.coord) and the level of use of the truncated exon (PSI).  The model is re-optimised 
again, significant predictors are retained, and the two models compared using 
ANOVA.  If no terms are retained in the model after optimization, the model terms are 
given as “None”.  If all TTN genotype terms are rejected during optimization of the 
second model then both models will be identical, and no P-value for comparison is 
returned. 
 
 
Phenotype N Model terms Whole population Fitted to TTNtv 
positive samples 
P value for 
model 
comparison 
R
2 Adjusted 
R
2 
Delta 
R
2 
Adjusted 
R
2 
Delta 
R
2 
LV EF 318 None 0 0 0 0 0 
0.006 
318 TTN, TTN:p.coord 0.03 0.03 0.03 0.19 0.19 
RV EF 314 Sex 0.05 0.04 0.05 0.05 0.05 
0.003 
314 Sex, TTN, TTN:p.coord 0.08 0.07 0.04 0.24 0.19 
Age at 
diagnosis 
292 None 0 0 0 0 0  
292 None 0 0 0 0 0 
LAVi 315 Age_at_scan 0.05 0.04 0.05 -0.14 -0.14  
315 Age_at_scan 0.05 0.04 0 -0.14 0 
LV EDVi 317 Sex 0.03 0.03 0.03 0.08 0.08  
317 Sex 0.03 0.03 0 0.08 0 
LV ESVi 317 Sex 0.03 0.03 0.03 0.10 0.10  
317 Sex 0.03 0.03 0 0.10 0 
LV SVi 317 None 0 0 0 0 0 
0.002 
317 TTN, TTN:p.coord 0.04 0.03 0.04 0.23 0.23 
LVMi 316 Sex 0.07 0.07 0.07 0.03 0.03  
316 Sex 0.07 0.07 0 0.03 0 
RV EDVi 313 Sex 0.04 0.04 0.04 -0.02 -0.02  
313 Sex 0.04 0.04 0 -0.02 0 
RV ESVi 313 Sex 0.05 0.05 0.05 0.04 0.04  
313 Sex 0.05 0.05 0 0.04 0 
RV SVi 313 None 0 0 0 0 0 
0.001 
313 TTN, TTN:p.coord 0.04 0.04 0.04 0.20 0.20 
Septal WTi 312 Age_at_scan 0.05 0.05 0.05 0.07 0.07  
312 Age_at_scan 0.05 0.05 0 0.07 0 
Lateral WTi 312 None 0 0 0 0 0 
0.004 
312 TTN 0.03 0.02 0.03 0.16 0.16 
Max WTi 310 Age_at_scan 0.08 0.08 0.08 0.11 0.11  
310 Age_at_scan 0.08 0.08 0 0.11 0 
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Table 6.11 Full Linear Model describes impact of multivariate TTN genotype on 
phenotype for 14 continuous variables in the unselected DCM cohort 
 
Definitive models were constructed, with TTN genotype defined by presence/absence 
of TTNtv, and the distance of the TTNtv from the N-terminus, together with a 
TTNtv:sex interaction term, as previous studies have suggested a more extreme 
phenotype in males with TTNtv.  Here the distance of the truncation from the N- 
terminus was scaled from 0-1, so the model coefficients are readily interpretable 
 
 
Phenotype Model terms Coefficient Standard Error 
Component 
P value 
Full model 
P value 
 
LV EF 
(Intercept) 37 0.74 3.9x10
-154
  
0.006 TTN 6.2 4.6 0.18 
TTN:p.coord -18 7.4 0.013 
 
RV EF 
(Intercept) 56 1.5 1.3x10
-114
  
7.3x10
-06
 
SexM -6.7 1.8 0.00022 
TTN 6.1 5.5 0.27 
TTN:p.coord -21 8.8 0.017 
Age at diagnosis (Intercept) 52 0.79 5.3x10
-179
 1 
LAVi 
(Intercept) 40 6.3 5.4x10
-10
 
0.00012 
Age_at_scan 0.0012 0.00031 0.00012 
LV EDVi 
(Intercept) 130 4 8.7x10
-98
 
0.0016 
SexM 15 4.7 0.0016 
LV ESVi 
(Intercept) 78 4.2 1.2x10
-52
 
0.0025 
SexM 15 4.9 0.0025 
 
LV SVi 
(Intercept) 48 0.78 4.2x10
-178
  
0.0017 TTN 7.7 4.8 0.11 
TTN:p.coord -22 7.8 0.0045 
LVMi 
(Intercept) 83 2.8 3.6x10
-92
 
2.2x10
-06
 
SexM 16 3.3 2.2x10
-06
 
RV EDVi (Intercept) 81 2.7 2.5x10
-95
 
0.00019 
SexM 12 3.1 0.00019 
RV ESVi (Intercept) 37 2.4 3.1x10
-40
 
4.7x10
-05
 
SexM 12 2.8 4.7x10
-05
 
RV SVi 
(Intercept) 44 0.78 1.8x10
-166
  
0.0013 TTN 7.9 5.1 0.12 
TTN:p.coord -23 8.1 0.0049 
Septal WTi (Intercept) 3.4 0.2 4.4x10
-44
 
3.4x10
-05
 
Age_at_scan 4.2x10
-05
 1.0x10
-05
 3.4x10
-05
 
Lateral WTi (Intercept) 3.1 0.044 3.4x10
-193
 
0.0041 
TTN -0.35 0.12 0.0041 
Max WTi (Intercept) 4 0.25 5.2x10
-44
 
5.9x10
-07
 
Age_at_scan 6.1x10
-05
 1.2x10
-05
 5.9x10
-07
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6.4 Discussion 
 
6.4.1 Limitations of sequence data 
Errors in NGS data can stem from experimental steps and from the bioinformatic 
analysis
227
.  Ideally all samples from all cohorts would be collected, prepared, 
sequenced and analysed in the same way, in the same facility at the same time. 
However this is not always possible, particularly when large cohorts with detailed 
phenotyping are required.  A pragmatic approach has been used here to combine 5 
cohorts of large size and deep data with the understanding that TTN was target 
enriched, sequenced and analysed at two different centres, and that ~50 samples 
were whole genome sequenced by a third party (Complete Genomics). 
 
 
Each sequencing platform can introduce unique biases and errors.  However 
technical sensitivity is high given adequate read depth and the significance of 
platform-specific errors in the data presented here can be expected to be trivial, 
particularly as variants are validated.  The population cohorts (FHS and JHS) were 
sequenced and analysed by the Seidman Laboratory at Harvard Medical School and 
TTNtv were checked by manual inspection of reads in the Integrative Genomics 
Viewer (IGV) (www.broadinstitute.org/igv/).  The DCM cases (both unselected and 
end-stage cohorts) and healthy volunteers were sequenced and analysed at Imperial 
College London and Sanger validation was used for all variants. As we see an 
increased burden of TTNtv in DCM and Sanger validation is more stringent than 
manual inspection of reads, it is likely that any potential bias introduced by using 
different validation strategies would decrease rather than increase the difference 
between cases and controls.  In support of the robustness of the findings presented 
here, the frequencies of variants across these 3 control cohorts and across two 
publically available control cohorts (ESP and 1000 genomes) are consistent.  The 
frequency of TTNtv in end-stage DCM was consistent with previously published 
frequencies for similarly selected cohorts enriched for severe and familial DCM.  The 
unselected DCM cohort with less severe and sporadic DCM is not equivalent to end- 
stage or familial DCM and, perhaps not unexpectedly, a lower prevalence of TTNtv is 
observed in this population as compared to previous reports. 
 
 
6.4.2 Limitation of novex-3 interpretation 
Only two novex-3 variants were observed in 529 DCM cases and confidence 
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intervals for the true frequency are therefore wide. However the frequency of novex-3 
and low expression variants in ESP and 1KG cohorts is consistent with that seen in 
the population and healthy volunteer cohorts presented here suggesting these values 
are likely to be accurate.  Additionally there are biological data to suggest these 
variants are unlikely to be pathogenic in that they are expressed at very low level in 
the heart and the novex-3 protein does not span sarcomere and so performs a 
different function to other TTN isoforms. It therefore seems reasonable to suggest  
that novex-3 variants are unlikely to be pathogenic despite lacking power to draw a 
definitive conclusion. 
 
 
6.4.3 Limitations of deriving and applying exon usage values 
All heart samples used for molecular studies reported here were from patients with 
advanced heart failure (n=84) The expression profile in a failing heart might be 
expected to differ from a healthy heart as many genes will be differentially regulated, 
either causing or in response to heart failure.  However LV samples from donor 
hearts that were acquired and stored in the same manner in the same facility (n=7, 
sequenced after preparation of this thesis) show that the source of the tissue sample 
does not affect the profile of TTN exon usage (Figure 6.8). 
 
Figure 6.8 TTN exon usage in DCM and control hearts 
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reflecting a lack of data, a low PSI represents the presence of confirmatory exclusion 
reads.  Thus the PSI profile would not be impacted by performance of library 
preparation or sequencing.  Using a large number of samples to derive a mean exon 
usage also reduced potential for bias due to outliers. 
 
 
6.4.4 Clinical stratification of DCM by TTN genotype 
Patient stratification is a cornerstone of precision medicine
194
. Data presented here 
suggest that DCM caused by TTNtv defines patients who may benefit from more 
tailored clinical management.  Sustained ventricular tachycardia, LV wall thickness
228 
and LV ejection fraction influence DCM outcomes
229
.  In comparison to TTNtv- 
negative DCM subjects, TTNtv-positive DCM subjects had increased risk for 
sustained ventricular tachycardia, perhaps related to increased wall stress 
230
, an 
observation that may warrant a lower threshold for device therapy, as has been 
recommended for DCM caused by LMNA mutations
231
. As distal TTNtv were over- 
represented in the end-stage DCM cohort (Figure 6.2) and were associated with 
worse LV function in the unselected DCM cohort, more aggressive clinical 
management may be appropriate in patients carrying these mutations. 
 
 
 
6.4.5 Interpretation of TTNtv in individuals without DCM 
Cardiomyopathy genes feature prominently in the American College of Medical 
Genetics and Genomics’ list of genes in which mutations should be reported 
regardless of the primary indication for sequencing
232
. Accurate interpretation of 
clinically actionable incidental findings in cardiomyopathy genes is both difficult and 
medically important because of the considerable population prevalence of protein- 
altering variants,
232,233  
a population prevalence of DCM of approximately 0.4%, and 
the associated medical consequences including heart failure and sudden death.
234-236 
Previous studies provided limited information about the prevalence of TTNtv in the 
general population and their impact on cardiovascular health
134,224,237,238
. Here TTN 
was sequenced in over 3900 subjects from population and healthy volunteer cohorts 
with detailed cardiac phenotyping and clinical data. 
 
 
TTNtv status does not seem to reliably predict DCM in the population cohorts: the 
majority of subjects with TTNtv in the general population do not appear to have DCM 
(population frequency of TTNtv 1:70, estimated frequency of DCM 1:250). Certain 
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subtypes of TTNtv appear clinically silent, approximately half of all TTNtv identified in 
control subjects occurred in Novex or other infrequently used exons, or altered non- 
canonical splice site sequences. These types of TTNtv were not associated with 
DCM, and as such it is likely that most of these variants are not pathogenic.  Despite 
these insights, half of TTNtv found in population subjects without DCM were in highly 
expressed exons and appear comparable to TTNtv enriched in DCM subjects 
(population frequency of likely pathogenic TTNtv 1:140, estimated frequency of DCM 
1:250; thus a frequency disparity remains). These TTNtv may cause DCM with 
reduced penetrance that is dependent on characteristics of the variant itself and/or 
the effects of additional protective and exacerbating genetic or environmental 
modifiers that are recognized in DCM
72,75
.  Such factors may also account for the 
mismatch between population prevalence of mutations in hypertrophic 
cardiomyopathy genes and overt disease.
233  
Alternatively it may be that these 
individuals will go on to develop DCM. 
 
 
6.4.6 Insights into TTN DCM disease mechanism 
The molecular mechanisms underlying TTN cardiomyopathy have been the subject   
of speculation
224
. It has been previously reported that variants impacting only a  
subset of gene transcripts are less likely to cause loss-of-function than variants 
impacting all isoforms 
225
.  The ability to determine which of the positional factors 
described are contributing to differences in phenotype is limited by their co-linearity. 
While a relationship with exon usage is potentially of profound clinical importance for 
diagnostic variant interpretation, a linear positional effect as seen within the DCM 
cohort would also have mechanistic implications favouring a dominant negative effect 
of an aberrant transcript or protein, rather than haploinsufficiency.  In support of this, 
a 2q31q32 deletion encompassing the entire TTN locus was not found to cause 
cardiac muscle disease
156
, and immunohistochemical studies have shown truncated 
TTN in the sarcomeres of skeletal muscles from patients with recessive TTN 
mutations
152
.  The position-dependent functional effects reported here strongly 
suggest a dominant negative effect, as occurs with MYBPC3 truncations that cause 
hypertrophic cardiomyopathy
239,240
, with increasing severity associated with longer 
mutant proteins.  Whether longer mutant TTN proteins cause more severe disease by 
perturbing force generation, placing greater energetic demands on the cell, by 
overwhelming protein degradation machinery, or indeed by acting through some 
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other mechanism, remains to be explored. Further elucidation of pathogenic 
mechanisms will be important to direct the development of appropriate therapies. 
 
This proposed dominant negative mechanism of TTNtv has also been questioned as 
at least half of all DCM is ‘sporadic’, i.e. no affected family members are identified. 
However, familial DCM has incomplete penetrance and highly variable expressivity. 
Moreover, family history may not be robust: DCM cannot reliably be excluded in any 
individual family member, even with the most thorough clinical and imaging 
assessment, until an advanced age (≥ age 50), given the late onset in many cases. 
Data presented here shows that TTNtv are associated with familial DCM (see Table 
6.9), and is supported by the fact that TTNtv only account for ~13% unselected DCM 
but ~22% of severe and familial DCM. 
 
 
6.5 Summary 
TTNtv were found in 1-2% of the general population, in 13% of unselected DCM 
patients and in 22% of patients with end-stage DCM.  These data show that TTNtv 
are the most common cause of DCM and illuminate important characteristics that 
distinguish TTNtv pathogenicity. Nonsense, frameshift, and canonical splice site 
TTNtv, particularly those that alter both principal isoforms of TTN and/or reside in the 
carboxyl A-band, cause DCM with severely impaired LV function and life-threatening 
ventricular arrhythmias. In contrast, truncations that occur in novex-specific exons or 
other infrequently used TTN exons are less likely to be deleterious. An immediate 
clinical utility of these findings is improved variant interpretation that enables cascade 
screening of relatives with pathogenic mutations and gene and genotype-guided 
stratified management of DCM
233,241
.  However, further study is necessary before 
TTN sequencing in the general population, in the absence of substantial clinical 
suspicion, will be sufficient to predict DCM.  Further elucidation of the myocyte 
processes altered by large dominant negative mutant TTN proteins will be important 
to direct the development of therapies that prevent or attenuate the progression of 
TTNtv related DCM. 
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7 Concluding  remarks 
 
 
7.1 Overview of thesis 
 
DCM is genetically and clinically heterogeneous, presenting a real impediment to 
genotype-phenotype correlation and the application of genetic information to   
augment patient management.  TTNtv were recently identified as a common cause of 
severe DCM, but their contribution to the full spectrum of DCM including mild disease 
was unknown.  This, together with the fact that TTNtv sometimes occur in healthy 
individuals, has posed significant challenges for the interpretation of these variants in 
an era of accessible genome sequencing. The mechanism by which TTNtv impact 
clinical outcomes is poorly understood, leading some to speculate that all  
titinopathies, including TTN+ve DCM, are recessive. 
 
In this thesis, the power of quantitative CMR has been integrated with the capacity of 
NGS to assess the relationship between TTN genotype and cardiac phenotype. 
 
First, a prospectively recruited DCM cohort was established following CMR 
assessment.  Cardiac dilatation and impaired contraction define DCM but are also a 
common final pathway in many cardiac pathologies including ischaemic 
cardiomyopathy.  Deep phenotyping by CMR and collation of detailed clinical data 
enabled curation of an unalloyed cohort, with greater power to detect genotype- 
phenotype  associations. 
 
An NGS assay was produced that captures all TTN coding exons and splice sites. 
Refinement and testing established optimal parameters for sequencing and analysis 
of variants.  Genotype data was generated for 374 prospective, unselected DCM 
cases, 155 end-stage retrospective cases, and 308 MRI phenotyped healthy 
volunteers. Integration of these data with that from 3603 population subjects 
identified molecular signatures that aid interpretation of TTN truncations both in  
DCM and as incidental findings. 
 
Overall, TTNtv were identified in 1.4% of controls, 13% of unselected and 22% of 
end-stage DCM cases confirming TTN as the commonest cause of genetic DCM in 
all patient groups. TTNtv-containing exons in DCM have higher usage than those in 
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controls.  Nonsense, frameshift and essential splice site TTNtv in frequently used 
exons are estimated to have >93% probability of pathogenicity (likelihood ratio 14). 
The findings in this thesis do not support pathogenicity of TTN variants predicted in 
silico to alter non-essential splice sites outside the two conserved intronic base 
pairs, in the absence of supportive segregation or RNA sequencing data. 
 
Finally, integration of TTN genotype with CMR sub-phenotypes and clinical outcomes 
in the DCM cohort revealed clinically important manifestations of TTNtv+ve DCM and 
suggest a length-dependent, dominant negative mechanism of disease. Compared to 
TTNtv-negative DCM, TTNtv-positive patients had lower LVEF (P=0.02), thinner LV 
walls (P=0.02), and a higher incidence of sustained ventricular tachycardia   
(P=0.001). C-terminus TTNtv were also associated with lower LVEF versus N- 
terminus (β=-18±7%, p=0.006) and were more common in end-stage disease. 
 
Incorporation of exon-specific usage annotation and variant position as described in 
this thesis could improve interpretation of TTNtv, enabling precision medicine. 
 
 
 
 
7.2 Novelty 
DCM phenotype data presented in this thesis relates to a population that is 
representative of the most commonly encountered form of DCM in the clinic. This 
population with less severe heart muscle disease and sporadic DCM is not   
equivalent to end-stage or familial DCM previously published 
17 
and the role of TTN in 
this patient group is largely undescribed. In addition, the depth of clinical data 
presented in this thesis for the unselected DCM cohort, goes far beyond that 
previously  possible. 
 
The volume of TTN genotype data for phenotyped DCM cases, population controls 
and healthy volunteers brought to bear in these analyses is far greater than that 
previously  available. 
 
 
7.3 Future work 
The emergence of TTNtv as a major cause of DCM sparked a great deal of interest in 
other TTN variants as a potential cause.  Most TTN missense variants do not cause 
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disease.  That truncating variants are more likely to cause disease than missense 
variants is not surprising: this is commonly seen in other inherited cardiac conditions, 
and truncating variants cause much more dramatic protein alterations than point 
substitutions. 
 
The problem of distinguishing those missense variants that are disease-causing from 
those that are not is likewise not unique, though the scale of the problem is perhaps 
unique for TTN given its size and the very significant burden of rare variants in the 
general population. 
 
Relatively little is known about the mechanism of action of those TTN missense 
variants that do cause DCM.  They are typically reported to follow a dominant 
inheritance pattern.  At the time of writing, only one published report describes 
functional characterisation of two TTN missense variants
146
, which suggest reduced 
binding of various interacting proteins, that would be unlikely to confer a dominant 
negative effect. 
 
However, it is not unusual for truncating and missense variants to cause the same 
disease through different mechanisms. For example, long QT syndrome may be 
caused by truncating variants in KCNQ1 leading to haploinsufficiency whereas, 
various missense variants in KCNQ1 can produce either a partial loss of function 
(typically with milder phenotype), or exert a dominant negative effect (with more 
severe phenotype) depending on the precise location of the variant in the protein
21
. 
 
 
Preliminary analyses by the Cardiovascular Genetics and Genomics group reveal 
that ~28% of both cases and healthy volunteers carry at least one novel TTN non- 
synonymous SNP (nsSNP). This number increases to ~45% when considering 
variants present in up to 0.1% of the Caucasian population (represented up to 10 
times in ESP/1KG data).  A detailed analysis of TTN missense mutations will require 
larger cohorts and domain-specific analyses using protein-modelling approaches. 
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